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7Chapter 1
General introduction
Adapted from: 
Pediatric AML: From Biology to Clinical Management
Jasmijn D. E. de Rooij, C. Michel Zwaan and Marry van den Heuvel-Eibrink
Journal of Clinical Medicine 2015 Jan 9;4(1):127-149.
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General introduction
Epidemiology of AML
In children, the most frequently occurring hematological malignancies include acute 
leukemias, of which 80% are classified as acute lymphoblastic leukemia (ALL) and 
15%–20% as acute myeloid leukemia (AML). Chronic leukemias are exceedingly rare 
in childhood and mainly comprise chronic myeloid leukemia (CML) and juvenile 
myelomonocytic leukemia (JMML). 
 The incidence of AML in infants is 1.5 per 100,000 individuals per year, 
subsequently the incicidence decreases to 0.9 per 100,000 individuals aged 1–4 and 
0.4 per 100,000 individuals aged 5–9 years, after which it gradually increases into 
adulthood, up to an incidence of 16.2 per 100,000 individuals aged over 65 years.1 The 
underlying cause of AML is unknown, and childhood AML generally occurs de novo. In 
adult and elderly patients, AML is often preceded by myelodysplastic syndrome (MDS), 
but in childre n, the occurrence of AML preceded by clonal evolution of preleukemic 
myeloproliferative diseases, such as MDS or JMML, is rare. Germline affected individuals, 
such as those with Fanconi anemia or Bloom syndrome, have an increased risk for 
developing AML as a secondary malignancy.2, 3 Recently, germ-line mutations in several 
genes, such as TP53, RUNX1, GATA2 and CEBPA, have been found in families with an 
unexplained high risk of AML, suggesting a familial predisposition to develop AML, but 
these cases are rare.4-8 
 Children with Down syndrome classically present with a unique 
megakaryoblastic subtype of AML, typically following a transient myeloproliferative 
disorder in the neonatal period, which is characterized by somatic mutations in the 
GATA1 gene. The leukemic cells of patients with Down syndrome are usually highly 
sensitive to chemotherapy with an exceptional high survival rate, and therefore it is 
pivotal to treat these patients with adjusted treatment protocols.9 In addition, AML may 
occur following previous radiotherapy or chemotherapy containing alkylating agents 
or epipodophyllotoxins, as secondary neoplasm. These are typically characterized by 
either KMT2A-rearrangements (formerly known as MLL) or by monosomy 7.10, 11
Diagnostic Approach and Classification
 AML is a heterogeneous disease with respect to morphology, 
immunophenotyping, cooperating underlying genetic abnormalities, as well as 
clinical behavior. The standard diagnostic process of AML is based on a combination 
of morphology, cytochemistry, immunophenotyping, cytogenetic and molecular 
characterization of the leukemic blasts derived from the bone marrow or peripheral 
blood.12 Each AML patient can be risk-classified into a clinically relevant subgroup. 
The previously used morphology-based French-American-British (FAB) classification is 
nowadays replaced by the World Health Organization (WHO) classification, which also 
takes karyotype and molecular aberrations into account (Table 1.1).13, 14 Cytochemistry, 
morphology and immunophenotyping is generally used to distinguish AML from 
ALL, which further classifies pediatric AML according to the cell lineage of origin 
and differentiation stage at which the differentiation arrest occurs. Especially for the 
diagnosis of FAB-types, M0 and M7 immunophenotyping is indispensable.12, 15 The 
majority of chromosomal abnormalities is detected by conventional karyotyping and 
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complemented with fluorescent in situ hybridization (FISH) or reverse transcriptase 
PCR to detect relevant (cryptic) translocations, fusion genes or loss of chromosome 
material.16 Nonetheless, the WHO classification is not fully applicable for pediatric AML, 
since it groups together specific genetic aberrations with clearly different oucome, and 
alocates ~44%, being the largest subgroup, as ‘AML not otherwise specified’.17
Treatment and Outcome
The clinical outcome of pediatric AML has improved significantly over the past few de-
cades, with current long-term survival rates of ~70% (Table 1.2).18-28 This improvement 
is due to intensification of chemotherapeutic regimens, better risk-group stratification, 
better salvage at relapse and improved supportive care. Risk-group stratification is usu-
ally based on (cyto)genetic abnormalities present in the leukemic blasts in combination 
with early response to treatment, either specified as complete remission (CR) rate after 
one or two courses or applying minimal-residual disease measurements, which in AML 
is mainly based on flow-cytometry.29 The chemotherapeutic regimens consist of 4–5 
cycles of intensive chemotherapy, typically including cytarabine combined with an an-
thracycline. The added value of hematopoietic stem cell transplantation (SCT) in new-
ly-diagnosed pediatric AML is under discussion, as in general, the occurrence of pro-
cedure-related deaths needs to be counterbalanced by the reduction in relapse risk. 
The procedure-related deaths are dependent on the intensity of the prior induction 
chemotherapy as well as on the condition regimen which is adjusted to the HLA-bar-
rier between the donor and the recipient. SCT in first CR is therefore currently only 
recommended for a selected subset of high risk cases in most European protocols.12, 
30, 31 SCT plays a more prominent role in most North-American treatment protocols. 
Currently, several trials include minimal residual disease (MRD) levels after Courses 1 
or 2 to allocate patients to the high risk group, and with that treatment including SCT.32 
 Despite intensive treatment, ~30% of the pediatric patients relapse, and 
outcome is poor following relapse, reflected by the ~30%–40% of patients surviving in 
the largest and most recent series reported to date.33, 34 
 Nevertheless, the high frequency of treatment-related deaths (5%–10%), both 
in treatment protocols for newly-diagnosed, as well as for relapsed disease, and the 
occurrence of long-term side effects, such as anthracycline-induced cardiomyopathy, 
illustrate that further intensification of chemotherapy seems hardly feasible.35 
Therefore, knowledge on the molecular and genetic background is of utmost relevance 
in order to detect novel, leukemia and patient-specific treatment targets.
Relevant Molecular and Genetic Aberrations in Pediatric AML
AML is thought to arise from at least two classes of cooperating genetic events.36 Type 
I abnormalities result in increased, uncontrolled proliferation and/or survival of the 
leukemic cell and are often activating mutations of genes involved in signal transduction 
pathways, such as FLT3, KIT,  N-RAS, K-RAS and PTPN11. Type II abnormalities impair 
differentiation and mainly result from genetic aberrations in hematopoietic transcription 
factors, due to, for instance, the AML-characteristic translocations t(8;21)(q22;q22)/
AML1-ETO and 11q23/KMT2A rearrangements or from mutations in single genes, such as 
NPM1 and CEBPA.7, 37-40 The most common cytogenetic abnormalities (Type II) in children 
are t(8;21)(q22;q22), inv(16)(p13.1q22) (together referred to as core binding factor 
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(CBF)-AML), t(15;17)(q22;q21) and 11q23/KMT2A-rearranged abnormalities (Figure 
1.1A).41-44 Together, these account for approximately half of all pediatric AML cases, 
a much higher frequency than in adults. Some translocations, for example t(1;22)
(p13;q13) and t(7;12)(q36;p13), are specific for young children and are rarely or never 
found in adults45-52. Translocations involving hematopoietic transcription factors often 
lead to dysregulated gene expression, either as a result of the fusion partner itself or 
the recruitment of different co-factors to the transcription complex. For example, the 
KMT2A gene has histone methyltransferase activity and is part of a chromatin modifying 
complex. More than 60 fusion partners have been identified in AML, but the breakpoint 
of the KMT2A gene is highly conserved.53, 54 Fusion proteins lead to a gain of function 
of the KMT2A-complex, resulting in inappropriate histone modification and increased 
expression of MEIS1 and, specifically, HOXA genes, maintaining a stem-cell phenotype. 
In addition, the presence of the DOT1L protein, which is recruited into the KMT2A-
complex, is required for the leukemogenic activity of several KMT2A rearrangements 
and may be a target for treatment.55, 56 
 Approximately 20%–25% of pediatric AML cases are cytogenetically 
normal.40, 57 Of interest in these cases, specific Type II mutations and translocations 
are identified in ~70% of the cases, such as NPM1 mutations, biallelic CEBPA 
mutations, as well as the cryptic translocations, NUP98/NSD1, all invisible with 
conventional karyotyping and, hence, requiring additional molecular diagnostics 
(Figure 1.1B).38, 51, 52, 58 
 The combination of the Type I and Type II mutations is not completely random 
as specific combinations frequently occur. Examples  are the Ras pathway mutations, 
which are  often found in combination with KMT2A-rearrangements; KIT mutations 
which are mainly found  in  CBF-AML; and FLT3-internal tandem duplications which are 
often seen in combination with PML/RARA and NUP98/NSD1 (Figure 1.1).40, 51
 In the study of Hollink et al51 patients were identified with a similar gene 
expression profile, but unknown aberration. The work shown in this thesis unravels 
several of these unknowns, with a specific search for type II mutations, to get a better 
understanding of the underlying biology of pediatric AML. 
 Mutations in epigenetic regulators, such as EZH2, ASXL1 and DNMT3A, add 
another level of complexity and contribute to both the maturation arrest and proliferative 
capacity, which are needed to develop AML (Figure 1.2).58-66 These mutations are more 
frequent in adult AML, and show the difference in leukemogenesis between AML in 
adults and children. Still, mutations in specific genes found in adult AML, may be of 
interest in pediatric AML, such as mutations in ETV6, BCOR, or PHF6, genes that were 
screened for mutations in this thesis. 
Prognostic Factors and Risk Group Stratification
The most important prognostic factors for the survival of pediatric AML patients are the 
initial response to treatment and the underlying genetic and molecular aberrations.12, 
68, 69 CBF-AML is a favorable prognostic subgroup.40, 44, 70 Outcome in KMT2A-rearranged 
AML is variable and depends on the translocation partner. For example, the KMT2A-
translocation t(1;11)(q21;q23) is associated with a very favorable outcome in pediatric 
AML. In contrast, poor survival rates were reported in pediatric AML with translocations 
t(6;11)(q27;q23) and t(10;11)(p12;q23).76,77 The acute megakaryoblastic leukemias 
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Figure 1.1 Distribution of Type I/II abnormalities in pediatric AML. (A) Cooperating type I and Type II 
mutations in pediatric AML. The circos plot depicts the frequency of the Type II mutations and co-
occurrence of Type I mutations in patients with de novo pediatric AML. The length of the arch corresponds 
to the frequency of the Type II mutation and the width of the ribbon with the percentage of patients with 
a specific Type I mutation or a combination of Type I mutations. FLT3/ITD denotes FLT3 internal tandem 
duplication. (B) Co operating Type I and Type II mutations in cytogenetically normal AML. The circos plot 
depicts the frequency of the Type II mutations and co-occurrence of Type I mutations in patients with 
de novo pediatric cytogenetically normal AML. The length of the arch corresponds to the frequency of 
the Type II mutation, and the width of the ribbon with the percentage of patients with a specific Type I 
mutation or a combination of Type I mutations. FLT3/ITD denotes FLT3 internal tandem duplication.
A
B
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Figure 1.2. Model of cooperating genetic events in AML. Different types of genetic and epigenetic events 
collaborate in leukemogenesis. 
Table 1.1. The WHO classification of acute myeloid leukemia (AML) and related 
neoplasms.14
WHO Classification of AML and Related Neoplasms
Acute myeloid leukemia with 
recurrent genetic abnormalities
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Acute promyelocytic leukemia with t(15;17)(q22;q12); PML-RARA
AML with 11q23 (KMT2A) abnormalities
AML with t(6;9)(p23;q34); DEK-NUP214
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
t(1;22)(p13;q13); RBM15-MKL1
Provisional entity: AML with mutated NPM1
Provisional entity: AML with mutated CEBPA
Acute myeloid leukemia with myelodysplasia-related changes
Therapy-related myeloid neoplasms
Acute myeloid leukemia, not 
otherwise specified
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia
Acute erythroid leukemia
Pure erythroid leukemia
Erythroleukemia, erythroid/myeloid
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to 
Down syndrome
Transient abnormal myelopoiesis
Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
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(AMKL, FAB-M7) in non-Down syndrome patients represent a subgroup with poor 
outcome, with the exception of AMKL harboring t(1;22)(p13;q13), which seems to 
confer a favorable prognostic group, in contrast to Down syndrome, where AMKL 
confers a favorable outcome.9, 52 The t(1;22)(p13;q13), or translocation RBM15/MKL1, 
comprises approximately 10% of the pediatric non-Down Syndrome AMKL cases. Given 
the poor prognostic outcome, identification of driving aberrations will contribute to risk 
stratification, and may lead to targeted therapy in the future. In this thesis we unravel 
more recurrent aberrations, and analyze outcome parameters of this group.
 A special subtype of pediatric AML is the cytogenetically normal (CN) AML 
group, where clinical outcome is highly dependent on the presence of single-gene 
mutations or cryptic translocations. Of special interest are NPM1 and bi-allelic CEBPA 
mutations, conferring a favorable prognosis, while the cryptic translocation NUP98/
NSD1 confers a poor prognosis, due to a poor response to treatment and a high risk for 
relapse, independent of the poor prognostic Type I FLT3-itd abnormality.38, 51, 71
 The described poor prognostic abnormalities in adult AML of chromosomes 
3q and 5q and the monosomal karyotypes are extremely rare in children.28, 72-74 
Overexpression of EVI1 caused by 3q26 abnormalities predicts an adverse outcome in 
adult AML, but EVI1 overexpression is not an independent prognostic factor in pediatric 
AML.75, 76 The Type I mutations of WT1 and FLT3-itd predict a poor outcome, the latter 
dependent on the allele ratio, and these mutations are described as events in clonal 
evolution towards relapse.77
 Deletion of 7q is described as an intermediate risk in the prognosis in adults, 
in contrast to the outcome of pediatric AML with a 7q deletion in children. In pediatric 
patients with a 7q deletion, the outcome seems to be dependent on other cytogenetic 
abnormalities in the leukemic cell.44, 78 Monosomy 7 is a well-known poor-prognostic 
factor and confers a worse outcome.44, 78 The specific genes contributing to this prognosis 
may give a better understanding of the leukemogenesis, and is therefore of interest for 
targeted therapy. In this thesis we elaborate on the genes that may cause the leukemic 
effect in the monosomy 7 cases. 
Genomic Approaches to Unravel the Biology of Pediatric AML
In order to provide more insight into the heterogeneity and biology of AML, apart from 
using candidate-gene approaches including split-signal FISH, PCR and multiplex ligand-
dependent probe amplification (MLPA), genome-wide approaches have been recently 
employed, although the success rate is variable. Array-based comparative genomic 
hybridization (array-CGH) and single-nucleotide polymorphism (SNP) arrays identified 
several regions with loss of heterozygosity and recurrent copy number variations (CNVs), 
albeit with low frequency in AML.79 These CNVs included aberrations in the WT1, NF1 
and TET2 genes, the latter being more common in adults than in children.39, 60, 62, 80 
 Gene expression profiling could predict the well-known cytogenetic subtypes of 
AML with high accuracy, although its value for diagnostic purposes remains limited, since 
most aberrations can be identified with conventional karyotyping.81-84 Nevertheless, 
novel genes involved in the pathogenesis of pediatric AML subtypes were identified 
using this method, such as BRE and IGSF4.85, 86 
 In addition to discovering novel gene mutations, next generation sequencing, 
such as RNA-sequencing and whole exome sequencing, has also proven to be a 
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powerful tool in the study of the clonal evolution of both adult and pediatric AML.87, 88 
By comparing the mutational spectrum of diagnosis-relapse pairs, it was shown that the 
founding clone gained novel mutations and evolved into the relapse clone. Moreover, 
minor subclones present at diagnosis can survive chemotherapy, gain mutations and 
present as dominant clones at relapse, illustrating their leukemia-driving capacity. 
Therapeutic targeting of novel identified mutations to prevent relapse may provide an 
improved outcome for selected patients.89, 90 In this thesis we combined candidate-gene 
approaches and next generation sequencing, in order to find new and/or recurrent 
aberrations in our pediatric AML cohort. 
Towards Optimized Therapy
The translation from molecular aberrations towards targeted therapy might be 
able to improve outcome in the next few decades, next to other therapies such as 
immunotherapy. Since further intensification of current chemotherapy treatment 
seems not feasible in pediatric AML, due to high morbidity and mortality rates, new 
therapeutic approaches that are more tumor-specific and cause less severe side effects 
are urgently needed. Some new compounds directed at specific molecular targets have 
already been investigated in early clinical trials in pediatric AML.32
 International collaboration, which has been pursued over the last few 
decades on the levels of the International Berlin-Frankfurt-Munster Study Group 
(BFM-SG), Innovative Therapies for Children with Cancer (ITCC), European Network 
for Cancer Research in Children and Adolescents  (ENCCA), Therapeutic Advances in 
Childhood Leukemia (TACL) and Childhood Oncology Group (COG), has been proven 
successful in clinical and biological studies and will speed up efforts to enhance 
therapeutic options and the availability of novel agents for individual pediatric 
AML patients.12, 26, 52, 78, 91, 92 
Outline of this thesis
The work described in this thesis focused on characterizing pediatric AML in the search 
for unknown aberrations, determine new outcome parameters and understanding the 
biological changes caused by specific molecular aberrations. 
 In part 1, the research focusses on the driving aberrations and their prognostic 
value in pediatric AMKL. Chapter 2 describes the identification and analyses of the 
frequency of NUP98/KDM5A as a recurrent event in pediatric AMKL, occurring in 
approximately 10% of all pediatric AMKL. In chapter 3 we focused on the identification 
of RB1 deletions as a specific event in NUP98/KDM5A translocated pediatric AMKL 
patients, and unraveled the biologic effect of the co-occurrence of these two aberrations 
using various techniques. Furthermore, we report on data using RNA-sequencing and 
DNA-sequencing to identify aberrations in pediatric AMKL, summarized in chapter 4. 
We were able to screen 98 pediatric AMKL samples, with international collaborators 
from among others the St. Jude Research Hospital (Memphis, TN, USA), the BFM-SG, 
the AIEOP (Bologna, Italy), and DCOG. In chapter 5, the results are shown of another 
international collaboration, with samples derived from the AIEOP, the COG, the BFM-SG 
and DCOG, we analyzed outcome parameters in pediatric AMKL, of the most recurrent 
(cryptic) cytogenetic aberrations, which in the future may benefit to risk-stratification. 
 Thereafter, part 2 describes mutations and translocations found in all 
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morphologic subtypes of pediatric AML. In the search for unknown aberrations, we 
used multiplex ligand probe amplification (MLPA) and identified IKZF1 deletions in 
pediatric AML. In chapter 6 we analyzed the frequency of ETV6 alterations in pediatric 
AML using MLPA, sequencing and FISH. Using the same MLPA kit we identified deletions 
of IKZF1, which we describe in chapter 7. In chapter 8 we describe the frequency of 
BCOR and BCORL1 mutations in pediatric AML, and in chapter 9 we focused on the 
frequency of PHF6 mutations, and found that these are not specific for male patients, 
as seen in other types of leukemia. In chapter 10 a new translocation fusing ZMYND11 
to MBTD1 resulting in high HOXA expression is described. Chapter 11 summarizes this 
thesis and chapter 12 comprises the general discussion and future perspectives.
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Abstract
Cytogenetic abnormalities and early response to treatment are the main prognostic 
factors in acute myeloid leukemia (AML). Recently, NUP98/NSD1, a cytogenetically cryptic 
fusion, was described as recurrent event in AML, characterized by dismal prognosis and 
HOXA/B-gene overexpression. Using split-signal FISH, other NUP98-rearranged pediatric 
AML cases were identified, including several acute megakaryoblastic leukemia (AMKL) 
cases with a cytogenetically cryptic fusion of NUP98 to JARID1A (t(11;12)(p15;q13)). In 
this study we screened 105 pediatric AMKL cases to analyse the frequency of NUP98/
JARID1A and other recurrent genetic abnormalities. NUP98/JARID1A was identified 
in 11/105 patients (10.5%). Other abnormalities consisted of RBM15/MKL1 (n=16), 
CBFA2T3/GLIS2 (n=13), and MLL-rearrangements (n=13). Comparing NUP98/JARID1A 
positive with other pediatric AMKL patients, no significant differences in sex, age, and 
white blood cell count were found. NUP98/JARID1A was not an independent prognostic 
factor for 5-year overall (pOS) or event-free survival (pEFS), although the 5-year pOS for 
the entire AMKL cohort was poor (42±6%). Cases with RBM15/MLK1 fared significantly 
better in terms of pOS and pEFS, although this was not independent from other risk 
factors in multivariate analysis. NUP98/JARID1A cases were characterized by HOXA/B 
gene overexpression, which is a potential druggable pathway. In conclusion, NUP98/
JARID1A is a novel recurrent genetic abnormality in pediatric AMKL.
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by recurrent 
genetic aberrations.1-3 At present, survival rates in pediatric AML are approximately 
60-70%.4, 5 The most important factors predicting clinical outcome are genetic and 
molecular aberrations, and early response to treatment. It is hypothesized that AML 
results from at least two different types of mutations which non-randomly collaborate 
in leukemogenesis.6 The type-I aberrations confer a proliferative or survival advantage, 
and consist for instance of mutations in tyrosine kinases, such as FLT3 or RAS mutations. 
Type-II mutations lead to impairment of the hematopoietic differentiation, and 
frequently consist of translocations, such as 11q23/MLL-rearrangements, AML1/ETO 
or CBFB/MYH11.1, 6 
Genome wide studies have revealed many novel single gene mutations.7, 8 
Recently, we described a cytogenetically cryptic translocation fusing nucleoporin 98 
(NUP98), located on chromosome 11p15, to nuclear receptor binding SET domain 
protein 1 (NSD1), located on chromosome 5q35, as a recurrent event in cytogenetically 
normal AML (CN-AML).9, 10 In children with CN-AML the frequency was 16.1%, 
whereas in adult CN-AML the frequency was 2.3%.9, 11 AML patients with NUP98/NSD1 
translocated leukemia had a dismal prognosis.9 Of interest, NUP98/NSD1-rearranged 
cases were associated with overexpression of HOXAB-genes, suggesting an oncogenic 
mechanism similar to AML cases characterized by MLL-rearrangements or NPM1-gene 
mutations.9, 12 Searching for other NUP98-driven leukemias, we screened a large cohort 
using split signal FISH to detect other NUP98 breaks, as NUP98 is known to have many 
different partner genes.10 
 In one patient another fusion partner was identified, i.e. JARID1A, which was 
previously described by Van Zutven et al in a single case from our institute.13 This case 
was classified as acute megakaryoblastic leukemia (AMKL), which can either occur de 
novo or in the context of Down Syndrome associated myeloid leukemia with mutations 
in GATA1. Non-Down Syndrome AMKL is characterized by a limited number of specific 
genetic abnormalities, including the t(1;22)(p13;q13) translocation fusing RBM15 to 
MKL1, formerly known as OTT/MAL.14 In addition, recently Gruber et al described an 
inversion of chromosome 16 resulting in CBFA2T3/GLIS2 gene fusion as a repetitive 
event in AMKL, with an overall frequency of 27%.15 This frequency was confirmed by 
Thiollier et al.16
In this study, we show that NUP98/JARID1A is a novel recurrent cryptic 
translocation in pediatric AMKL. In addition, we characterized the genetic abnormalities 
of a larger series of pediatric AMKL patients, including the RBM15/MKL1 translocation 
and the recently identified fusion of CBFA2T3 to GLIS2, and investigated the prognostic 
significance of these aberrations.
Material and methods
Patient samples
The cohort of newly diagnosed pediatric AML patients with available peripheral blood 
or bone marrow samples taken at initial diagnosis included in this study was previously 
described by Hollink et al (n=293; age, 0-18 years).9 Samples were provided by the 
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Dutch Childhood Oncology Group (DCOG, The Hague, The Netherlands; n=141), the 
AML–Berliner-Frankfurt-Münster (BFM) Study Group (Germany and Czech Republic; 
n=128), and the Saint-Louis Hospital (Paris, France; n=24) (Supplementary Table 2.1).9 
Morphological classification and karyotyping were centrally reviewed by each study 
group. Cytogenetic aberrations in this group were distributed representative for the 
frequencies seen in pediatric AML.17, 18
Based on the identification of NUP98/JARID1A in AMKL patients, 105 additional 
samples of newly diagnosed pediatric non-Down Syndrome AMKL patients were 
obtained. These were kindly provided by the aforementioned study groups (n=45), 
and the North-American Children’s Oncology Group (COG, Arcadia, California, United 
States of America; n=60). In total 33 samples, consisting of viable frozen BM or PB were 
available, as well as 72 samples of which only RNA or cDNA was available. 
To investigate the presence of NUP98/JARID1A in Down Syndrome AMKL 
patients, a series (n=16) was provided by the DCOG and the AML-BFM Study Group.
After thawing the samples, leukemic cells were purified as previously described.19 
Blast percentages were assessed morphologically using cytospins stained with a May-
Grünwald-Giemsa staining. Isolation of genomic DNA and total cellular RNA from the 
samples was performed using Trizol reagent. All patients were treated with intensive 
collaborative group cytarabine-anthracycline based pediatric AML treatment protocols. 
Each collaborative study group provided us with centrally reviewed morphological and 
cytogenetic classification and clinical follow-up data of the AMKL patient cohort. 
Institutional review board approval for these studies had been obtained in the 
participating centers. 
Split signal FISH for NUP98
For detection of NUP98 rearrangements, FISH experiments were performed on newly 
diagnosed pediatric AML cases, excluding cases where the driving oncogenic type-II 
abnormality was already known, such as PML/RARA or MLL-rearrangements. Dual-
color FISH analysis for detection of NUP98 breaks was performed on thawed cytospin 
slides using the 44-kb overlapping bacterial artificial chromosome probes RP11-120E20 
and RP11-348A20 (BACPAC Resources Center, Oakland, USA), as described previously.20
Detection of the NUP98/JARID1A transcript
The presence of NUP98/JARID1A and the reciprocal JARID1A/NUP98 were determined 
by RT-PCR (Supplementary Table 2.2a). Purified PCR products were directly sequenced on 
a PRISM 3100 genetic analyzer (Applied Biosystems) and analyzed using CLCWorkbench 
(Version 3.5.1; CLC Bio). 
Cytogenetic and molecular characterization
Samples were screened for cytogenetic aberrations using standard chromosome 
banding analysis at initial diagnosis by the collaborative study groups. All cases with 
unknown karyotype were screened for MLL-rearrangements, and those with a 
reported MLL-rearrangement were confirmed, using split signal FISH for MLL. In case 
of a positive split signal as seen with FISH, partner gene identification was performed 
with translocation-partner specific PCR for the following translocations; MLL/AF6 (also 
known as MLL/MLLT4), MLL/AF9 (also known as MLL/MLLT3), MLL/AF10 (also known as 
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MLL/MLLT10), MLL-ENL (also known as MLL/MLLT1), and MLL-ELL.21 Fusions of RBM15/
MKL1 and CBFA2T3/GLIS2 were detected using conventional karyotyping, RT- PCR and 
sequencing. 
To identify other aberrations, RT-PCR was performed on hotspot areas of the 
following genes; N-RAS, K-RAS, NPM1, MLL-PTD, CEBPA, FLT3, PTPN11, KIT and WT1 as 
previously described by Balgobind et al.1 Primers and probes used for analysing these 
molecular aberrations are shown in Supplementary Table 2.2a. 
Gene expression profiling
Gene expression profiling (GEP) data of 274/293 pediatric AML patients, of which 8 
were classified as AMKL cases, were available from earlier studies.22 Checking RNA 
integrity, processing the Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, 
Santa Clara, CA, USA), and normalizing and analyses of the data were performed as 
described previously.9 Original data are available in the Gene Expression Omnibus 
repository (http://www.ncbi.nlm.nih.gov/geo;accession GSE17855).
Taqman validation of HOX-gene expression levels
GEP data were only available for a limited number of patients with AMKL, hence we 
performed specific real-time quantitative PCR (RT-qPCR) for various HOXA and -B 
genes to study HOX gene expression in AMKL patients. Results obtained with GEP were 
validated with RT-qPCR in a series of pediatric AML cases, and in addition pediatric 
AMKL cases were studied with RT-qPCR. RT-qPCR was performed in duplicate in cases 
with at least 70% blasts. Primer and probe sets are shown in Supplementary Table 2.2b. 
The average cycle threshold (CT) value was used to determine the expression levels of 
the different HOX-genes in comparison to the expression levels of the reference gene 
GAPDH, using the comparative cycle time method. Correlation between GEP data and 
RT-qPCR was examined. 
Statistical analysis
Statistical analyses were performed with SPSS 17.0 (SPSS). Correlation coefficients were 
measured using Spearman’s correlation. Categorical variables were compared using 
the chi-square or Fisher exact test and continuous variables using Mann-Whitney U 
test. To assess outcome the following parameters were used; complete remission (CR), 
defined as less than 5% blasts in the bone marrow, with regeneration of tri-lineage 
hematopoiesis, plus absence of leukemic cells in the cerebrospinal fluid or elsewhere, 
probability of event-free survival (pEFS), defined as the time between diagnosis and first 
event including non-responders (calculated as an event on day 0), death of any cause 
and second malignancies, and probability of overall survival (pOS), defined as the time 
between diagnosis and death. Both pEFS and pOS were estimated by the Kaplan-Meier 
method and groups were compared with the log-rank test. The cumulative incidence 
of non-response or relapse (pCIR), defined as time between diagnosis and relapse and 
with non-responders included as an event on day 0, was analysed by the Kalbfleisch 
and Prentice method and groups were compared with the Gray’s test. Multivariate Cox 
regression analysis was used to determine the independency of prognostic markers. 
Statistical significance was considered if p-values were below 0.05. 
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Results
Identification of the NUP98/JARID1A fusion
Of 293 well-characterized pediatric AML cases, 122 patients with available material 
and in which the driving oncogenic type-II abnormality had not been identified, were 
analyzed with split signal FISH for NUP98-abnormalities. In 26 patients a split signal was 
detected, suggesting a break in the NUP98 gene. Using a candidate gene approach to 
identify potential cytogenetically cryptic fusion partners, we identified JARID1A to be 
fused to NUP98. Subsequently, the entire cohort (n=293) was screened for presence 
of the NUP98/JARID1A fusion, which revealed three additional cases, of whom no 
material for FISH was available. In all patients the fusion was cryptic. Three out of 4 
NUP98/JARID1A positive cases were morphologically diagnosed with AMKL (FAB M7). 
One patient was classified as an acute monoblastic leukemia (FAB M5), and this patient 
was the only NUP98/JARID1A positive case out of 65 (1.5%) acute monoblastic leukemia 
patients (Supplementary Table 2.1).
Figure 2.2. NUP98/JARID1A is a recurrent event in pediatric AMKL. Pie chart showing percentage of 
different type-II aberrations found in pediatric AMKL for the 96 patients of whom all data were available. 
All patients were tested with RT-PCR for NUP98/JARID1A, RBM15/MKL1, CBFA2T3/GLIS2, and tested with 
FISH on MLL-rearrangements, or in case of unavailable material for FISH tested with RT-PCR on MLL-AF6, 
MLL-AF9, MLL-AF10, and MLL-ELL. * Partner gene unknown, tested for fusion to JARID1A, NSD1, NSD3, 
TOP1, DDX10 and PHF23.
Figure 2.1. Sequence analysis of a NUP98/JARID1A positive case. RT-PCR analysis using NUP98- and 
JARID1A-specific primers revealed a NUP98/JARID1A fusion. Sequence analysis confirmed an in-frame 
fusion between NUP98 exon 13 and JARID1A exon 27. The in-frame fusion was identical in 10 out of 11 
cases. 
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NUP98-aberrations in AMKL
To identify the frequency of NUP98/JARID1A in de novo AMKL, we screened an extended 
pediatric AMKL cohort of 105 de novo non-Down Syndrome samples using RT-PCR. 
The NUP98/JARID1A fusion was detected in 11 out of 105 (10.5%) AMKL patients, and 
confirmed with direct sequencing. Sequence analysis showed an identical in-frame 
fusion of exon 13 of NUP98 to exon 27 of JARID1A in 10 cases (Figure 2.1). In 1 case the 
breakpoint of NUP98 was detected in exon 14, and part of exon 14 of NUP98 was fused 
in-frame to exon 27 of JARID1A. The reciprocal product was found in 2 out of 8 cases 
only, three cases could not be tested due to lack of material. 
Split signal FISH of NUP98 could be performed in 25 AMKL cases, and revealed 
four additional cases with a break in the NUP98 gene. In three patients the fusion 
partner has not been identified yet. These patients were negative for NUP98 fusion to 
PHF23, NSD1, TOP1, DDX10, and JARID1A with breakpoints previously described.9, 23, 
24 One patient carried the NUP98/NSD1 fusion. Among the 16 Down Syndrome AMKL 
patients, no NUP98/JARID1A fusions were found. 
Extensive genetic characterization of the AMKL cohort
We further investigated the 105 pediatric AMKL cases for various type-II abnormalities, 
as depicted in Figure 2.2. The classical t(1;22)(p13;q13) fusing RBM15 to MKL1 was 
found in 16 out of 105 patients (15.2%). In 13 out of 105 cases we found the recently 
reported CBFA2T3/GLIS2 fusion, as described by Gruber et al.15 MLL-rearrangements 
were identified in 10/96 cases with available material, i.e. MLL-AF9 (n=6), MLL-AF6 
(n=1), MLL-AF10 (n=1), MLL-AF17 (n=1), and MLL-ENL (n=1). In addition, three MLL-
PTD cases were identified. Other translocations consisted of one case with t(16;21)
(p11;q22), resulting in the FUS/ERG fusion gene, and a t(7;12)(q36;p13), resulting in a 
fusion of HLXB9 with ETV6 in another patient. All aberrations were mutually exclusive.
In 39% of the AMKL cases, currently no type-II aberration could be detected 
using RT-PCR or FISH screening for the abnormalities mentioned above. However, in 
36 cases cytogenetic data did reveal various complex and other random aberrations.
Forty-five out of 105 patients had material available for type-I mutation 
screening. Only 3 out of these 45 patients harboured a type-I mutation in one of the 
screened hot spot areas. All three consisted of a RAS mutation (Table 1.1a). No other 
mutations were found.
Characteristics of genetically distinct groups of pediatric AMKL
When we compared the clinical characteristics of the children with AMKL included in 
this study versus a population-based AMKL cohort included in the AML-BFM 93/98 
studies no significant differences in sex (p=0.88), age (p=1.0) or white blood cell count 
(p=1.0) were seen. Concerning clinical outcome, there were no significant differences 
in event-free (p=0.44) or overall survival (p=0.56), nor in the cumulative incidence of 
relapse (p=0.93).
 The median age at diagnosis of the 105 pediatric AMKL cases was 1.5 years 
(0.1-15.4 years). NUP98/JARID1A positive cases (Table 2.1b) did not differ significantly 
from the other pediatric AMKL cases concerning age at diagnosis (median age 1.8 
years, range 0.9-4.9 years) compared to 1.5 years (range 0.1-15.1 years), respectively 
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Figure 2.3. Distinct HOX expression pattern in NUP98/JARID1A positive cases. (A) Principal component 
analysis of pediatric AML subgroups characterized by specific type-II aberrations was carried out based on 
all HOXA and –B annotating probe sets present on the HGU133 Plus 2.0 microarray by Affymetrix. Each 
circle represent an individual case. Three clusters are observed as indicated by the grey circles. The cluster 
harbouring the NUP98/JARID1A positive cases is the cluster with both HOXA and –B expression. (B) RT-
qPCR expression of HOXA5, -A7, -A9, -A10, -B2, -B3, -B4, -B5 and –B6 in percentage of GAPDH expression 
of pediatric AMKL cases (n=36) grouped by their specific type-II aberration. NUP98/JARID1A cases were 
characterized by high HOXA5, -A9, -A10, -B2, -B3, -B4, -B5 and –B6 expression.
A
B
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(p=0.169); nor in sex (respectively 55% female vs. 53% female); nor in white blood cell 
count at diagnosis (median respectively 11.8 x109/L vs. 16.0 x109/L, p=0.141, Table 2.1a). 
Also in patients with the CBFA2T3/GLIS2 fusion (n=13, Table 2.1c) age at diagnosis, sex 
and white blood cell count did not differ significantly in comparison to all other AMKL 
patients. Patients with AMKL characterized by t(1;22)(p13;q13) (Supplementary Table 
2.3a) were significantly younger in comparison to all other AMKL cases (median 0.5 
yrs vs. 1.6 yrs, p<0.01), but sex, and white blood cell count at diagnosis did not differ 
significantly (Table 2.1a). Moreover, the MLL-rearranged AMKL cases (Supplementary 
Table 2.3b) did not differ significantly from the other AMKL cases for the aforementioned 
clinical characteristics (Table 2.1a). 
HOX-gene expression
Principal component analysis based on HOXA and -B gene expression in the 274 patients 
with available gene expression profiles, as we reported previously, showed that AML 
can be subdivided in three clusters based on HOXA and HOXB expression.9 All four 
NUP98/JARID1A fused patients of whom GEP data were available were categorized 
in the cluster with overexpression of both HOXA and HOXB genes, together with the 
NUP98/NSD1 rearranged cases, DEK/NUP214 rearranged cases and the NPM1-gene 
mutated cases (Figure 2.3a).
Strong correlations (r=0.6192-0.9184, p<0.05) between GEP data and RT-qPCR were 
found for HOXA5, -A7, -A9, -A10, -B2, -B4, -B5, and –B6 (n=40, selection of well-
characterized representative pediatric AML cases, Supplementary Figure 2.1).
We further studied HOXA and –B expression with RT-qPCR in 36 AMKL cases, 
of which 6 were positive for NUP98/JARID1A. The other 30 cases comprised of other 
NUP98 rearrangements (n=4), CBFA2T3/GLIS2 (n=7), MLL-rearrangements (n=4), 
RBM15/MKL1 (n=1), MLL-PTD (n=1), t(7;12) (n=1) and 12 cases with unidentified type-II 
aberration. Significantly higher expression levels of HOXA5, -A9, -A10, and HOXB2,-B3, 
-B4, -B5, and –B6 were found in the NUP98/JARID1A fused patients in comparison to 
the other pediatric AMKL patients (p<0.01) (Figure 2.3b). Of interest, CBFA2T3/GLIS2 
and RBM15/MKL1 translocated patients did not have aberrant HOX gene expression. In 
the MLL-rearranged patients, as expected, we could confirm higher HOXA5, -A7, -A9, 
and –A10 expression, but not HOXB over expression, in comparison to other AMKL 
patients.
Prognostic relevance of NUP98/JARID1A and other genetic subgroups in AMKL
Follow-up data for survival analysis was available in 73 cases. Follow-up data was not 
available for the AAML00531 study of the COG. Patient characteristics did not differ 
between the total cohort (n=105) and the cases used for prognostic markers (n=73), 
and was comparable to other studies earlier described. Overall 5-year pOS in pediatric 
AMKL was 42±6%, and pEFS was 34±6%. The pOS, pEFS and pCIR of the included cohort 
did not show significant differences compared to the pediatric non-DS AMKL patients 
included in the BFM93/98 protocols (p=0.56, p=0.44 and p=0.93 respectively).
 The CR rate of NUP98/JARID1A positive cases was 78%, similar to the 
negative cases (78%). The 5-year pEFS was 22±14% in NUP98/JARID1A positive cases 
(n=9), and 36±6% in the negative cases (p=0.54). Although the 5-year pOS of NUP98/
JARID1A positive cases was 22±14% compared to 45±7% for NUP98/JARID1A negative 
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cases, this difference was not statistically significant (p=0.22). In addition, there was 
no significant difference in pCIR; 56±19% in NUP98/JARID1A positive versus 54±7% in 
NUP98/JARID1A negative cases (p=0.94, Figure 2.4). Out of the 9 patients positive for 
NUP98/JARID1A, 2 were non-responders, 3 died after relapse and 2 patients died in 
complete remission due to treatment-related mortality. Cases with a positive split signal 
FISH on NUP98 or other NUP98-aberration did not differ significantly from other cases 
with respect to pOS, pEFS and pCIR.
 In CBFA2T3/GLIS2 positive patients (n=8), the 5-year pEFS, pOS and pCIR did not 
differ significantly from all other AMKL cases; pEFS was 19±16% in positive cases and 
35±6% in negative cases (p=0.66), 5-year pOS was 35±20% in positive cases compared 
to 42±6% in negative cases (p=0.52), pCIR was 81±21% versus 51±7% at 5-years 
respectively (p=0.21, Figure 2.4).
 The 5-year pOS was significantly better for RBM15/MKL1 positive patients 
(n=11, 82±12% versus 36±6% in negative cases, p=0.043), and 5-year pEFS was also 
significantly better with 73±13% in the positive cases versus 27±6% in other AMKL 
Figure 2.4. Survival estimates of specific type-II aberrations compared to other AMKL. (A) Kaplan-Meier 
estimates of the 5-year overall survival in specific type-II aberrations compared to other AMKL. RBM15/
MKL1 fusion has a significantly higher pOS compared to other AMKL. (B) Kaplan-Meier estimates of the 
5-year event-free survival in specific type-II aberrations compared to other AMKL. Significantly higher pEFS 
is seen in RBM15/MKL1 positive cases versus other AMKL. (C) Cumulative incidence of relapse according to 
the Kalbfleisch and Prentice method in specific type-II aberrations compared to other AMKL. Significantly 
lower relapse rate is seen in RBM15/MKL1 positive patients as pCIR was also significantly better in this 
subgroup versus other AMKL.
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(p=0.039). This was mainly caused by a lower relapse rate as pCIR was also significantly 
lower in this group (9±9% versus 62±7%, p=0.004, Figure 2.4). 
 As cases with RBM15/MKL1 are associated with younger age, we performed 
multivariate analysis for RBM15/MKL1 including age at diagnosis and white blood cell 
count as co-variable. We found that RBM15/MKL1 was not an independent prognostic 
factor for pOS (HR 0.31 [95%CI 0.07-1.36], p=0.12) or pEFS (HR 0.40 [0.12-1.37], 
p=0.15), nor was age for pOS (HR 0.56 [0.24-1.32], p=0.19); and pEFS (HR 0.65 [0.30-
1.41], p=0.28).
Discussion
In this study, we identified fusion of NUP98 located on chromosome 11p15 to JARID1A 
located on chromosome 12p13 as a novel recurrent event in approximately 11% of 
patients with pediatric AMKL. The NUP98/JARID1A fusion is cryptic as NUP98 is located 
3Mb from the 11p telomere and JARID1A is located at the telomeric end of 12p13, and 
therefore undetectable with conventional karyotyping. This fusion gene was mutually 
exclusive with other type-II aberrations. This provides further evidence for the role of 
NUP98 abnormalities in pediatric AML, in addition to the 16% of pediatric CN-AML 
cases which harbour a NUP98/NSD1 fusion.9
The frequency of the NUP98/JARID1A fusion in AMKL is comparable to the 
RBM15/MKL1 fusion (14% in our series), which is a well-known aberration in AMKL, and 
also comparable to the frequency of the recently described CBFA2T3/GLIS2 fusion.16 In 
our series the CBFA2T3/GLIS2 fusion was detected in 12% of the AMKL cases, which 
is lower than reported by Gruber et al (27%) and Thiollier et al (31%).15, 16 The latter 
studies included less patients (n=35 and n=22 respectively) and extensive information 
about selection bias concerning age at diagnosis in these studies is not available. 
Altogether, with the identification of NUP98/JARID1A specific non-random 
type-II abnormalities can now be defined in roughly 60% of pediatric AMKL cases. 
NUP98 breaks were seen in 3% of the cases, but the underlying aberration could not 
be identified. 
 Interestingly, the number of patients with a type-I aberration was very low (7%, 
n=45), as previously reported by Hama et al.25 According to the Gilliland hypothesis, 
collaborating type-I and -II aberrations are needed in order to develop full-blown 
leukemia.6 Recent evidence suggests that different types of NUP98 fusions are frequently 
associated with FLT3/ITD (56-91%) and WT1 (36-50%).9, 26, 27 However, all AMKL patients 
were negative for WT1 and FLT3/ITD mutations, including the NUP98-rearranged cases. 
Therefore, the collaborating type-I events in AMKL remain to be elucidated.
Recently, we described NUP98/NSD1 as an independent variable for dismal 
outcome in pediatric AML, due to a high frequency of relapsed/refractory disease.9 
Although outcome of the NUP98/JARID1A cases was poor, there was no significant 
difference compared with other AMKL cases. However, outcome in AMKL patients 
in general was poor with a 5-year survival rate of only 41%, and a high incidence of 
refractory disease or relapse despite modern intensive therapy. Exceptions were 
patients with the RBM15/MKL1 fusion, which had a clearly better outcome with 
approximately 80% overall survival, which was due to a low relapse rate. However, this 
fusion transcript could not be confirmed as an independent prognostic factor, probably 
due to the number of patients.
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By unravelling the driving oncogenic events, the potential for targeted therapy 
needs to be taken into account which may ultimately increase survival rates. A prime 
example of the potential for targeted therapy in HOX-upregulated AML is the activity 
of DOT1L inhibitors in MLL-rearranged AML in vitro and in mouse-models.28 Similar to 
NUP98/NSD1 positive patients, NPM1 mutated patients and in patients with a DEK/
NUP214 fusion, NUP98/JARID1A is associated with higher expression of several HOXA 
and –B genes, suggesting a common mechanism of leukemogenesis in these cases. This 
expression pattern is distinct from MLL-rearranged cases, which are characterized by 
overexpression of HOXA genes only. The leukemogenic role of activation of HOXB genes 
is however unknown to date. 
NUP98, like MLL, has many different partner genes.10 Almost all fusion genes 
contain the NUP98 promoter and nearly all the NUP98 FG/GLFG repeats. These 
GLFG-repeats result in recruitment of the co-activator CREBBP/p300, causing histone 
acetylation, resulting in transcriptional activation of different target genes including 
several HOX-genes as shown by he principal component analysis (Figure 2.2).6, 29, 30 
This may suggest that specific histone acetyltransferase inhibitors may be potential 
candidate drugs in NUP98-rearranged leukemias.
JARID1A contains three plant homeodomain (PHD) fingers of which the 
C-terminal PHD finger is fused to NUP98 in the NUP98/JARID1A fusion. This is essential 
for leukemogenic transformation as demonstrated by Wang et al.31 This PHD finger 
recognizes various histone 3 lysin 4 methylation (H3K4me) states.32 Fusion of NUP98 
to this PHD finger of JARID1A leads to methylation of H3K4, which results in sustained 
upregulation of HOX-genes and other transcription factors, maintaining a stem-cell 
phenotype.31, 33 This mechanism might function as second druggable target in NUP98/
JARID1A positive patients. In absence of available cell-lines we are currently generating 
a model to study this further. 
As AMKL is rare and frequently associated with myelofibrosis, it is often difficult 
to obtain sufficient material for additional laboratory studies. Therefore we had to 
obtain samples from various regions of Europe and from North America. A potential 
drawback of that approach is that patients were treated on different protocols over 
a longer period of time. However, all protocols consisted of intensive chemotherapy 
using an anthracycline and cytarabine backbone, including stem-cell transplantation 
in selected cases. Moreover, when comparing the clinical characteristics and outcome 
data of the patients presented in this paper versus a population-based cohort of the 
AML-BFM Study Group no significant differences were found in those parameters, 
suggesting that our cohort was representative for pediatric AMKL. 
In conclusion, we report NUP98/JARID1A as a novel recurrent cryptic 
translocation which appears to be specific for pediatric AMKL. NUP98/JARID1A is 
associated with a high expression of HOXA and HOXB genes, indicative of a stem-
cell phenotype, similar to what we reported for NUP98/NSD1. With exception of the 
RBM15/MKL1 translocated patients, non-Down-Syndrome AMKL in general has a poor 
outcome, including the NUP98/JARID1A cases.
Taken together, with the identification of the NUP98/JARID1A fusion, a type-II 
aberration can now we found in approximately 60% of pediatric AMKL cases.
ch1-6.indd   39 13-4-2016   21:58:51
Chapter 2: NUP98/JARID1A in pediatric AMKL
Table 2.1a. Patient characteristics of different subgroups identified in pediatric 
AMKL.
* Significant younger age at diagnosis in RBM15/MKL1 positive patients versus others (p<0.01).
Abrreviations: n indicates number of cases; y, years; WBC, white blood cell count.
NUP98-JARID1A 
positive 
RBM15/MKL1 
positive 
CBFA2T3/GLIS2 
positive
MLL-
rearranged
Other 
Total, n 11 16 13 13 52
Age, y
   Median 1.8 0.5 * 1.4 1.8 1.6
   Range 0.9-4.8 0.1-2.7 0.6-3.4 0.7-12.0 0.1-15.1
Sex, %
   Female 55 67 77 20 48
   Male 45 33 23 80 52
WBC, x109/L
   Median 11.8 15.6 19.1 11.2 14.8
   Range 5.9-20.1 5.6-32.7 9.5-300.1 1.1-31.0 1.1-378.5
Karyotype, 
n (%)
   MLL - - - 9 (90) -
   t(7;12) - - - - 1 (1.9)
   CN-AML - 2 (13.3) 1 (7.7) - 5 (9.6)
   Other 10 12 (80) 8 (61.5) - 37 (71.2)
   Unknown 1 1 (6.7) 4 (30.8) 1 (10) 9 (17.3)
Mutations, 
n (%)
   RAS - - - 1 (7.7) 2 (3.8)
   CEBPA - - - - -
   MLL-PTD - - - - -
   FLT3-ITD - - - - -
   FLT3-TKD - - - - -
   KIT - - - - -
   WT1 - - - - -
   PTPN11 - - - - -
   NPM1 - - - - -
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Table 2.1b. Individual characteristics of the NUP98/JARID1A-positive (n=12) 
pediatric AML cases, including one FAB M5 case. 
* Mutations screened are hotspot areas in NRAS, KRAS, KIT, WT1, CEBPA, FLT3, and PTPN11. See 
materials and methods section for more details. Abbreviations: y indicates years; Sex M, male; Sex F, 
female; WBC, white blood cell count; FAB, French-American-British classification; NA, not available.
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Table 2.1c. Individual characteristics of the CBFA2T3/GLIS2-positive (n=13) pediatric 
AMKL cases. 
* Mutations screened are NRAS, KRAS, KIT, WT1, CEBPA, FLT3, and PTPN11. See materials and methods 
section for more details. Abbreviations: y indicates years; Sex M, male; Sex F, female; WBC, white blood 
cell count; FAB, French-American-British classification; NA, not available. 
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Supplementary data
Supplementary figure 2.1. Correlation of GEP-data and qRT-PCR in several HOX genes. Correlation bet-
ween HOXA5, -A7, -A9, -A10, -B2, -B4, -B5, and –B6 expression values as measured by Affymetrix Human 
Genome U133 Plus 2.0 Array and RT-qPCR, assessed with Spearman’s rho correlation coefficient. Strong 
positive correlation was found for HOXA5, -A7, -A9, -A10, -B2, -B4, -B5, and –B6.
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Supplementary table 2.1. Clinical and molecular characteristics of NUP98/JARID1A positive 
versus –negative cases in pediatric AML (n=293).
NUP98-JARID1A 
positive patients (n=4)
NUP98-JARID1A negative 
patients (n=289) p
Age, y 0.008
     Median 1.6 9.5
      Range 1.2-5.9 0.1-18
Sex, % 0.637
      Female 40 42.7
      Male 60 57.3
WBC, x109/L 0.253
      Median 14.9 42.3
      Range 8.4-155.9 1.1-483.0
FAB type, n (%)
      M0 - 13 (4.5)
      M1 - 38 (13.1)
      M2 - 53 (18.3)
      M3 - 20 (6.9)
      M4 - 80 (27.7)
      M5 1 (25.0) 64 (22.1)
      M6 - 4 (1.4)
      M7 3 (75.0) 6 (2.1)
      Mixed lineage - 2 (0.7)
      Missing - 9 (3.1)
Cytogenetic aberrations
      MLL - 66 (22.8)
      AML-ETO - 25 (8.7)
      CBFB-MYH11 - 35 (12.1)
     t(15;17) - 18 (6.2)
     CN-AML - 62 (21.5)
      Other 4 (100.0) 64 (22.1)
      Unknown - 19 (6.6)
Mutations, n (%)
     RAS 1 (25.0) 56 (19.4)
     CEBPA - 21 (7.3)
     MLL-PTD - 6 (2.1)
     FLT3-ITD - 60 (20.8)
     FLT3-TKD - 10 (3.5)
     KIT - 20 (6.9)
     WT1 - 29 (10.0)
     PTPN11 - 4 (1.4)
     NPM1 - 21 (7.3)
Abbreviations: n indicates number of cases, y, years; WBC, white blood cell count; FAB, French-American-
British classification.
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Supplementary table 2.2A. Primers and PCR conditions molecular characterization.
Gene Region Direction Primer-sequence PCR condition
NUP98
JARID1A
Exon 12
Exon 27
Forward
Reverse
5’-TGGACAGGCATCTTTGTT-3’
5’TCAGCTCCTTTGATTTGTCT 3’
10’ 95°C, 40 x (15” 95°C, 1’60°C), 10’ 72°C
JARID1A
NUP98
Exon 26 
Exon 14
Forward
Reverse
5’CACCCCAAGGAAACAAC3’
5’GCCCATCAAAGAGATGTG 3’
10’ 95°C, 40 x (15” 95°C, 1’60°C), 10’ 72°C 
RBM15
MKL1
Exon 1
Exon 6-7
Forward
Reverse
5’ TTCCCACCTTGTGAGTTCT 3’ 
5’ TCAGCCGAGGTCTCTTC 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
CBFA2T3
GLIS2
Exon 11
Exon 5
Forward
Reverse
5’ AGCGCACGAGCTCAT 3’
5’ GAGGGGCAGGAAGAACT 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C 
NUP98
TOP1
Exon 12
Exon 10
Forward
Reverse
5’ TGGACAGGCATCTTTGTT 3’
5’ GTCATGAAGCTGAGCCC 3’
10’ 95°C, 35x (15” 95°C, 1’ 60°C), 10’ 72°C
NUP98
DDX10
Exon 12
Exon 7
Forward
Reverse
5’ GTTTTGGCACAAATACCAG 3’ 
5’ TGCAGCTCACAGACTATGTAG 3’
 10’ 95°C, 35x (15” 95°C, 1’ 60°C), 10’ 72°C
KRAS Exon 2
Forward
Reverse
5’ CGTCGATGGAGGAGTTT 3’ 
5’ AACCCAAGGTACATTTCAGA 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
NRAS
Exon 2
Exon 3
Forward
Reverse
Forward
Reverse
5’ GGGGGTTGCTAGAAAACTA 3’
5’ ATCCGACAAGTGAGAGACA 3’
5’ CCCAGGATTCTTACAGAAAA 3’
5’ TCCCCATAAAGATTCAGAAC 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C 
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
CEBPA
Whole 
gene
Forward
Reverse
Forward
Reverse
5’ CGCCATGCCGGGAGAACTCT 3’
5’ CTTGGCTTCATCCTCCTCGC 3’
5’ CGGCCGCTGGTGATCAAG 3’
5’ CCAGGGCGGTCCCACAGC 3’ 
10’ 95°C, 35x (15” 95°C, 1’ 60°C, 1’ 72°C), 10’ 72°C
10’ 95°C, touchdown 20 cycles (15” 95°C, 1’ 70-60°C, 
1’ 72°C), 20x (15” 95°C, 1’ 60°C, 1’ 72°C), 10’ 72°C
KIT
Exon 8
Exon 17
Forward
Reverse
Forward
Reverse
5’ CCGCCTCCTTGTACCTT 3’ 
5’ TTCAGCAAACAAAATTAATGTCTA 3’
5’ TCCTCCAACCTAATAGTGTATTC 3’
5’ CATTCCGAAATCAAACAGTT 3’
10’ 95°C, touchdown 20 cycles (15” 95°C, 1’ 66-56°C, 
1’ 72°C), 14x (15” 95°C, 1’ 56°C, 1’ 72°C), 10’ 72°C 
10’ 95°C, touchdown 20 cycles (15” 95°C, 1’ 66-56°C, 
1’ 72°C), 14x (15” 95°C, 1’ 56°C, 1’ 72°C), 10’ 72°C 
MLL PTD’s
Forward
Reverse
5’ AGGAGAGAGTTTACCTGCTC 3’
5’ GGAAGTCAAGCAAGCAGGTC 3’ 
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
WT1
Exon 7
Exon 9
Forward
Reverse
Forward
Reverse
5’ CATGGGGATCTGGAAGCAGGTC 3’
5’ TGGGTCCTTAGCAGTGTGAGA 3’
5’ TAGGGCCGAGGCTAGACC 3’
5’ TTCCAATCCCTCTCATCACAAT 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C 
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
FLT3
Exon 14,15
Exon 20
Forward
Reverse
Forward
Reverse
5’ GCAATTTAGGTATGAAAGCCAGC 3’
5’ CTTTCAGCATTTTGACGGCAACC 3’
5’ TCACCGGTACCTCCTACTG 3’
5’ AAATGCACCACAGTGAGTG 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C 
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
PTPN11
Exon 3
Exon 13
Forward
Reverse
Forward
Reverse
5’ TTGGGTTTCTTTCAACACTT 3’
5’ GCCTTTGGAGTCAGAGAGT 3’ 
5’ TGGCTCTGCAGTTTCTCT 3’
5’ CATTCCGAAATCAAACAGTT 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
 
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
NPM1 Exon 12
Forward
Reverse
5’ CTGGTGGTAGAATGAAAAATAGAT 3’ 
5’ GGCAGGGACATTCTCATAG 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C), 10’ 72°C
Abbreviations: PCR indicates polymerase chain reaction; PTD, partial tandem duplication.
Supplementary table 2.2B. Primers and probes RT-qPCR HOX genes.
Abbreviations: PCR indicates polymerase chain reaction.
Gene Direction Primer-sequence PCR condition
HOXB2
Forward
Reverse
Probe
5’ CCTCCCGGTCCTTTC 3’ 
5’ TGCCCAATATTTTAGAAGAAG 3’ 
5’ AAATCGAGCCTCTCCCACCC 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C)
HOXB3 Forward
Reverse
5’ TGCTGCCTCCATCTCA 3’ 
5’ TGCCTGGGACAGTTTG 3’
10’ 95°C, 40x (15” 95°C, 1’ 61°C)
HOXB4
Forward
Reverse
Probe
5’ AGGGCCTTCCTCTGAAA 3’ 
5’ GAGGGGCACATTTTATTTC 3’ 
5’ AGTTCTGGGAGCTGGGCACTACT 3’ 
10’ 95°C, 40x (15” 95°C, 1’ 60°C)
HOXB5 Forward
Reverse
5’ AAGGGATGGTATTGAGAAGAG 3’ 
5’ CCGCAAAGACAGATTTCA 3’ 
10’ 95°C, 40x (15” 95°C, 1’ 60°C)
HOXB6 Forward
Reverse
5’ CCCGCTGAGACATTACC 3’
5’ CCCAAAGGAGGAACTGTT 3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C)
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Supplementary table 2.3A. Individual characteristics of the RBM15/MKL1-positive (n=16) 
pediatric AMKL cases.
* Mutations screened are NRAS, KRAS, KIT, WT1, CEBPA, FLT3, and PTPN11. See materials and methods 
section for more details. Abbreviations: y indicates years; Sex M, male; Sex F, female; WBC, white blood cell 
count; FAB, French-American-British classification; NA, not available.
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Supplementary table 2.3B. Individual characteristics of the 11q23-mutated (n=13) pediatric 
AMKL cases.
* Mutations screened are NRAS, KRAS, KIT, WT1, CEBPA, FLT3, and PTPN11. See materials and methods 
section for more details. Abbreviations: y indicates years; Sex M, male; Sex F, female; WBC, white blood cell 
count; FAB, French-American-British classification; NA, not available.
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Abstract
Pediatric acute megakaryoblastic leukemia (AMKL) in non-Down Syndrome patients is a 
rare subtype of pediatric acute myeloid leukemia (AML), characterized by poor outcome. 
The fusion NUP98/KDM5A, which is present in ~10% of these cases, is hypothesized to 
result in a differentiation arrest. KDM5A, formerly known as retinoblastoma binding 
protein2 (RBP2), forms complexes with pRB that are detected in response to signals that 
affect cell-cycle exit and induction of differentiation. While studying IKZF1 alterations 
in pediatric AML using MLPA, we were triggered to study the role of RB1, located on 
chromosome 13, since this method identified RB1 loss exclusively in three patients 
with NUP98/KDM5A translocated AMKL. We screened a selected cohort of pediatric 
AMKL cases (n=31), non-AMKL NUP98/KDM5A translocated cases (n=2), and pediatric 
AML cases with a karyotypic chromosome 13 abnormality (n=5) for RB1 deletions 
and mutations. All 8 NUP98/KDM5A translocated AMKL cases exclusively showed a 
heterozygous RB1 deletion. Aditionally, one of these cases also showed a mutation in 
RB1, resulting in a stopcodon. 
To analyze the effect of NUP98/KDM5A and RB1 deletions on differentiation 
and proliferation, we transduced the murine 32D cell-line with NUP98/KDM5A, and 
performed shRNA knockdown of Rb1. Expression of NUP98/KDM5A alone resulted in a 
partial differentiation arrest, accompanied by overexpression of HOXA and HOXB genes, 
and a partial G1 cell cycle arrest. Knockdown of Rb1 reverted the arrest to normal cell 
cycle progression. 
We conclude that RB1 deletions cooperate with the NUP98/KDM5A 
translocation in AMKL leukemogenesis to offset the cell cycle arrest induced by the 
fusion gene.
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Introduction
Pediatric acute megakaryoblastic leukemia (AMKL) in non-Down Syndrome patients 
is a rare subtype of pediatric acute myeloid leukemia (AML) with a poor prognosis.1-5 
AML arises as a result of collaborative genetic aberrations.6, 7 Recently, several novel 
abnormalities have been described in pediatric AMKL, such as CBFA2T3/GLIS2, and 
NUP98/KDM5A, in addition to well-known aberrations such as KMT2A-rearrangements 
and t(1;22)(p13;q13). 1, 2, 4 NUP98/KDM5A occurs in ~10% of pediatric AMKL, and thus 
far no collaborative genetic aberrations have been identified.1, 2, 4, 8   
KDM5A is a histone lysine specific demethylase, originally identified as a 
retinoblastoma 1 (RB1) binding protein and previously named Retinoblastoma Binding 
Protein 2 (RBP2), although its role in the RB1 pathway has not been fully understood.9-11. 
RB1 is a tumor suppressor gene localized on chromosome band 13q14. RB proteins (pRB) 
play an important role in regulating the cell cycle checkpoint from the G1 to S phase, 
by repressing E2F. The effects of RB1 inactivation are cell type specific, and described 
in a wide variety of cancers.12-14 Depletion of KDM5A has been shown to result in a 
block of proliferation and expression of differentiation markers in Saos-2 cells, a human 
osteosarcoma cell line, and similar effects were seen with overexpression of Rb1.15 
Triggered by our MLPA results, that showed RB1 loss in three patients with 
NUP98/KDM5A translocated AMKL while studying IKZF1 alterations in pediatric AML16, 
we further explored the role of RB1 in the leukemogenesis of pediatric AMKL with 
NUP98/KDM5A rearrangements, by screening a large representative cohort of pediatric 
AML cases (n=259) for RB1 deletions, and an additional cohort (n=38), selected for 
AMKL, NUP98/KDM5A-rearrangements and cases with chromosome 13 aberrations in 
the karyotype, for deletions and mutations of RB1. We showed that in pediatric AML 
RB1 deletions were exclusively found in all included NUP98/KDM5A positive AMKL. In a 
cell line model, NUP98/KDM5A alone resulted in a differentiation arrest, accompanied 
by a partial G1 arrest. NUP98/KDM5A in combination with a RB1 deletions did not 
result in a G1 arrest. We conclude that RB1 deletions cooperate with the NUP98/
KDM5A translocation in AMKL leukemogenesis to offset the cell cycle arrest induced by 
the fusion gene.
Material and Methods
Patient samples and clinical characteristics
Patient samples, clinical characteristics and follow-up data were kindly provided by the 
Dutch Childhood Oncology Group (DCOG, The Netherlands), the AML–Berliner-Frankfurt-
Münster Study Group (Germany and Czech Republic), the Saint-Louis Hospital (Paris, 
France), and the St Jude Children’s Research Hospital (Memphis, TN, USA). Institutional 
review board approval for these studies had been obtained in the participating centers. 
Morphological and cytogenetic classification were centrally reviewed by each study 
group. Data on frequently seen mutations was available from earlier studies.1, 16 
Leukemic cells were purified as previously described.17 Blast percentages were assessed 
morphologically using cytospins stained with a May-Grünwald-Giemsa staining. 
Isolation of genomic DNA and total cellular RNA from the samples was performed using 
Trizol reagent. Gene expression profiles using the HGU133 Plus 2.0 microarray platform 
(Affymetrix, Santa Clara, CA, USA) were available from earlier studies.18 Original data 
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are available in the Gene Expression Omnibus repository (http://www.ncbi.nlm.nih.
gov/geo; accession GSE17855).
Multiplex ligant-dependent probe amplification
Multiplex ligation-dependent probe amplification (MLPA) was performed on 250ng DNA 
using the SALSA MLPA-kit p335-B1;ALL-IKZF1 for analysis of RB1 exon 6, 14, 19, 24 and 
26 and the p047-C1/D1;RB1 kit for analysis of all RB1 exons (MRC Holland, Amsterdam, 
The Netherlands, data available on http://www.mlpa.com). The data were analyzed 
with GeneMarker (version 1.85; SoftGenetics, State College, PN, USA). The data were 
normalized to reference probes and control samples. A deletion was defined as a peak 
ratio below 0.75, an amplification was defined as a peak ratio above 1.25.19
Mutational analysis of RB1
Using reverse transcriptase polymerase chain reaction (RT-PCR) and direct-sequencing, 
the complete coding region of RB1 (exon 1 through exon 27) was screened for 
mutations (Primers; Supplementary Table 3.1). Purified PCR products were directly 
sequenced on a PRISM 3100 genetic analyzer (Applied Biosystems) and analyzed using 
CLCWorkbench (Version 3.5.1; CLC Bio, Aarhus, Denmark). Reference genome used was 
ENST00000267163. 
Rb1 knockdown experiments in an inducible NUP98/KDM5A translocated cell line model
To create a cell line model the Zeocin resistant and doxycycline inducible pTripZ vector 
was used (Open Biosystems (GE Healthcare Dharmacon), Eindhoven, The Netherlands). 
The full length fusion of NUP98/KDM5A was PCR amplified using cDNA of a positive 
patient, and cloned into this vector, resulting in pTripZ-NUP98/KDM5A (pT-NK). As a 
leukemic fusion control full length NUP98/NSD1 was PCR amplified from cDNA of a 
positive patient, and cloned into the vector, resulting in pTripZ-NUP98/NSD1 (pT-NN). As 
a negative control, a pTripZ vector without the fusion gene was used (pT-Empty). Lentiviral 
particles were produced in HEK293T cells and transduction occurred during a 45 
minute 1800 rpm spin-oculation of 5x106 32D cells (DSMZ, Braunschweig, Germany, 
authentication using DNA fingerprinting, last tested December 2015), an IL3 growth 
factor dependent cell line established from murine bone marrow cells, altered with 
overexpression of the human granulocyte colony stimulating factor receptor (kindly 
provided by M. Jongen-Lavrencic, department of Hematology, Erasmus MC, Rotterdam, 
the Netherlands; 32D cell line purchased from DSMZ, Braunschweig, Germany). 36 
hours after transduction, cells were positively selected for Zeocin resistance, with 
750ug/mL Gibco Zeocin (Life Technologies, Bleiswijk, the Netherlands). 
pLKO.1 mission short-hairpin RNA vector TRCN0000218099 (/sh99) against 
murine Rb1 with G418 (Geneticin) selection marker was purchased from Sigma-
Aldrich (Zwijndrecht, the Netherlands). Using restriction enzymes for removal of the 
Rb1 targeting sequence of the pLKO.1 mission vector, an empty control (/shEmpty) was 
created. Virus production and transduction was performed as above in 5x106 cells 
of 32DpT-NK, 32DpT-NN, 32DpT-Empty and in 32D non-infected (32DNI) cells. After 36h cells 
were positively selected for G418 resistance, using 500ug/mL G418 (Life Technologies, 
Bleiswijk, the Netherlands), and a non-infected shRNA control (/NI) was included for all 
aforementioned conditions as negative controls. 
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All cell cultures were divided in two, of which in one condition the vector was 
induced by adding 1.0 ug/mL doxycycline hyclate (Sigma-Aldrich, Zwijndrecht, the 
Netherlands) on day -2, 0, 3, 5, 7 and 10. 
RNA was extracted using a Rneasy minikit (Qiagen, Venlo, the Netherlands) 
according to manufacturer’s protocol. Expression levels of Rb1, the fusion genes 
NUP98/KDM5A and NUP98/NSD1, and several Hoxa and Hoxb genes were analysed 
using a SybrGreen based quantitative real-time PCR, with murine Gapdh as reference 
gene (primers; Supplementary Table 3.1). 
DNA content analysis to assess cell-cycle distribution was done using Vybrant 
DyeCycle Violet (Life Technologies, Bleiswijk, the Netherlands) according manufacturers’ 
protocol. Experiments were performed in quintuplet and repeated two times.
Differentiation assay in an inducible NUP98/KDM5A translocated cell line model
Differentiation analyses were performed in duplicate by depletion of IL3 from the cell 
culture medium followed by the addition of 100ng/mL recombinant human granulocyte 
colony stimulating factor (rh G-CSF, ImmunoTools, Friesoythe, Germany) for 11 days. 
Differentiation towards the granulocyte lineage was assessed by flow cytometry 
using the anti-mouse Ly-6G (Gr-1) antibody (BD Biosciences, Breda, The Netherlands) 
in addition to morphologic analysis of May-Grunwald-Giemsa stained cytospins. Cell 
cultures were analysed on days 0, 3, 4, 6, 7, 10 and 11.
Statistical analyses 
Statistical analyses were performed with IBM SPSS 21 (IBM, Armonk, NY, USA). To 
compare the gain of percentages of cells in different cell cycle phases, the Mann-
Whitney test was used to compare two groups, and the Kruskal-Wallis test to compare 
three or more groups. Statistical significance was considered if p-values were below 
0.05. 
Results
Deletions of RB1 are exclusively found in NUP98/KDM5A rearranged pediatric AMKL
In total, samples of 259 pediatric de novo AML cases, including 8 (3%) AMKL cases, 
were screened with the MLPA p335-B1;IKZF1 kit as previously described.16 The median 
age of children included in this cohort was 9.6 years (range 0.1-18.0 years). Five cases 
were positive for NUP98/KDM5A, 3 of which were AMKL cases, and 2 with FAB-M5 
morphology. Of the 259 pediatric cases, 3 cases showed a heterozygous RB1 deletion of 
exon 6, 14, 19, 24 and 26. All 3 RB1 deleted cases were NUP98/KDM5A rearranged AMKL 
cases (Table 3.1A). The non-AMKL NUP98/KDM5A cases both carried an amplification 
of IKZF1, as a result of a trisomy of chromosome 7, as evident from the karyotype (Table 
3.1B). 
To confirm the association between RB1 deletional events and NUP98/KDM5A, 
an additional cohort, specifically selected for AMKL, NUP98/KDM5A-rearrangements 
and cases with cytogenetic aberrations of chromosome 13, was collected. In total, 38 
cases, of which 11 were included in the aforementioned cohort, were analyzed for 
mutational screening and MLPA for RB1, including 8 samples of NUP98/KDM5A positive 
AMKL, 23 pediatric non-DS AMKL cases lacking NUP98/KDM5A rearrangements, 2 non-
AMKL NUP98/KDM5A positive cases, and 5 cases with a chromosome 13 abnormality 
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in the karyotype (Table 3.1B, Supplementary Table 3.2). To analyze the frequency of 
partial or complete RB1 deletions in this cohort, we used the MLPA p047-C1/D1;RB1 kit, 
containing an unique probe in every exon of RB1. 
This analysis revealed 8/38 carried a heterozygous deletion of RB1 (Figure 3.1). 
Remarkably, all 8 RB1-deleted cases were present in NUP98/KDM5A rearranged AMKL 
(Table 3.1B, Supplementary Table 3.2). Of the RB1 deleted cases, three had germline 
or remission DNA material available, all of which carried two copies of RB1, suggesting 
that the deletions in RB1 are somatic. None of the other samples in this selected cohort 
showed a deletion of RB1.
In one patient harboring a heterozygous RB1 deletion, a point mutation resulting 
in a stop-codon on the remaining allele was found with mutational screening. No other 
patients were identified that carried a RB1 mutation, however 13 of the samples had 
low blast counts (<50%) after purifying the cells, therefore we cannot exclude false-
negative results in some patients. Both non-AMKL NUP98/KDM5A positive cases 
showed a trisomy 7 and therefore presented with an IKZF1 amplification based on 
MLPA; in addition one of these cases was identified with a mutation in the RAS-pathway 
(Table 3.1B).
Gene expression profiles show low RB1 and high KDM5A expression in NUP98/KDM5A 
positive AMKL cases. 
Gene expression data was available from 254 pediatric AML cases from previous studies, 
including 4 NUP98/KDM5A positive cases, of which 3 were AMKL combined with an 
RB1 deletion, and one FAB-M5 case with two copies of RB1.1, 18 Despite small numbers, 
analysis suggested a lower expression level of RB1 in the RB1 deleted cases (n=3 vs 
n=255, p=0.038, Supplementary Figure 3.1A), and a higher KDM5A expression in the 
NUP98/KDM5A positive cases (n=4 vs n=254, p=0.031, Supplementary Figure 3.1B). 
Expression levels obtained with micro-array were validated with qPCR, and expression 
was strongly correlated for RB1 as well as for KMD5A (r=0.745 and r=0.719 respectively, 
Supplementary Figure 3.1C and 3.1D). These results indicate that heterozygous deletion 
of RB1 leads to lower RB1 expression, and the presence of the NUP98/KDM5A fusion 
gene leads to higher expression of KDM5A. 
32D cells transduced with NUP98/KDM5A and NUP98/NSD1 show high Hoxa and Hoxb 
gene expression 
32D cells (32DNI) were transduced with constructs carrying either NUP98/KDM5A (pT-
NK), NUP98/NSD1 (pT-NN), or empty vector control (pT-Empty) and samples were 
analyzed for expression of the fusion genes by qPCR at 0, 3, 5, 7, and 10 days after 
transduction. 32DpT-NK and 32DpT-NN cells demonstrated low level expression of their 
fusion genes in the absence of doxycycline, and high expression levels upon induction 
with doxycycline (Supplementary Figure 3.2).
No expression of the fusion genes was found when not introduced to the cell, 
regardless of induction with doxycyline. Expression of the fusion gene was stable during 
the experiment, with measurements over 10 consecutive days. Expression of NUP98/
KDM5A and NUP98/NSD1 protein of the pTripZ-vector with NUP98/KDM5A and NUP98/
NSD1 respectively, was confirmed by western blotting and immunofluorescence in 
HEK293 cells (Supplementary Figure 3.3). 
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Patients with the NUP98/KDM5A and NUP98/NSD1 translocation are 
characterized with high HOXA and HOXB expression.1, 18 In the doxycycline induced 
32DpT-NK and 32DpT-NN cells we found similar elevations in Hoxa and Hoxb expression, 
whereas 32DpT-Empty showed sustained low level expression of Hox genes after induction 
with doxycycline (Supplementary Figure 3.4).
To evaluate the effect of Rb1 depletion on Hox locus upregulation, an Rb1 
specific shRNA (sh99) or a control shRNA lentiviral construct (shEmpty) was introduced 
into the cell lines. Knockdown of Rb1 was confirmed by qPCR and showed more than 
70% reduction in Rb1 expression in the cells after selection with G418 (Supplementary 
Figure 3.2B). Hoxa and Hoxb expression was found to be independent of Rb1 knockdown, 
suggesting that RB1 deletion is not required for Hox upregulation by the fusion gene 
(Supplementary Figure 3.4).
NUP98/KDM5A positive cells show a differentiation arrest
To assess the effects of NUP98/KDM5A and NUP98/NSD1 fusion proteins on 
differentiation, 32DpT-NK, 32DpT-NN and 32DpT-Empty were exposed to human G-CSF. The 32D 
cells containing an empty vector differentiated over time as demonstrated by increasing 
Gr1 expression with greater than 65% positivity by day 11, whereas NUP98 fusion positive 
cells lacked this granulocyte differentiation phenotype with less than 30% Gr1 positivity 
at the same time point (Figure 3.2) , indicative of a differentiation arrest. This confirmed 
the results previously described.20-22. Analyses of the cells with Rb1 knockdown showed 
that this differentiation arrest persists, suggesting the differentiation arrest to be 
driven by the fusion gene and not dependent on Rb1 depletion. May-Grünwald-Giemsa 
staining of the cells for morphology was consistent with flow cytometry results with a 
paucity of mature granulocytes in fusion containing cells (Figure 3.2). 
NUP98/KDM5A positive cells show a G0-G1 arrest dependent of Rb1 expression
To evaluate cell cycle progression in our model, the transduced cells and controls were 
analyzed with DyeCycle Violet staining. A significant increase in G0-G1 arrested cells 
was found in 32DpT-NK, but not in 32DpT-NN, 32DNI, and 32DpT-Empty as measured by a gain 
in G0-G1% upon doxycycline induction (mean increase of cells in G0-G1 phase 15.8%, 
versus -2.2%, -1.6% and 0.5%, respectively, p<0.0001, Figure 3.3A). This suggests that 
NUP98/KDM5A induces a portion of cells to undergo cell cycle arrest that may limit its 
ability to transform cells in the absence of a cooperating mutation.
Rb1 has a known role in cell cycle progression, therefore we examined the 
ability of Rb1 knockdown to relieve NUP98-KDM5A carrying cells of the observed G0-
G1 arrest. Rb1 knockdown did not alter the number of cells in G0-G1 phase in cells 
lacking the NUP98/KDM5A fusion gene (data not shown). In contrast, a significantly 
lower number of cells were in the G0-G1 phase was found in Rb1 depleted NUP98/
KDM5A cells compared to Rb1 expressing cells (mean 8.4%, versus 15.8% in 32DpT-NK/NI 
and 14.9% in 32DpT-NK/shEmpty, p<0.005, Figure 3.3B). We conclude that deletion of Rb1 in 
NUP98-KDM5A positive cells relieves the cell cycle arrest induced by the fusion.
Discussion
We recently described NUP98/KDM5A as a recurrent fusion gene in pediatric non-DS 
AMKL. This translocation is not fully exclusive for this morphological subtype, but very 
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Figure 3.2. 32D cells expressing NUP98/NSD1 and NUP98/KDM5A arrest differentiation of myeloid 
progenitors. Cells were untreated or treated with 1.0µg/mL of doxycycline. After depleting the cells from 
IL3, cells were induced for differentiation for 11 days with 100ng/ml of GCSF. (A) May-Grunewald-Giemsa 
staining of 32D cells expressing NUP98-NSD1, NUP98/KDM5A or control (empty vector). (B) Fluorescence-
activated cell sorting analysis was carried out for GR1 positive cells.
Figure 3.1. MLPA using the p047-RB1 kit shows a deletion of RB1 in NUP98/KDM5A positive AMKL cells. 
Left panel shows a normal control, with a peak ratio of 0.75-1.25 of all RB1 probes included in the p047-
RB1 kit indicated in green, and control probes in blue. Right panel shows a heterozygous deletion of the 
probes located in RB1 as indicated in red, and a normal peak ratio of the control probes, indicated in blue. 
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Figure 3.3. NUP98/KDM5A leads to a significant higher gain in G0-G1 percentage. RB1 knockdown 
results in a significant decrease of G0-G1 percentage in NUP98/KDM5A positive cells. (A) Induction with 
doxycycline leads to a significantly higher gain in G0-G1 percentage in 32DpT-NK compared to the other 
conditions (p<0.0001), indicating a G0-G1 arrest in NUP98/KDM5A expressing cells. The boxplot shows the 
values found in the experiment that was performed in quintuplet and, except for 32DpT-NN, repeated two 
times. (B) Rb1 knockdown results in a significantly decrease of G0-G1 percentage in 32DpT-NK (p<0.01). The 
boxplot shows the results of the experiment that was performed in quintuplet and repeated two times. 
Groups were compared using Mann Whitney-test. 
rare in other morphologic subtypes of AML.1 Myeloid leukemogenesis requires at least 
two different aberrations. 6, 7 RB1 is a well-known tumor suppressor gene which is linked 
to proliferation by its role in cell cycle checkpoints, but RB1 deletions have thus far 
not been reported in pediatric AML. Deletions of chromosomal band 13q14 have been 
detected by conventional karyotyping and array comparative genomic hybridization in 
pediatric AMKL, but the role of RB1 was not yet identified as a potential critical event 
in these cases.1, 23 In this study, we found that RB1 deletions exclusively occurred in all 
non-Down Syndrome AMKL cases with a NUP98/KDM5A rearrangement. Interestingly 
we did not find any RB1 deletions in non-AMKL NUP98/KDM5A rearranged cases, nor in 
any other case of AML without NUP98/KDM5A rearrangement.
 Non-random combinations of genetic aberrations are well-known in pediatric 
AML and are considered to collaborate in leukemogenesis.1, 7, 24 For instance, the 
NUP98/NSD1 translocation is often seen in combination with a FLT3-ITD, conferring a 
poor outcome.18, 25, 26 The translocation NUP98/NSD1 results in a differentiation arrest, 
but FLT3-ITD is required to induce leukemia in mouse models.22 In the present study, 
we provide evidence that loss of RB1 offsets a NUP98/KDM5A induced cell cycle arrest, 
and the combination of the two aberrations results in both a differentiation arrest and 
proliferation advantage.
KDM5A was originally identified as a RB1-binding protein.9, 27 The RB1 protein 
promotes senescence and differentiation, and these activities coincide with its ability 
to bind KDM5A.11, 15, 28 Interestingly, Kdm5a deficient mouse embryo fibroblasts have 
a decreased proliferation rate, which could partially be rescued by depletion of Rb1.11 
These data demonstrate an intimate functional relationship between Kdm5a and 
Rb1. We have observed a decreased proliferation rate in NUP98/KDM5A expressing, 
early myeloid cells, accompanied with a G0-G1 arrest, which could be rescued by Rb1 
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depletion. This is consistent with the concept that the NUP98/KDM5A fusion protein 
constitutes a loss of KDM5A function in regulating RB1, leading to an anti-proliferative 
effect. While we show that the NUP98/KDM5A fusion also prevents differentiation 
through upregulation of HOXA and HOXB genes, creating a stem cell phenotype, this anti-
proliferative effect may hinder the development of leukemia. We therefore hypothesize 
that loss of one RB1 allele compensates for this effect. We note that in the majority of 
cases the other RB1 allele was intact, contrary to the “classical” loss of RB1 function in 
other cancer types, which requires loss of both alleles.29, 30 The differentiation arrest as 
seen in NUP98/KDM5A positive 32D cells suggests that the translocation of NUP98/
KDM5A can indeed be classified as a type-2 aberration, as postulated by Kelly et al, and 
confirmed by Wang et al.6, 20 The effect of the Rb1 knockdown on proliferation, with a 
decreased percentage of cells in G0-G1 phase, suggests that the observed Rb1 deletion 
in the NUP98/KDM5A positive AMKL cases cooperates to induce leukemia in NUP98/
KDM5A positive AMKL by enhancing proliferation. 
The pediatric AMKL cases with NUP98/KDM5A typically arise at very young age, 
but young age is a characteristic of most pediatric AMKL.1-4, 8 In DS AMKL the somatic 
mutation in GATA1 resulting in the leukemia is already present at birth, resulting in 
a transient myeloproliferative disease followed by spontaneous remission, and in 
approximately 20% followed by the development of AMKL.31-34 Greaves et al showed 
that fusion genes can be detected in material derived from neonatal Guthrie cards, 
suggesting the presence of the fusion gene, although in small subclones, is present in 
utero.35 In cases for which germline material was available, we confirmed the identified 
deletion of RB1 in the leukemic cells to be somatic. Guthrie cards may show whether 
the most frequent identified somatic aberrations in non-DS AMKL, such as NUP98/
KDM5A, might be present at birth as well, which later, in combination with a second 
hit, such as a RB1 deletion, provides a proliferative advantage and the development of 
clinically overt leukemia. 
In conclusion, we found heterozygous RB1 deletions in pediatric AML were 
restricted to NUP98/KDM5A positive pediatric AMKL cases. We confirm that NUP98/
KDM5A results in a differentiation arrest as has been previously shown, and Rb1 
knockdown in combination with this fusion results in a proliferation advantage. RB1 
deletions in NUP98/KDM5A positive cases are likely to be a compensatory aberration 
to the translocation, offsetting the anti-proliferative side effects of the differentiation 
inhibiting fusion gene.
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other pediatric AML cases 
(n=256)
RB1 deleted cases 
(n=3)
Age at dx Median (y) 9,6 1,4
Range (y) 0,1-18,0 1,4-1,8
Sex Female (%) 0,42 0,67
WBC Median (x109/L) 47,9 14,9
Range (x109/L) 1,2-438,0 11,5-19,0
FAB-type M0 16 0
M1 32 0
M2 45 0
M3 20 0
M4 73 0
M5 55 0
M6 2 0
M7 5 3
Type-2 Aberrations KMT2A-rearrangement 62 0
RUNX1/RUNX1T1 23 0
inv(16) 33 0
PML/RARA 18 0
ETV6/MNX1 4 0
DEK/NUP214 6 0
KAT6A/CREBBP 6 0
NUP98/NSD1 13 0
NUP98/KDM5A 2 3
CEBPAdm 13 0
NPM1 17 0
Other 3 0
RBM15/MKL1 0 0
CBFA2T3/GLIS2 0 0
Unknown 56 0
Table 3.1A. Patient characteristics of the pediatric AML cohort (n=259).
Abbreviations: dx indicates diagnosis; WBC, white blood cell count; FAB, French-American-British 
classification; y, years.
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Table 3.1B. Patient characteristics of the selected cohort for NUP98/KDM5A positive 
samples (n=10). 
Abbreviations: UPN indicates unique patient number; FAB, French-American-British classification; wt, 
wildtype; dx, diagnosis; yrs, years; NA, not available; SCT, stem cell transplantation; COD, cause of death.
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Supplementary data
Supplementary Figure 3.1 (A) RB1 expression seems lower in RB1 deleted pediatric AML cases (n=3), 
compared to other pediatric AML (n=255; mean 7.68 compared to 8.69 of micro-array VSN normalized 
data, p=0.038). (B) KDM5A expression seems higher in NUP98/KDM5A positive pediatric AML (n=4) 
compared to other pediatric AML (n=254; mean 7.61 compared to 7.41 of micro-array VSN normalized 
data, p=0.031). (C) RB1 expression as found with GEP validated with qPCR (n=38). RB1 shows a strong 
correlation (r=0.745) comparing micro-array values with qPCR values. (D) KDM5A expression as found 
with GEP validated with qPCR (n=38). KDM5A shows a strong correlation (r=0.719) comparing micro-array 
values with qPCR values.
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Supplementary Figure 3.2 (A) Left panel shows expression levels of NUP98/KDM5A and NUP98/NSD1 
measured with qPCR. Doxycycline induction gives a >9-fold higher expression of NUP98/KDM5A in the 
pTripZ-NUP98/KDM5A induced cells. Right panel shows expression levels of NUP98/NSD1 measured with 
qPCR. Doxycycline induction gives a 4-fold higher expression of NUP98/NSD1 in the pTripZ-NUP98/NSD1 
induced cells. (B) Rb1 expression as measured with qPCR. Knockdown with sh99 results in >60% reduction 
of Rb1 compared to cells without knockdown.
Supplementary Figure 3.3 (A) NUP98/KDM5A protein is expressed after induction with doxycycline. 
Western blot analysis of NUP98 and KDM5A in total lysates from HEK293T cells transfected with pTNK, 
before and after induction with doxycycline (1ug/ml) for 24hours. Equal amounts of total protein was 
loaded. (B) NUP98/KDM5A localizes to nucleus after induction with doxycycline. The 414 antibody was 
used as a general nucleoporin staining antibody, and localization of NUP98 was performed after induction 
with doxycycline (1ug/ml) for 24 hours in HEK293T cells transfected with pTNK or pTempty. 
A
B
BA
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Supplementary Figure 3.4. Increased Hoxa and Hoxb gene expression was found in NUP98/KDM5A 
transduced 32D cells. NUP98/KDM5A and NUP98/NSD1 transduced 32D cells with doxycycline induction 
are indicated in the red bars.
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Supplemental Table 3.1. Overview of primers.
Gene Location Direction Sequence 5' > 3' Amplification conditions
RB1 mutational Exon 1 Forward CTCCCCGGCGCTCCTCCACAGC 10’94, 40x(30”94, 1’60,30”68),10’68
screening Reverse GGGCGCCCTTCCCGCGTGAG
RB1 mutational Exon 2 Forward TGTAAAACGACGGCCAGTAACAAGTATGTACTGAATCAATTTG  2’ 94, 40X(1’94, 35”57,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCCTATCTTTCAATTTTTGTATAGTGA
RB1 mutational Exon 3 Forward TGTAAAACGACGGCCAGTGACTGACCCCTAAAGTTTCCACA 10’ 95, 40X(15”95, 1’60, 30”72), 10’72
screening Reverse CAGGAAACAGCTATGACCCGTTTCCTTTTATGGCAGAGGCTT
RB1 mutational Exon 4 Forward ACAAATTTTTAAGGTTACTGATTTAC 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CCAGAATCTAATTGTGAACAATGAC
RB1 mutational Exon 5 Forward AACTACTATGACTTCTAAATTACG 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CTTAATTTATGAAGTAGCCTGCTA
RB1 mutational Exon 6 Forward TGTAAAACGACGGCCAGTCTGGAAAACTTTCTTTCAGTGATA 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCGGAATTTAGTCCAAAGGAATGCC
RB1 mutational Exon 7 Forward TGTAAAACGACGGCCAGTCTCTACCCTGCGATTTTCTCTC 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCCATCCTGTCAGCCTTAGAACCA
RB1 mutational Exon 8 Forward TGTAAAACGACGGCCAGTAAACAGCTGTTATACCCATT 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCTCATCTATATTACATTCAT 
RB1 mutational Exon 9 Forward TGTAAAACGACGGCCAGTGTTCAAGAGTCAAGAGATTAGATT 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCCAATTATCCTCCCTCCACAGTCTCA
RB1 mutational Exon 10 Forward TGTAAAACGACGGCCAGTGCCTCTGTGTGCTGAGAGATGTA 2’ 94, 40X(1’94, 35”57,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCAATGATATCTAAAGGTCACTAAGC
RB1 mutational Exon 11 Forward TGTAAAACGACGGCCAGTGATTTTATGAGACAACAGAAGCA 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCATCTGAAACACTATAAAGCCATG
RB1 mutational Exon 12 Forward TGTAAAACGACGGCCAGTAGAGACAAGTGGGAGGCAGTG 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCGATAACTACATGTTAGATAGGAG
RB1 mutational Exon 13 Forward TGTAAAACGACGGCCAGTCCTAAAGAACTGCACAGTGAATCC 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCAATGGGGTGGGAGGTAGTT
RB1 mutational Exon 14 Forward TGTAAAACGACGGCCAGTATTGTGATTTTCTAAAATAGCAGG 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCCAGGATGATCTTGATGCCTTG
RB1 mutational Exon 15 Forward TGTAAAACGACGGCCAGTCAATGCTGACACAAATAAGGTT 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Exon 16 Reverse CAGGAAACAGCTATGACCAAGAAACACACCACATTTTAACT
RB1 mutational Exon 17 Forward TGTAAAACGACGGCCAGTAGCTCAAGGGTTAATATTTCATAA 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCAATTTGTTAGCCATATGCACATG
RB1 mutational Exon 18 Forward TGTAAAACGACGGCCAGTATGTACCTGGGAAAATTATGCTT 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCCTTTATAGAATGTTACATTGCAC 
RB1 mutational Exon 19 Forward TGTAAAACGACGGCCAGTATCTGTGATTCTTAGCCAACTTG 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCAGTCAGCCTAGTTTCAGAGTC
RB1 mutational Exon 20 Forward TGTAAAACGACGGCCAGTCTGGGGGAAAGAAAAGAGTGG 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCGAGGAGAGAAGGTGAAGTGCT
RB1 mutational Exon 21 Forward TGTAAAACGACGGCCAGTGAACAAAACCATGTAATAAAATTCT 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCACCTATGTTATGTTATGGATATGG
RB1 mutational Exon 22 Forward TGTAAAACGACGGCCAGTACTGTTCTTCCTCAGACATTCA 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCTTGGTGGACCCATTACATTAGA
RB1 mutational Exon 23 Forward TGTAAAACGACGGCCAGTCTAATGTAATGGGTCCACCAAA 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCTCCCCCTCTCATTCTTTACTAC
RB1 mutational Exon 24 Forward TGTAAAACGACGGCCAGTTCATCTCTGCAAAATTGTATATGG 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCTATGCAATATGCCTGGATGAGG
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Gene Location Direction Sequence 5' > 3' Amplification conditions
RB1 mutational Exon 25 Forward TTGCTAACTATGAAACACTGGC 10’ 95, 40X(15”95, 1’60, 30”72), 10’72
screening Reverse ATGACCATCTCAGGCTACTGGA
RB1 mutational Exon 26 Forward TGTAAAACGACGGCCAGTTCGAAAGCATCATAGTTACTGG 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCATGCATAAACAAACCTGCCAACT
RB1 mutational Exon 27 Forward TGTAAAACGACGGCCAGTTGCAAGGTCCTGAGCGCCAT 2’ 94, 40X(1’94, 35”52,40”72), 4’72
screening Reverse CAGGAAACAGCTATGACCGAGAGACAATGAATCCAGAGGTG
RB1 qPCR Forward TGGCAGAAATGACTTCTACTC 10'95, 40x(15"95, 1'60)
Reverse CTGGGAAAGTTATACAGTCACA
KDM5A qPCR Forward CTGCAAGGACAAGGTAGACT 10'95, 40x(15"95, 1'60)
Reverse TCCTCCATTGGTAGTTTGTAG
murine qPCR Forward TGGCCTGTGCTCTTGA 10'95, 40x(15"95, 1'60)
Rb1 Reverse TTGGCTTCCACTTTGATAA
murine qPCR Forward CTCCTGCGACTTCAACAG 10'95, 40x(15"95, 1'60)
Gapdh Reverse TCTGGGATGGAAATTGTG
murine qPCR Forward ATGGCATGGATCTCAGC 10'95, 40x(15"95, 1'60)
Hoxa5 Reverse TTGCCCAGGGAGTTTT
murine qPCR Forward GCCGGACAACAAATCAC 10'95, 40x(15"95, 1'60)
Hoxa7 Reverse TCGGCATTTTGGAAGAG
murine qPCR Forward CCTGCTGCAGTGTATCATC 10'95, 40x(15"95, 1'60)
Hoxa9 Reverse GCTGGGTTGTTTTTCTCTATC
murine qPCR Forward GAGCGAGTCCTAGACTCCA 10'95, 40x(15"95, 1'60)
Hoxa10 Reverse CGGCGAAGCTTTACTGT
murine qPCR Forward TCCCCTGGATGAAAGAG 10'95, 40x(15"95, 1'60)
Hoxb2 Reverse GGCCATCTGATGGTGAT
murine qPCR Forward CCGCACCTACCAGTACC 10'95, 40x(15"95, 1'60)
Hoxb3 Reverse TGCCTCGACTCTTTCATC
murine qPCR Forward CCGGAGGGTGGAGAT 10'95, 40x(15"95, 1'60)
Hoxb4 Reverse TGGGCAACTTGTGGTC
murine qPCR Forward GCCCGGACTATCAGTTG 10'95, 40x(15"95, 1'60)
Hoxb5 Reverse TCCATCCCATTGTAATTGTAG
murine qPCR Forward CGGCGTCCTCCTATTAC 10'95, 40x(15"95, 1'60)
Hoxb6 Reverse GGCGTGGAGCACTTC
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Supplemental Table 3.2. Patient characteristics of NUP98/KDM5A negative samples screened 
for RB1 deletions. 
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Introductory paragraph
Acute Megakaryoblastic Leukemia (AMKL) is a subtype of acute myeloid leukemia 
(AML) that morphologically resembles abnormal megakaryoblasts. While extremely 
rare in adults, pediatric cases comprise 4-15% of newly diagnosed AML patients.1-3 A 
significant proportion of pediatric cases occur in children with Down syndrome (DS). 
These patients have excellent outcomes and are characterized at the genomic level by 
a founding GATA1 mutation.4-6 In contrast, AMKL in patients without DS (non-DS-AMKL) 
have poor outcomes. Previous efforts have identified chimeric oncogenes in a significant 
number of cases, including RBM15-MKL1, CBFA2T3-GLIS2, KMT2A gene rearrangements 
and NUP98-KDM5A7-9. The etiology of 30-40% of cases, however, remains unknown. To 
better understand the genomic landscape of non-DS-AMKL, we performed RNA and 
exome sequencing on specimens from 99 patients. We demonstrate that pediatric 
non-DS-AMKL is a heterogeneous malignancy that can be divided into seven subgroups 
with varying outcomes. These subgroups are characterized by chimeric oncogenes with 
cooperating mutations in epigenetic and kinase signaling genes. In contrast, epigenetic 
mutations predominate in adults. These data shed light on the etiology of AMKL. 
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The earliest insight into the genomic alterations that drive non-DS-AMKL occurred 
with the recognition of a recurrent t(1;22) found in infants.10 Ten years after this 
initial report, the RBM15 and MKL1 genes involved in this translocation event were 
characterized.7, 11 Subsequent to this, a high resolution study of DNA copy number 
abnormalities (CNAs) and loss of heterozygosity (LOH) on pediatric de novo AML 
identified a significant number of alterations in non-DS-AMKL cases, suggesting that 
additional gene rearrangements may be present in this population.12 To define the 
functional consequences of these structural variations, diagnostic leukemia specimens 
from 14 pediatric patients have previously undergone RNA and exome sequencing.8 
This effort identified chimeric transcripts encoding fusion proteins in 12 of 14 cases, 
including the novel recurrent CBFA2T3-GLIS2 fusion which renders a poor prognosis. 
In parallel, a separate non-DS-AMKL cohort was evaluated by PCR and split-signal 
fluorescence in situ hybridization (FISH) for fusion events associated with myeloid 
malignancies including NUP98 and KMT2A gene rearrangements (KMT2Ar).9 In this 
cohort, NUP98 and KMT2Ar were identified in 15% and 10% of cases respectively. To 
gain a more comprehensive understanding of the genomic alterations that lead to non-
DS-AMKL, specimens from 99 patients (75 pediatric and 24 adult cases) were subjected 
to RNA and/or exome sequencing. Combined with the 14 cases previously described, 
the pediatric cohort described in this manuscript yields 89 cases, the largest of this rare 
malignancy to undergo next generation sequencing to date.  
 Of the 93 patients for whom sufficient RNA was available, 5.5% (1/17) adult 
and 72.4% (55/76) pediatric cases carried a structural variation (SV) predicted to lead 
to a fusion product by RNAseq. Ten additional fusion events in patients that lacked 
RNA for sequencing could be recognized by RT-PCR, florescent in situ hybridization 
(FISH) or southern blotting (Figure 4.1). In the pediatric cohort, the most frequent 
fusion events include CBFA2T3-GLIS2 (18.6%; 16/86), KMT2Ar (17.4%; 15/86), NUP98-
KDM5A (11.6%; 10/86), and RBM15-MKL1 (10.5%; 9/86). Previously described low 
frequency non-DS-AMKL fusions identified in this expanded cohort, include a case of 
NIPBL-HOXB9 and a novel, but functionally analogous NIPBL-HOXA9 fusion.8 Similarly, 
a case carrying GATA2-HOXA10 was identified, which is functionally equivalent to the 
GATA2-HOXA9 fusion that has been reported in a single case.8 Chimeric transcripts not 
previously described include several fusions involving genes within the HOX cluster 
(EWSR1-HOXB8, PLEK-HOXA11-AS, BMP2K-HOXD10, and EP300-HOXA7). Collectively, 
fusions involving a HOX cluster gene (HOXr) occurred in 14% (12/86) of this cohort 
(Table 4.1). Many of the HOXr are predicted to lead to an in-frame functional fusion 
protein. As proof of principal, we evaluated three of these fusion events and found 
all three to enhance self-renewal as determined by an in vitro colony replating assay 
(Supplementary Figure 4.1). Several fusions, however, involve non-coding RNA species 
and are predicted to result in a loss of function of these regulatory transcripts. 3.5% 
(3/86) of the cases carried non-recurrent fusion proteins involving hematopoietic 
transcription factors and epigenetic regulators such as MN1-FLI1, BCR-ABL1, and 
MAP2K2-AF10. 3.5% (3/86) of cases were found to have chimeric transcripts involving 
the cohesin gene STAG which were all predicted to lead to a truncation in the protein. 
In 21% (18/86) of cases, no potentially oncogenic fusion event could be detected. 
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Figure 4.2. Gene expression analysis confirms genomic subgroups. (a) Unsupervised hierachical clustering 
of the gene expression correlation matrix of 100 most variant RNAs. Colors indicate patient samples 
with similar genomic aberrations.  (b) t-SNE visualization. (c) Expression of myeloid HOXA9 target genes 
most highly associates with gene expression in HOX-rearranged AMKL. Global association between AMKL 
subgroup and HOXA9 target gene expression was estimated using a global test.23 Contributions of gene to 
the overall association p value are shown ranked according to covariate p value and colored according to 
most highly associating subgroup.  
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Figure 4.1. Pediatric and adult non-DS-AMKL are 
genomically distinct. Distributions of recurrent 
chromosome translocations and GATA1 mutations in 
pediatric and adult non-DS-AMKL. p value according 
to Pearson’s Chi squared test.
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However, in 50% of these cases, a truncating mutation in exon 2 or 3 of GATA1 was 
found, amounting to 10.1% (9/89) of the pediatric cohort overall (further discussed 
below, Figure 4.1).
 To determine if these fusion events contribute significantly to gene expression 
patterns, samples with greater than 60% purity were subjected to unsupervised 
clustering using the top 100 most variant genes by standard deviation (Figure 4.2A and 
B). Confirming the strength of the fusions in determining gene expression signatures, 
samples clustered according to fusion status, specifically KMT2Ar, HOXr, NUP98-
KDM5A, and CBFA2T3-GLIS2 cases formed distinct clusters. When analyzing expression 
of the HOX gene cluster, we found upregulation of the HOX gene involved in the fusion 
construct (Supplementary Figure 4.2), often accompanied by upregulation of adjacent 
HOX genes. To determine whether this upregulation had downstream effects on HOX 
targets, we evaluated expression of a gene set defined by HOXA9 overexpression in 
hematopoietic cells.13 This demonstrated the highest association for the majority of 
target genes with the HOXr subgroup, providing further evidence of a HOX signature 
(Figure 4.2 and Supplementary Figure 4.3). Combined with KMT2Ar and NUP98-
KDM5A, chimeric oncogenes known to upregulate HOX cluster genes, roughly half of 
pediatric non-DS-AMKL patients carry a HOX gene expression program. These cases 
were distinct from those carrying the cryptic CBFA2T3-GLIS2 inversion which clustered 
away from all other non-DS-AMKL as has been previously shown8.
 In addition to RNAseq data, 68 pediatric patients had DNA available for whole 
exome sequencing (WES), of which 30 had paired germline material. To identify single 
nucleotide variants and insertion/deletion events (SNV/Indels) in cases lacking WES, 
RNAseq data was also interrogated for these mutational events. To identify high 
confidence somatic calls, unpaired samples underwent a vigorous filtering process as 
described in the online methods. Of 83 pediatric cases at diagnosis for which SNV/
Indel analysis was available, the most highly recurrent mutations occurred in GATA1 
(13.3%; 11/83), JAK kinase or STAT genes (16.9%; 14/83), Cohesin/CTCF genes (18.1%; 
15/83), and RAS pathway genes (15.7%; 13/83, Figure 4.3). Additionally, 18.1% (15/83) 
of patients carried mutations in a cytokine receptor gene, the most frequent of which 
was the MPL receptor (n=10) that plays a role in normal megakaryoblast growth and 
survival. In contrast, in the adult cohort (n=24), the most highly recurrent mutations 
were in TP53 (20.8%; 5/24), cohesin genes (16.7%; 4/24), splicing factor genes (16.7%; 
4/24), ASXL genes (16.7%; 4/24) and DNMT3A (12.5%; 3/24). Paired exome specimens 
and single nucleotide polymorphism (SNP) arrays were available in 29 specimens for 
copy number alterations analysis to identify additional cooperating mutations (Figure 
4.3). The tumor suppressor RB1 was found to be recurrently targeted with focal 
deletional events (Supplementary Table 4.1). Combined with SNV/Indels and structural 
variations, RB1 mutational events occurred in 14.3% (12/84) of the pediatric cohort 
and 8.3% (2/24) of the adult cohort. Confirming previous reports, gains in chromosome 
19 and 21 were also recurrent in the pediatric cohort as determined by WES and/or 
cytogenetics in 24% (19/79) and 39.2% (31/79) of cases respectively.14,15 
 Of the ten cases carrying GATA1 truncating mutations in the pediatric cohort, 
none had physical stigmata consistent with DS (Supplementary Table 4.2). Karyotypes 
were available for all patients and found to be negative for constitutional trisomy 21. 
Four pediatric cases had matched germline available with an average coverage of 110X. 
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Figure 4.3. Cooperating mutations in pediatric non-DS-AMKL. (a) Recurrent genes in diagnostic and relapsed specimens 
targeted by SNV/Indel mutations. Genes for which four or more cases carried a lesion are shown. (b) Frequency of copy 
number alterations for cases with a paired germline specimen. The outer track indicates the chromosomal location. 
Amplifications are shown in red, deletions in blue, and loss of heterozygosity is shown in orange. (c) Non-random 
associations between genomic AMKL subgroup and cooperating mutation. Circos plot showing co-occurence in patients 
between grouped (n) cooperating mutations (top) and AMKL subgroup (bottom). CTCF/Cohesin: CTCF, STAG2, STAG3, 
SMC1A, NIPBL, SMC3, RAD21; JAK/STAT: JAK1, JAK2, JAK3, STAT5B; RAS: NRAS, KRAS, PTPN11. Global association p value 
of 1.3x10-8 is estimated according to global test using a multinomal regression model.23
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Figure 4.4. Clinical outcomes in pediatric non-DS-AMKL. (A) Overall survival of pediatric non-DS-AMKL patients 
according to subgroup. Medium follow up of survivors: 89 months. (B) Event free survival of pediatric non-DS-AMKL 
patients according to subgroup. (C) Cummulative incidence of relapse or non-response.
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With the exception of one case that had evidence of low level tumor contamination in 
the germline specimen, GATA1 mutant calls were absent from these samples, including 
a case with 160X coverage, arguing against low level mosaicism. The strong association 
of GATA1 truncations in DS patients suggests cooperativity between amplification of the 
Down syndrome critical region (DSCR) on chromosome 21 and the GATA1 mutant. We 
therefore evaluated cases for amplification of the DSCR using SNP arrays and exome read 
depth in paired samples. Nine of ten GATA1 mutant cases had amplifications in the DSCR 
(Supplementary Table 4.2). Across the entire cohort, amplifications of chromosome 21 
were found to be one of the most highly recurrent copy number alterations (Figure 
4.3). Candidate genes in this region that play a role in megakaryopoiesis include 
ERG, a member of the ETS transcription gene family.16 Furthermore, over-expression 
of ERG in hematopoietic progenitor cells by retroviral transduction and subsequent 
transplantation into mice results in megakaryoblastic leukemia, consistent with a 
role for this oncogene in promoting megakaryocytic disease.17 GATA1 mutant cases 
comprised a distinct subset at the gene expression level (Figure 4.2), and this signature 
was strongly correlated with that found in DS-AMKL. Confirming cooperativity with 
chromosome 21, the GATA1s subset significantly overexpressed chromosome 21 
genes, even in comparison to other samples carrying extra copies of this chromosome, 
including UBASH3A and LINC00478/MONC, genes previously implicated in AML and 
AMKL respectively (Supplementary Figure 4.4).18, 19 Combined with RNA-seq data, this 
led us to divide our cohort into seven subsets based on genomic lesions for further 
analysis: CBFA2T3-GLIS2, RBM15-MKL1, NUP98-KDM5A, KMT2Ar, HOXr, GATA1s, and 
“Other” which is comprised of cases not falling into any of the aforementioned subsets 
(Figure 4.1). 
 Cooperating mutations as identified by exome sequencing revealed a significant 
association between subgroups and recurrent mutations (p = 1.3e-8, global test, 
Figure 4.3). NUP98-KDM5A cases carried mutations in RB1 almost without exception; 
as has been previously described KMT2Ar often associated with RAS pathway lesions 
(p = 0.09 for enrichment, Fisher exact test) and JAK kinase or STAT5B mutations were 
commonly identified in GATA1 mutant cases (p = 0.003).5, 20 HOXr cases were found 
to be significantly enriched in activating MPL mutations (p = 0.007) and the “Other” 
category was enriched for mutations in cohesin and CTCF (p = 0.04).    
 Clinical outcomes for DS-AMKL are uniformly excellent, whereas studies on 
non-DS-AMKL are more variable with the majority reporting inferior survival rates 
compared to other AML subtypes.2,3,6,21,22 Furthermore, the recommendation for stem 
cell transplant (SCT) in first remission for non-DS-AMKL patients is not uniform among 
pediatric cooperative groups. To further understand the association between genomic 
subgroups and outcome, we first utilized the global test to determine if subgroups 
correlated with survival and found a statistically significant association, with CBFA2T3-
GLIS2 carrying the strongest negative association and GATA1 mutant cases carrying 
the strongest positive association (p=1.7x10-5 for overall survival, p=3.4x10-5 for event 
free survival)23. Kaplan-Meier visualizations of event free survival (EFS), overall survival 
(OS) and cumulative incidence of relapse or non-response (CIR, p[Gray] = 1.4x10-4) 
calculations confirmed this trend (Figure 4.4). Specifically, CBFA2T3-GLIS2, KMT2Ar 
were found to have statistically significant inferior EFS and OS in addition to higher CIR. 
NUP98-KDM5A cases had a trend towards inferior outcomes, however this did not reach 
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statistical significance. Conversely, GATA1 and HOXr subgroups carried significantly 
superior outcomes. Of note, all GATA1 mutant cases that lacked a fusion gene were 
cured, mimicking the excellent outcomes seen in DS-AMKL.6 Thus these patients are 
not only biologically but clinically similar as well, suggesting they may benefit from the 
less intensive chemotherapy regimens given to DS-AMKL patients.24, 25 Based on these 
results, we recommend all pediatric non-DS-AMKL patients be tested for the presence 
of NUP98-KDM5A, CBFA2T3-GLIS2 and KMT2Ar. Patients carrying one of these fusion 
genes have inferior outcomes and may benefit from transplant in first remission. In 
contrast, patients lacking these lesions have outcomes on par with or superior to other 
subtypes of pediatric AML and transplant in first remission should be reserved for those 
that have a poor response to therapy.      
 In summary, pediatric non-DS-AMKL is a heterogenous malignancy comprised 
of distinct subsets as defined by next generation sequencing with varying outcomes. 
Chimeric oncogenes that define two subsets, CBFA2T3-GLIS2 and NUP98-KDM5A are 
missed by conventional karyotyping and therefore require split-signal FISH or RT-PCR 
for detection. The presence of CBFA2T3-GLIS2 and KMT2Ar should be determined on all 
newly diagnosed pediatric non-DS-AMKL patients as they may benefit from transplant 
in first remission.   
Methods
Patient samples 
Specimens were compiled from multiple institutions. All samples were obtained with 
patient or parent/guardian provided informed consent under protocols approved by 
the Institutional Review Board at each institution. Samples were deidentified prior to 
nucleic acid extraction and analysis.
Next Generation Sequencing
RNA and DNA library construction for RNA and whole exome DNA sequencing were done 
as per manufacturer’s instructions using the Illumina True-seq RNA sample preparation 
V2 and Nextera rapid capture exome kits, respectively. Sequencing was completed on 
the Illumina HiSeq 2000 as per manufacturer’s instructions. Analysis of RNA and whole-
exome sequencing data which includes mapping, coverage and quality assessment, SNV/
Indel detection, tier annotation for sequence mutations, and prediction of deleterious 
effects of missense mutations have been described previously.8,26 Open reading frames 
predictions of fusion transcripts detected by RNAseq were validated by RT-PCR followed 
by Sanger sequencing of the purified PCR products.
Exome filtering
To identify high confidence somatic calls, unpaired samples underwent a vigorous 
filtering process including the removal of low quality calls and known polymorphisms. 
Rare variants (defined as a mutant allele frequence of <0.1% in the non-cancer NHLBI 
ESP cohort) were retained for further analysis. Known recurrent somatic variants 
present in the catalogue of somatic mutations in cancer database (COSMIC) were 
designated as high confidence lesions. Remaining calls were evaluated by damage-
prediction algorithms. Those with mutations occurring in a conserved domain of a 
cancer consensus gene and predicted to be damaging were designated as intermediate 
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confidence lesions. 
Gene expression analysis
Transcript expression levels were estimated as Fragments Per Kilobase of transcript per 
Million mapped reads (FPKM); gene FPKMs were computed by summing the transcript 
FPKMs for each gene using Cuffdiff2.27, 28 A gene was considered “expressed” if the 
FPKM value >= 0.5 based on the distribution of FPKM gene expression levels. Genes 
that were not expressed in any sample group were excluded from the final data matrix 
for downstream analysis. For hierarchical clustering and t-SNE the top 100 most variant 
RNAs by standard deviation were used, excluding those encoded by sex specific genes, 
sno and miRNAs and mRNAs correlating with inflammatory response.
Associations of AMKL subgroups with cooperating mutations
High confidence SNVs/Indels from initial diagnostic samples excluding mutations in 
GATA1 were combined with structural alterations excluding those identifying genomic 
subgroups were subjected to mutational frequency analysis. One hypermutated sample 
was excluded from this analysis. Genes mutated in >4 cases were identified as RB1, 
MPL, CTCF, JAK2 and NRAS. Based on these 5 genes, five non-overlapping proximal gene 
sets were constructed from mutated genes, covering 44% of identified cooperating 
mutations. Global association with AMKL subgroup was calculated using multinomal 
regression with the global test.23 Enrichment of gene set mutations in AMKL subgroups 
was determined by one-sided Fisher exact tests.
Colony forming assay
All experiments involving mice were reviewed and approved by the Institutional Animal 
Care and Use Committee. Bone marrow from 4-6 week old female C57BL/6 mice was 
harvested, lineage depleted, and cultured in the presence of recombinant murine 
SCF (rmSCF, Peprotech, 50ng/ml), IL-3 (rmIL3, Peprotech, 50ng/ml), and IL-6 (rmIL6, 
Peprotech, 50ng/ml) for 24 hours prior to transduction on RetroNectin (Takara Bio 
Inc.) coated plates. Cultured supernatants containing ecotropic envelope pseudotyped 
retroviral vectors were produced by transient transfection of 293T cells as previously 
described.29 Murine bone marrow cells were harvested 48 hours following transduction, 
sorted for vector-encoded mCherry or GFP expression, and plated on methylcellulose 
containing IL-3, IL-6, SCF and erythropoietin (EPO) (Stem Cell technologies, Vancouver, 
BC) as per manufacturer’s instructions. Colonies were counted after 7 days of growth at 
37°C, harvested and serially replated.
Affymetrix SNP arrays 
Affymetrix SNP 6.0 array genotyping was performed for 14 of 15 AMKL cases in the 
discovery cohort, and array normalization and DNA copy number alterations identified 
as previously described.30-33 To differentiate inherited copy number alterations from 
somatic events in leukaemia blasts from patient’s lacking matched normal DNA, 
identified putative variants were filtered using public copy number polymorphism 
databases and a St. Jude database of SNP array data from several hundred samples.34, 35 
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Outcome analysis
Kaplan-Meier curves for overall survival (OS), event free survival (EFS) and cumulative 
incidence of relapse or non-response (CIR) were calculated and plotted using the 
survival package in R based on clinical survival data. Gray’s test statistic and p value 
for CIR were calculated using the cuminc() function in the cmprsk package in R. Events 
in EFS calculations included relapses, deaths in remission by any cause and non-
responses, which were included as events at date of diagnosis. For CIR, only relapses 
and non-responses were included. No significant differences were present in cumulative 
incidences of competing risk (p=0.7). For asssociation of disease outcome with AMKL 
subgroup, EFS and OS survival were formatted using the Survival package and used as 
response variables in the global test in R in a Cox regression model with group label as 
covariate.
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Chimeric Transcript Junction Breakpoint Predicted Product
GATA2-HOXA9 exon 4 - exon 2 TTCAG/ATAAC Protein coding
GATA2-HOXA10 exon 4 - exon 2 TTCAG/GCAAT Protein coding
NIPBL-HOXA9 exon 6 - exon 1 ACAAG/TTGAT Protein coding
NIPBL-HOXB9 exon 6 - exon 2 ACAAG/CCAAC Protein coding
EP300-HOXA7 exon 31 - 5’UTR TGGGA/TTCAA Protein coding
EWSR1-HOXB8 exon 12 - 5’UTR TTGAT/CCCCCA Protein coding
BMP2K-HOXD10 exon 15 - exon 2 TTCAG/AGGAA Protein coding
C8orf76-HOXA11AS exon 1 - exon 1 ATCAG/GAGGT Non-coding RNA
PLEK-HOXA11AS exon 1 - 5’UTR AGAAG/GAGGT Non-coding RNA
HOXA9-ANGPT1 3’UTR - intergenic AGGGT/GGAAA Unknown
HOXA10AS-CD164 5’UTR - exon 3 TCCAG/ATGAG Non-coding RNA
Table 4.1. HOX cluster gene rearrangments identified in pediatric AMKL patients.
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Supplementary Figure 4.1. HOX fusions enhance self-renewal capacity. Murine bone marrow was 
transduced with a retrovirus carrying one of three HOX fusion genes or the empty mCherry reporter 
construct as described in online methods. mCherry positive cells were flow sorted and grown on 
methylcellulose supplemented with cytokines. At one week intervals colonies were counted and cells 
were replated for a total of four platings. Each bar donates colony counts for a replating round. Error bars 
indicate standard error of the mean. 
Supplementary data
Supplementary Figure 4.2. HOX fusion partner genes are upregulated in HOX rearranged cases. Relative 
HOX gene expression values (row percentiles) are indicated by heat color (color key). Genes are ordered 
by chromosomal position. Arrows indicate direction of transcription of protein coding HOX genes. Fusion 
genes are divided by coding (top) and non-coding HOX fusions and ordered by HOX fusion partner. Left 
column summarized expression value of rearranged HOX gene.
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Supplementary Figure 4.3. HOXA9 target genes are upregulated in the HOX rearranged subgroup. 
Distribution of expression of genes within the HOXA9 target upregulated gene set showing the highest 
association with AMKL subgroup4. Expression is highest in the HOX rearranged cases for both protein 
coding and non-protein coding HOX fusions (red circles). 
Supplementary Figure 4.4. Chromosome 21 expression levels. Relative expression of genes on chromosome 
21 in the AMKL subgroups is shown. Genomic amplification status for each sample is indicated by the 
circles. Filled circles represent amplified chromosome 21; open circles represent diploid chromosome 21.
ch1-6.indd   87 13-4-2016   21:59:01
Chapter 4: Next generation sequencing in pediatric AMKL 
Supplementary Table 4.1.  Overview of RB1 mutations.
Event 1 Event 2
UPN Cohort Group Assignment
Genomic 
Alteration Result
Genomic 
Alteration Result
1 Adult NA CNA Deletion
2 Adult NA SNV V833E
3 Pediatric NUP98-KDM5A CNA Deletion Structural 
Variation
RB1-FNDC3A Fusion Protein
4 Pediatric NUP98-KDM5A CNA Deletion
5 Pediatric NUP98-KDM5A CNA Deletion
6 Pediatric NUP98-KDM5A CNA Deletion SNV Q354*
7 Pediatric HOXr CNA Deletion
8 Pediatric NUP98-KDM5A CNA Deletion
9 Pediatric GATA1s CNA Deletion
10 Pediatric HOXr CNA Deletion
11 Pediatric NUP98-KDM5A CNA Deletion
12 Pediatric NUP98-KDM5A CNA Deletion
13 Pediatric NUP98-KDM5A CNA Deletion Structural 
Variation
RB1 fused to a non-coding region of 
the genome
14 Pediatric NUP98-KDM5A CNA Deletion SNV R445*
Abbreviations: UPN indicates unique patient number; NA, not available; CNA, copy number alteration; 
SNV, single nucleotide variant.
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Supplementary Table 4.2. Overview of GATA1s mutations in diagnostic material.
Abbreviations: UPN indicates unique patient number; Peds, pediatric cohort; NA, not available; Chr, 
chromosome. 
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Abstract
Genetic abnormalities and early treatment response are the main prognostic factors 
in acute myeloid leukemia (AML). Acute megakaryoblastic leukemia (AMKL) is a rare 
subtype of AML. Recently, deep sequencing has identified CBFA2T3/GLIS2 and NUP98/
KDM5A as recurrent aberrations, occurring in similar frequencies as RBM15/MKL1 and 
KMT2A-rearrangements. We studied whether these cytogenetic aberrations can be 
used for risk-group stratification.
 To assess frequencies and outcome parameters of recurrent cytogenetic 
aberrations in AMKL, samples and clinical data of patients treated between 1998 and 
2014 by the AIEOP, BFM-SG, COG, DCOG Centers and the Saint Louis Hopital were 
collected, enabling us to screen 153 newly diagnosed pediatric AMKL cases for the 
aforementioned aberrations, and to study their clinical characteristics and outcome.
 CBFA2T3/GLIS2 was identified in 16% of the cases, RBM15/MKL1 in 12%, 
NUP98/KDM5A and KMT2A-rearrangements in 9% each. These aberrations were 
mutually exclusive, and none of these aberrations were detected in the remaining 54% 
of patients. RBM15/MKL1-rearranged patients were significantly younger. No significant 
differences in sex, and white blood cell count were found between these subgroups. 
NUP98/KDM5A, CBFA2T3/GLIS2 and KMT2A-rearranged (NCK) lesions predicted a poor 
outcome; compared to RBM15/MKL1-rearranged patients and to those with AMKL not 
carrying these molecular lesions, NCK-patients (n=52) showed a 4-yr pOS of 37±7% vs 
66±5% in the RBM15/MKL1-other groups (n=101, p=0.001), and 4-yr pEFS of 34±7% 
vs 59±5% (p=0.011), the 4-yr cumulative incidence of relapse being 43±7% and 21±4% 
(p=0.006), respectively. 
 We conclude that these genetic aberrations may be used for risk-group 
stratification of pediatric AMKL and for treatment tailoring.
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Introduction
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease characterized by 
recurrent genetic aberrations. The most important factors predicting clinical outcome 
are presence of (molecular) genetic aberrations and early response to treatment.1, 2 
Acute megakaryoblastic leukemia (AMKL) is a rare subtype of AML and is seen mostly 
in Myeloid Leukemia of Down Syndrome (ML-DS) patients, where it is associated 
with mutations in the transcription factor GATA1.3 In pediatric non-Down syndrome 
AML, AMKL accounts for approximately 10% of the cases, and has been reported to 
be associated with poor outcome.4-7 Most study groups consider non-Down syndrome 
AMKL as high-risk AML, and some consider it to have the indication for allogeneic 
hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1). 4, 8-10 
However, risk group stratification and treatment protocols are not yet optimized for 
this subtype of pediatric AML.11
Translocation t(1;22)(p13;q13), resulting in a chimeric fusion of RBM15 and 
MKL1, formerly known as OTT/MAL, until recently was the only recurrent aberration 
described in pediatric AMKL, occurring in ~10% of the patients.12-14 Conflicting 
results on the prognostic relevance of RBM15/MKL1 have been reported, as some 
series suggested the outcome to be poor and others favorable.5, 6, 13, 15 Recently, the 
cytogenetically cryptic translocation t(11;12)(p15;p13), resulting in the chimeric fusion 
gene NUP98/KDM5A, was identified as recurrent aberration, found in ~10% of AMKL 
cases.5, 7, 16 Moreover, another cytogenetically cryptic event, inv(16)(p13q24), resulting 
in a fusion between CBFA2T3 and GLIS2, and accounting for ~15% of the cases, was 
identified as a recurrent aberration in this specific subtype of AML.5, 7, 16, 17. Both 
NUP98/KDM5A and CBFA2T3/GLIS2 fusion transcripts were reported to confer poor 
outcome, but numbers of patients analysed to support this conclusion were small. 
Moreover, CBFA2T3/GLIS2 was also reported to behave as an aggressive leukemia in 
mouse models.7, 16 Another recurrent abnormality consists of KMT2A-rearrangements, 
which are seen in ~10% of the pediatric non-Down syndrome AMKL cases.5 The clinical 
outcome of KMT2A-rearranged leukemia is dependent on the fusion-partner gene.18, 
19 NUP98/KDM5A, CBFA2T3/GLIS2 and RBM15/MKL1 are rarely or never seen in other 
pediatric AML subtypes, with CBFA2T3/GLIS2 being the least specific for AMKL. 5, 17, 20
In this study, we present the clinical, cell-biological and genetic characteristics of 
153 pediatric patients with non-Down syndrome AMKL patients from the Associazione 
Italiana Ematologia Oncologia Pediatrica (AIEOP, Italian Association of Pediatric 
Hematology and Oncology, Italy), the Berlin-Frankfurt-Munster-Study Group (BFM-
SG, Essen, Germany), the Dutch Childhood Oncology group (DCOG, The Hague, The 
Netherlands), the Saint Louis Hospital (SLH, Paris, France) and the Children’s Oncology 
Group (COG, Philadelphia, United States of America), which were fully characterized 
for the aforementioned genetic aberrations; we also investigated the frequencies and 
prognostic relevance of these recurrent aberrations. 
Material and methods
Patient inclusion
We collected data on clinical characteristics and outcome of newly diagnosed pediatric 
(younger than 18 years at disease onset) patients with non-Down syndrome AMKL. 
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These patients were diagnosed between 1998 and 2014, and must have available RNA 
or cDNA for molecular studies and a blast percentage over 20%; they were from 3 
consortia: 1) AIEOP, 2) BFM-SG, DCOG and SLH, and 3) COG. Approval for this study 
had been obtained from the Institutional review board of the participating Centers. 
Morphological classification, karyotyping and the presence of KMT2A-rearrangements 
were centrally reviewed by each study group. 
Screening for recurrent translocations 
Screening for molecular aberrations was performed in the Erasmus MC-Sophia Children’s 
Hospital for samples provided by the AML BFM-SG, COG, DCOG and the SLH, while 
samples provided by the AIEOP group were screened at the University of Padova and 
Bologna. All patients were screened for NUP98/KDM5A, CBFA2T3/GLIS2 and RBM15/
MKL1 with RT-PCR, using specific primers for each fusion gene, as previously described 
(Primers; Supplementary Table 5.1). 5, 17 In case of a positive sample, purified PCR 
product was directly sequenced on a PRISM 3100 genetic analyzer (Applied Biosystems) 
and analyzed using CLCWorkbench (Version 3.5.1; CLC Bio) to confirm the translocation. 
A higher incidence of AMKL is seen in Down syndrome patients, and these children are 
usually characterized by a GATA1s mutation.21-23 To analyze the presence of NUP98/
KDM5A, CBFA2T3/GLIS2 and RBM15/MKL1 also in Down syndrome AMKL, a cohort of 
16 cases was provided by DCOG and AML BFM-SG. All positive KMT2A-rearranged cases 
(diagnosis being based on either KMT2A split signal FISH or cytogenetic analysis as 
performed by each study group) were screened for partner genes using specific primers 
for KMT2A/MLLT3, KMT2A/MLLT10, KMT2A/MLLT4(MLL/AF6), KMT2A/MLLT1(MLL/
ENL), KMT2A/ELL, and KMT2A/MLLT6(MLL/AF17), and the purified PCR product was 
directly sequenced (Primers; Supplementary Table 5.1).18, 19
Statistical analyses
Statistical analyses were performed with SPSS Statistics 20 (IBM, Armonk, NY, United 
States of America). To assess outcome, the following parameters were used; i) probability 
of achieving CR1; ii) probability of event-free survival (pEFS); iii) probability of overall 
survival (pOS); and iv) cumulative incidence of relapse or induction failure (pCIR). CR 
was defined as less than 5% blasts in the bone marrow, with regeneration of tri-lineage 
hematopoiesis, and absence of leukemic cells elsewhere. pEFS was defined as the 
time between diagnosis and first event, including relapse, death due to any cause, and 
second malignancy, whichever occurred first. For calculation of EFS, lack of achieving 
CR was considered an event occurring on day 0. pOS was defined as the time between 
diagnosis and death. Both pEFS and pOS were estimated by the Kaplan-Meier method, 
and groups were compared with the log-rank test. pCIR was defined as time between 
diagnosis and relapse, with non-responders being attributed an event on day 0, and 
was analysed by the Kalbfleisch and Prentice method taking into account death and 
second malignancy as competing event; groups were compared with the Gray’s test. A 
Cox regression analysis was performed for EFS, OS and for the probability of relapse-
free survival (pRFS) considering the following co-variables: cytogenetic subgroup, age, 
sex, white blood cell count (WBC) at diagnosis, and HSCT (as time-dependent variable), 
as well as the previously described risk factor monosomy 7.11,24,25 Furthermore, we 
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included a hyperdiploid karyotype in the Cox regression, which was reported to result 
in a better outcome.26,27 Statistical significance was considered if p-values were <0.05.
Results
Clinical characteristics
The AIEOP group included 47 patients, the BFM-SG, DCOG and SLH consortium 
included 45 patients, and COG provided 61 patients. All 153 patients were eligible 
for screening of the four aberrations. Median age was 1.6 years (range 0.1-17.1), 
median WBC at diagnosis was 13.7x109/L (range 1.1-378.5x109/L), and 46% of the 
included patients were males (Table 1). Patients were treated with different treatment 
protocols according to their respective study group. All protocols consisted of intensive 
chemotherapy using an anthracycline and cytarabine backbone for both induction and 
consolidation; in addition, 41% of patients received HSCT in CR1. HSCT was performed 
in 66% of the patients reported by the AIEOP group, in 44% of the COG cases, and in 
11% of the cases provided by DCOG, BFM and SLH. Patient characteristics are shown 
in Table 1. 
Twenty-four (16%) samples were positive for CBFA2T3/GLIS2, eighteen (12%) 
samples harbored the RBM15/MKL1 fusion gene, NUP98/KDM5A was present in 14 
(9%) of cases, and fourteen samples were positive for a KMT2A-rearrangement, all 
diagnosed with FISH. Three KMT2A-positive cases had no karyotype available, in the 
other 11 the KMT2A rearrangement was also detected through karyotype analysis. 
Different fusion partners were identified; 9/14 were positive for KMT2A/MLLT3, three 
were identified with fusion KMT2A/MLLT10, one case each harbored either KMT2A/
MLLT1 or KMT2A/MLLT6 (Supplementary Table 2).  Age at diagnosis was significantly 
lower in the RBM15/MKL1 positive group, compared to the other pediatric AMKL cases 
(0.7 years, range 0.1-2.7, p=0.035). Eighty-three patients were characterized as ‘other’, 
as they were negative for any of the above mentioned genetic aberrations. Other 
karyotypes identified were t(1:22)(p13;q13), but this case was negative for RBM15/
MKL1 using RT-PCR, and t(16;21)(q24;q22.1), which was positive for RUNX1/CBFA2T3 
(Supplemental Table 3). The ‘other’ subgroup had a median age of 1.6 years (range 0.1-
17.1), and a median WBC of 13.8 x109/L (range 1.1-378.5 x109/L).
Detailed data on karyotype was lacking in 34/153 cases. Twenty cases were 
cytogenetically normal. Cytogenetics showed 30 cases with an acquired trisomy 21, 
another 8 cases were identified to carry monosomy 7, 33 cases were hyperdiploid 
with 49-84 chromosomes, and 31 showed a complex karyotype (defined as 3 or more 
aberrations excluding trisomy’s). Some of these cases belonged to more than one of 
these cytogenetic subgroups (see also Supplementary Table 4 for details). 
Survival analyses
The median follow-up of surviving patients was 67 months (range 2.7-259.0). The 
4-year pOS of the entire pediatric non-Down syndrome AMKL cohort was 56±4%, the 
4-year pEFS was 51±4% and the 4-year pCIR 29±4%. To test whether our cohort (n=146, 
excluding the 7 cases present in both this study and the study published by Inaba et 
al11) had a selection bias, our patients were compared for outcome with all non-Down 
syndrome AMKL cases in the BFM cohort recently published by Inaba et al11 (n=97), and 
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outcome was comparable for pOS (56±4% vs 60±5%, p=0.51), pEFS (51±4% vs 47±5%, 
p=0.62) and pCIR (29±4% vs 32±5%, p=0.62). 
Outcome did not differ significantly between the different collaborative groups. 
The 4-year pEFS of all non-Down syndrome AMKL cases was 57±7%, 45±8%, and 49±6% 
for the AIEOP, BFM/DCOG/SLH, and COG cohorts, respectively (p=0.32, Figure 5.1A). 
The 4-year pOS was 60±7%, 48±8%, and 59±6% (p=0.32, Figure 5.1B), and 4-year pCIR 
was 28±7%, 36±8%, and 23±5% (p=0.29, Figure 5.1C). 
When we analyzed the outcome of patients according to the specific recurrent 
molecular lesions, we found that RBM15/MKL1 and other pediatric AMKL showed 
Figure 5.1. Survival curves of pediatric non-Down Syndrome AMKL patients. (A-C) 4-year pOS, pEFS and 
pCIR comparing the outcome of patients of the different enrolled study groups. There is no significant 
difference in outcome between the study groups. (D-F) 4-year pOS, pEFS and pCIR comparing the described 
cytogenetic subgroups as identified in pediatric non-Down syndrome AMKL. RBM15/MKL1 positive cases 
and other pediatric non-Down syndrome AMKL have a favorable outcome compared to NUP98/KDM5A, 
CBFA2T3/GLIS and KMT2A-rearranged cases. (G-I) 4-year pEFS, pOS and pCIR of the NUP98/KDM5A, 
CBFA2T3/GLIS2 and KMT2A-rearranged cases compared to the RBM15/MKL1 and other pediatric non-
Down syndrome AMKL cases. Harboring NUP98/KDM5A, CBFA2T3/GLIS2 or KMT2A-rearrangements 
confers to poor outcome.
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a favorable prognosis with 4-year pOS of 70±11% and 66±5%, respectively, versus a 
poorer outcome in NUP98/KDM5A, CBFA2T3/GLIS2 and KMT2A-rearranged (collectively 
referred to as ‘NCK-positive’) patients (4-year pOS 36±13%, 38±10% and 36±13%, 
respectively; p=0.022), with a favorable but not statistically significant different pEFS 
(p=0.16, Figure 5.1D-E). The difference in outcome was mainly due to the presence 
of relapsed and refractory cases, as 22 and 9 of the 52 NCK patients either relapsed 
or did not achieve CR, respectively. The pCIR of RBM15/MKL1 translocated cases was 
6±6%, compared with 36±14%, 42±10% and 50±14% for the cases positive for NUP98/
KDM5A, CBFA2T3/GLIS2 and the KMT2A rearrangements respectively (p=0.03, Figure 
5.1F, Supplementary Table 5.2). The pCIR differed significantly between the NCK-
positive patients and the remaining patients (4-yr pCIR of NCK-cases being 43±7% vs 
21±4% for RBM15/MKL1 and other cases, p=0.006). This lower pCIR translated into a 
worse EFS (34±7% for NCK-cases vs 59±5% for RBM15/MKL1 and other cases, p=0.011), 
and a lower probability of OS (37±7% vs 66±5%, p=0.001, Figure 5.1G-I). 
Apart from relapsed and refractory cases, other events leading to mortality 
among the patients with one of the identified fusions consisted of infections (n=3, all 
CBFA2T3/GLIS2 positive), toxicity (n=2, in a NUP98/KDM5A-positive and a RBM15/
MKL1-positive case), graft-versus-host disease (GVHD) after HSCT (1 KMT2A-rearranged 
and 1 RBM15/MKL1-positive case), hemorrhage in a RBM15/MKL1 translocated 
case, and acute respiratory distress syndrome (ARDS) in a KMT2A-rearranged case 
(Supplementary Table 5.2). 
Multivariate analysis
Harboring NUP98/KDM5A, CBFA2T3/GLIS2 or a KMT2A-rearrangement was the an 
independent risk factor for RFS and OS (HR 2.13, 95% CI;1.08-4.23, p=0.030; and HR 
2.17, 95% CI;1.26-3.77 p=0.006, respectively, Table 2), when other risk factors such 
as sex, age at diagnosis, WBC, HSCT,  monosomy 7 or hyperdiploid karyotype were 
included in the model. Harboring a monosomy 7 was found to be an independent risk 
factor for overall survival, but not for EFS or RFS, and a hyperdiploid karyotype resulted 
in a favorable outcome for EFS and OS (Table 2).
In the NCK groups, 35% of the patients received HSCT, compared with 28% 
in the RBM15/MKL1 and other cases. HSCT did not influence the RFS (HR 0.93, 95% 
CI;0.46-1.84, p=0.0.824, Table 2). Moreover, the study group reporting cases did not 
influence the outcome in multivariate analysis. 
Discussion
We report the results of an international collaborative study on the prognostic value 
of the recently identified, recurrent (cyto-) genetic aberrations found in non-Down 
syndrome pediatric AMKL. Pediatric AMKL is a rare entity, which comprises 5-10% of 
the pediatric non-Down syndrome AML cases and is considered to be characterized 
by poor outcome. The high incidence of myelofibrosis may complicate cytogenetic 
diagnosis based on conventional karyotyping, and robust prognostic markers are still 
to be identified.1, 4-6, 8, 11 In our cohort, the translocations CBFA2T3/GLIS2, NUP98/
KDM5A, RBM15/MKL1 and rearrangements of KMT2A accounted for 46% of the 
pediatric AML cases, and harboring translocation CBFA2T3/GLIS2, NUP98/KDM5A, or 
a KMT2A-rearrangement appeared to be an independent prognostic factor for poor 
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outcome. This poor outcome was mainly due to a high incidence of non-response and 
relapse in these patients, as seen in 43% of these cases in our cohort. Pediatric non-
Down syndrome AMKL arises in very young patients, the median age at diagnosis being 
below 2 years. Our study shows that neither age, nor , sex, or WBC at diagnosis are 
independent prognostic factor in pediatric non-Down syndrome AMKL. In addition, 
there were no differences in presenting characteristics between the various genetic 
groups, with the exception of RBM15/MKL1 positive cases, which had a significant 
younger age at diagnosis.
Our data confirm the poor prognosis for overall survival of monosomy 7 cases, 
which was previously described in pediatric AML.11,24,25,28 Previous studies showed the 
association between a hyperdiploid karyotype and AMKL, and it was suggested that 
hyperdiploidy is associated with better outcome, a finding confirmed in this study for 
EFS and OS.26,27 The outcome of RBM15/MKL1 positive cases is not uniform in different 
studies due to the nature of the events. The studies of Inaba et al and Schweitzer et 
al describe an intermediate outcome, with low EFS. However, Inaba et al reported 
that most events were early deaths. Schweitzer et al also described an intermediate 
outcome, but low EFS (event described in 6/8), and a high non-remitter rate was 
reported in this group. In our study, only 1/18 patients harboring RBM15/MKL1 suffered 
from early death, while two cases die due to treatment-related mortality, and two cases 
died due to leukemia progression. This better outcome may be the result of differences 
in supportive care, which is especially in patients of very young age.   
An important difference between the treatment protocols of the various 
collaborative groups in this study was the inclusion of HSCT in first CR in case of an 
available donor. However, in multivariate analysis, HSCT did not influence the pRFS. 
The added value of HSCT for pediatric AML in general is under discussion. There is clear 
evidence that allogeneic HSCT has a greater anti-leukemic potential than chemotherapy 
as post-remissional treatment, but this favorable effect may be blunted by a higher risk of 
treatment-related mortality. 9,10,29 Nevertheless, HSCT in first remission is recommended 
in many AML treatment protocols for high-risk cases as defined by presence of genetic 
aberrations or early response to treatment (i.e. high levels of minimal residual disease, 
MRD, after 1 or 2 courses of induction chemotherapy). Based on our results, a benefit 
of HSCT could be demonstrated in this retrospective analysis of pediatric AMKL. 
Pediatric AMKL is seen in >70% of ML-DS patients.6,11,30 ML-DS AMKL cases are 
characterized by mutations in the hematopoietic transcription factor GATA1, and these 
patients have a good prognosis when treated with reduced-intensity chemotherapy 
due to the unique sensitivity of leukemia cells to chemotherapeutic agents.21,22,30-34 
GATA1 mutations have been described in non-Down syndrome AMKL, often seen with 
an acquired trisomy 21, and it was suggested that these cases fare well in terms of 
prognosis, although numbers were small.6,23,35-37 We did not identify the fusion genes 
CBFA2T3/GLIS2, NUP98/KDM5A or RBM15/MKL1 in the group of Down syndrome 
patients we screened. Cases of non-Down syndrome AMKL that we could not classify 
based on the four studied translocations may harbor a GATA1 mutation, since we were 
lacking DNA material of a large number of patients in this cohort. Next generation 
sequencing techniques may be instrumental to unravel other recurrent aberrations in 
the near future in this relatively large group of AMKL cases, negative for any of the 
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aforementioned aberrations. 
Recently, Inaba et al described AMKL risk groups based on cytogenetic data 
obtained with conventional karyotyping, proposing three groups: good risk including 
patients carrying 7p abnormalities; poor risk including cases with monosomy 7, or 
9p abnormalities, including KMT2A/MLLT3, -13/13q- and -15, and intermediate risk 
which encompasses all other AKML patients.11 This risk classification may be difficult 
to use, since AMKL is frequently associated with myelofibrosis, which contributes to 
difficulties in obtaining sufficient material for cytogenetic analysis. In our study, 34/153 
(22%) patients lacked data on karyotype, and could therefore not be included in any 
of the risk groups as proposed by Inaba et al. The percentage of missing karyotypes in 
our cohort is comparable to the findings of Inaba et al11, although this is higher than 
that reported in pediatric AML including all morphology subtypes (7-13%).25 Moreover, 
conventional karyotyping will not reveal cryptic translocations, such as CBFA2T3/GLIS2 
or NUP98/KDM5A. Through screening by RT-PCR, we were able to classify 38 cases with 
these cryptic events, of which 12 did not have an available karyotype, and the remaining 
had an analysis not showing the occurrence of these events. Therefore, screening for 
the most frequent recurrent aberrations will provide additional information to a risk 
stratification based on conventional karyotyping, revealing additional groups with poor 
outcome.
 With international collaborations novel prognostic subgroups may be identified, 
which may lead to improved risk-group stratification. Although the overall survival is 
poor for non-Down syndrome AMKL in general, with an 4-yr pOS of 56% in this study, 
NUP98/KDM5A, CBFA2T3/GLIS2 and KMT2A-rearranged cases fare worse. We suggest 
that NUP98/KDM5A, CBFA2T3/GLIS2 and KMT2A-rearrangements in pediatric non-
Down syndrome AMKL identify as high-risk patient subgroup, while children belonging 
to either RBM15/MKL1 or other pediatric non-Down syndrome AMKL should be 
considered as a standard risk subgroup. 
Altogether, our results indicate that non-Down syndrome AMKL is a 
heterogeneous disease, and that presence of NUP98/KDM5A, CBFA2T3/GLIS2 or KMT2A-
rearrangements confers poor clinical outcome. Screening for these translocations 
combined with conventional karyotyping in pediatric non-AMKL is advisable in 
future studies for improving risk-group stratification and tailoring treatment intensity 
according to the biological characteristics of the leukemic clone. 
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Table 5.1. Presenting clinical characteristics of pediatric non-Down syndrome AMKL 
patients (n=153). 
* significant lower age at diagnosis (p=0.038). 
Abbreviations: KMT2A-r indicates KMT2A-rearrangement; y, years; WBC, white blood cell count.
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Table 5.2. Hazard ratios of cytogenetic and clinical markers for event-free, relapse-
free and overall survival in multivariate analysis. 
Abbreviations; HR indicates Hazard Ratio; CI, confidence interval; NCK, NUP98/KDM5A, CBFA2T3/GLIS2 or 
KMT2A-rearranged; EFS, event free survival; RFS, relapse free survival; WBC, white blood cell count; HSCT, 
hematopoietic stem cell transplantation. 
HR 95%CI p-value (χ2)
NCK-positive EFS 1.61 0.98-2.66 0.061
RFS 2.13 1.08-4.23 0.030
OS 2.17 1.26-3.77 0.006
Monosomy 7 EFS 2.44 0.99-6.01 0.052
RFS 2.91 0.81-10.52 0.103
OS 3.58 1.41-9.11 0.007
Hyperdiploidy EFS 0.43 0.21-0.89 0.023
RFS 0.42 0.16-1.12 0.084
OS 0.43 0.19-0.96 0.040
Sex (male) EFS 1.33 0.82-2.14 0.248
RFS 1.11 0.59-2.10 0.748
OS 1.37 0.81-2.31 0.237
Age <2 years EFS 0.71 0.44-1.15 0.167
RFS 0.58 0.30-1.10 0.097
OS 0.83 0.49-1.39 0.471
WBC > 20.0x 109/L EFS 1.30 0.78-2.16 0.312
RFS 1.67 0.86-3.25 0.132
OS 1.57 0.92-2.69 0.098
HSCT EFS 1.11 0.60-2.05 0.731
RFS 0.93 0.46-1.84 0.824
OS 1.15 0.66-2.01 0.620
ch1-6.indd   101 13-4-2016   21:59:03
Chapter 5: Risk-group stratification in pediatric AMKL 
References
1. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis 
and management of acute myeloid leukemia in children and adolescents: recommendations 
from an international expert panel. Blood 2012 Oct 18; 120(16): 3187-3205.
2. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric 
acute leukemias: an update. J Clin Oncol 2011 Feb 10; 29(5): 551-565.
3. Xavier AC, Ge Y, Taub JW. Down syndrome and malignancies: a unique clinical relationship: a 
paper from the 2008 william beaumont hospital symposium on molecular pathology. The Journal 
of molecular diagnostics : JMD 2009 Sep; 11(5): 371-380.
4. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, et al. Biology and outcome of 
childhood acute megakaryoblastic leukemia: a single institution‘s experience. Blood 2001 Jun 15; 
97(12): 3727-3732.
5. de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, et al. 
NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia 
with a distinct HOX gene expression pattern. Leukemia 2013 Dec; 27(12): 2280-2288.
6. Schweitzer J, Zimmermann M, Rasche M, von Neuhoff C, Creutzig U, Dworzak M, et al. Improved 
outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. 
Annals of hematology 2015 Aug; 94(8): 1327-1336.
7. Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, et al. Characterization of 
novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia 
xenograft models. The Journal of experimental medicine 2012 Oct 22; 209(11): 2017-2031.
8. Hama A, Yagasaki H, Takahashi Y, Nishio N, Muramatsu H, Yoshida N, et al. Acute megakaryoblastic 
leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. British 
journal of haematology 2008 Mar; 140(5): 552-561.
9. Hasle H. A critical review of which children with acute myeloid leukaemia need stem cell 
procedures. Br J Haematol 2014 Jul; 166(1): 23-33.
10. Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P, et al. Hematopoietic SCT in 
Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone 
Marrow Transplant 2014 Jun; 49(6): 744-750.
11. Inaba H, Zhou Y, Abla O, Adachi S, Auvrignon A, Beverloo HB, et al. Heterogeneous cytogenetic 
subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective 
international study. Blood 2015 Sep 24; 126(13): 1575-1584.
12. Baruchel A, Daniel MT, Schaison G, Berger R. Nonrandom t(1;22)(p12-p13;q13) in acute 
megakaryocytic malignant proliferation. Cancer genetics and cytogenetics 1991 Jul 15; 54(2): 
239-243.
13. Carroll A, Civin C, Schneider N, Dahl G, Pappo A, Bowman P, et al. The t(1;22) (p13;q13) is 
nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology 
Group Study. Blood 1991 Aug 1; 78(3): 748-752.
14. Mercher T, Busson-Le Coniat M, Nguyen Khac F, Ballerini P, Mauchauffe M, Bui H, et al. Recurrence 
of OTT-MAL fusion in t(1;22) of infant AML-M7. Genes Chromosomes Cancer 2002 Jan; 33(1): 22-
28.
15. O‘Brien MM, Cao X, Pounds S, Dahl GV, Raimondi SC, Lacayo NJ, et al. Prognostic features in 
acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 
multicenter trial and the Children‘s Oncology Group Study POG 9421. Leukemia 2013 Mar; 27(3): 
731-734.
16. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, et al. An Inv(16)(p13.3q24.3)-
encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute 
megakaryoblastic leukemia. Cancer cell 2012 Nov 13; 22(5): 683-697.
17. Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, et al. CBFA2T3-GLIS2 fusion transcript 
is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 
subtype. Blood 2013 Apr 25; 121(17): 3469-3472.
18. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric 
ch1-6.indd   102 13-4-2016   21:59:03
103
5
MLL-rearranged acute myeloid leukemia. Leukemia 2011 Aug; 25(8): 1239-1248.
19. Pigazzi M, Masetti R, Bresolin S, Beghin A, Di Meglio A, Gelain S, et al. MLL partner genes drive 
distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an 
AIEOP study. Leukemia 2011 Mar; 25(3): 560-563.
20. Mercher T, Courtois G, Berger R, Bernard OA. [Molecular basis of the t(1;22)(p13;q13) specific for 
human acute megakaryoblastic leukemia]. Pathologie-biologie 2003 Feb; 51(1): 27-32.
21. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and 
acute megakaryoblastic leukemia of Down syndrome. Blood 2003 Jun 1; 101(11): 4301-4304.
22. Magalhaes IQ, Splendore A, Emerenciano M, Figueiredo A, Ferrari I, Pombo-de-Oliveira MS. 
GATA1 mutations in acute leukemia in children with Down syndrome. Cancer genetics and 
cytogenetics 2006 Apr 15; 166(2): 112-116.
23. Reinhardt K, Zwaan C, Dworzak M, Rooij Jd, Kaspers G, Lernbecher T, et al. High Frequency of 
GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia. 2012: 
Available online: https://ash.confex.com/ash/2012/webprogram/Paper51445.html (accessed 
July 51415th 52015).
24. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents 
with acute myeloid leukemia: an international retrospective study. Blood. 2007;109(11):4641-
4647.
25. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: 
United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 
2010;28(16):2674-2681.
26. Chilton L, Hills RK, Harrison CJ, Burnett AK, Grimwade D, Moorman AV. Hyperdiploidy with 49-65 
chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with 
differential outcome. Leukemia. 2014;28(2):321-328.
27. Sandahl JD, Kjeldsen E, Abrahamsson J, et al. Ploidy and clinical characteristics of childhood acute 
myeloid leukemia: A NOPHO-AML study. Genes Chromosomes Cancer. 2014;53(8):667-675.
28. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal 
aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly 
according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682-2689.
29. Bastos-Oreiro M, Perez-Corral A, Martinez-Laperche C, Bento L, Pascual C, Kwon M, et al. 
Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute 
myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Eur J 
Haematol 2014 Sep; 93(3): 239-246.
30. Taga T, Saito AM, Kudo K, Tomizawa D, Terui K, Moritake H, et al. Clinical characteristics and 
outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 2012 
Aug 30; 120(9): 1810-1815.
31. Crispino JD. GATA1 mutations in Down syndrome: implications for biology and diagnosis of 
children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. 
Pediatric blood & cancer 2005 Jan; 44(1): 40-44.
32. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, et al. Acquired mutations 
in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature genetics 2002 Sep; 32(1): 
148-152.
33. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, et al. Different 
drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral 
blood mononuclear cells in children with and without Down syndrome. Blood 2002 Jan 1; 99(1): 
245-251.
34. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, et al. The landscape of somatic 
mutations in Down syndrome-related myeloid disorders. Nature genetics 2013 Nov; 45(11): 
1293-1299.
35. Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. Blood 2015 
Aug 20; 126(8): 943-949.
36. Ono R, Hasegawa D, Hirabayashi S, Kamiya T, Yoshida K, Yonekawa S, et al. Acute megakaryoblastic 
leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children. Eur 
ch1-6.indd   103 13-4-2016   21:59:03
Chapter 5: Risk-group stratification in pediatric AMKL 
J Pediatr 2015 Apr; 174(4): 525-531.
37. Reinhardt D, Reinhardt K, Neuhoff C, Sander A, Klusmann JH, Pekrun A, et al. [GATA1-mutation 
associated leukemia in children with trisomy 21 mosaic]. Klin Padiatr 2012 Apr; 224(3): 153-155.
ch1-6.indd   104 13-4-2016   21:59:03
105
5
Supplementary data
Supplementary Table 5.1. Primer design and PCR program for identification of NUP98/KDM5A, 
RBM15/MKL1, CBFA2T3/GLIS2 and specific KMT2A-rearrangements.
* The KMT2A forward primer is used for every KMT2A-rearrangement with a specific reverse primer. 
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Supplementary Table 5.2. Clinical outcome of patients positive for CBFA2T3/GLIS2, NUP98/
KDM5A, RBM15/MKL1 and KMT2A-rearrangements. 
PIN Patient origin Aberration Sex Age at diagnosis
WBC at 
diagnosis
CR 
achieved Relapse SCT Event Death COD
1 AIEOP CBFA2T3/GLIS2 male 0,7 12,79 yes no yes no event no
2 AIEOP CBFA2T3/GLIS2 female 0,5 22,8 no no no non-remitter yes infection
3 AIEOP CBFA2T3/GLIS2 female 2,0 9,6 yes no yes no event no
4 AIEOP CBFA2T3/GLIS2 female 1,4 65,08 no no no non-remitter yes infection
5 AIEOP CBFA2T3/GLIS2 female 3,2 13,63 yes yes yes relapse yes leukemia
6 AIEOP CBFA2T3/GLIS2 female 3,0 13,25 yes no yes no event no
7 AIEOP CBFA2T3/GLIS2 male 4,0 7,52 no no yes no event no
8 AIEOP CBFA2T3/GLIS2 female 0,7 55,48 yes yes yes relapse yes leukemia
9 AIEOP CBFA2T3/GLIS2 female 1,6 13,6 yes no NA died in CR yes infection
10 AIEOP CBFA2T3/GLIS2 female 1,9 24,22 yes yes yes relapse yes
11 COG CBFA2T3/GLIS2 male 1,2 155,5 no no no non-remitter yes leukemia
12 COG CBFA2T3/GLIS2 male 2,6 9,5 yes yes yes relapse no
13 COG CBFA2T3/GLIS2 female 3,1 21,9 yes yes yes relapse yes leukemia
14 COG CBFA2T3/GLIS2 female 3,3 19,6 no no yes non-remitter no
15 COG CBFA2T3/GLIS2 female 0,8 300,1 no no no non-remitter yes leukemia
16 COG CBFA2T3/GLIS2 female 1,1 18,6 yes yes no relapse yes unknown
17 COG CBFA2T3/GLIS2 female 2,1 31,1 yes yes yes relapse yes leukemia
18 COG CBFA2T3/GLIS2 female 1,7 24,6 yes no no no event no
19 COG CBFA2T3/GLIS2 female 0,8 11,7 yes no no no event no
20 COG CBFA2T3/GLIS2 female 3,4 16 yes no no no event no
21 DCOG/BFM CBFA2T3/GLIS2 male 1,2 9,5 yes yes no relapse yes leukemia
22 DCOG/BFM CBFA2T3/GLIS2 female 1,4 12,4 yes yes no relapse yes leukemia
23 DCOG/BFM CBFA2T3/GLIS2 female 0,6 10,5 yes yes NA relapse yes leukemia
24 DCOG/BFM CBFA2T3/GLIS2 male 1,5 19,1 yes no NA no event no
25 AIEOP NUP98/KDM5A male 0,8 188 yes yes yes relapse yes leukemia
26 AIEOP NUP98/KDM5A female 2,1 5,83 yes no yes no event no
27 AIEOP NUP98/KDM5A female 2,3 28,4 yes yes NA relapse yes leukemia
28 COG NUP98/KDM5A female 1,8 9,7 no no yes non-remitter yes leukemia
29 COG NUP98/KDM5A male 3,2 5,9 yes no no no event no
30 COG NUP98/KDM5A female 3,3 13,1 yes no no no event no
31 COG NUP98/KDM5A male 2,5 20,1 yes yes yes relapse yes leukemia
32 DCOG/BFM NUP98/KDM5A male 1,3 8,4 yes no no no event no
33 DCOG/BFM NUP98/KDM5A female 1,4 14,9 yes no no no event no
34 DCOG/BFM NUP98/KDM5A male 1,8 11,5 no no no non-remitter yes leukemia
35 DCOG/BFM NUP98/KDM5A female 1,4 19 yes yes no relapse yes leukemia
36 DCOG/BFM NUP98/KDM5A male 8,5 11,7 yes no no died in CR yes toxicity
37 DCOG/BFM NUP98/KDM5A female 4,9 NA yes yes no relapse yes leukemia
38 DCOG/BFM NUP98/KDM5A female 1,7 NA yes no no died in CR yes died in CR
39 COG KMT2A/MLLT1 male 12,0 1,1 yes no yes no event no
40 AIEOP KMT2A/MLLT10 male 2,1 6,8 yes yes yes relapse yes leukemia
41 DCOG/BFM KMT2A/MLLT10 male 4,1 NA yes no no no event no
42 DCOG/BFM KMT2A/MLLT10 male 7,6 2,3 yes yes no relapse yes leukemia
43 AIEOP KMT2A/MLLT3 female 4,0 6,3 yes no yes no event no GVHD
44 AIEOP KMT2A/MLLT3 male 2,7 7,4 yes no yes no event no
45 AIEOP KMT2A/MLLT3 female 1,1 14,8 yes yes yes relapse yes leukemia
46 AIEOP KMT2A/MLLT3 male 1,0 12,5 yes no yes no event no
47 COG KMT2A/MLLT3 male 1,4 6,6 yes yes yes relapse yes leukemia
48 COG KMT2A/MLLT3 male 1,4 15,8 no no yes non-remitter yes leukemia
49 DCOG/BFM KMT2A/MLLT3 male 1,8 16,3 yes yes no relapse yes leukemia
50 DCOG/BFM KMT2A/MLLT3 female 1,8 NA yes yes no relapse yes leukemia
51 DCOG/BFM KMT2A/MLLT3 male 0,7 31 yes yes no relapse yes leukemia
52 COG KMT2A/MLLT6 female 4,0 5,6 yes no yes ARDS yes ARDS
53 AIEOP RBM15/MKL1 female 1,5 10,69 yes no yes no event no
54 AIEOP RBM15/MKL1 male 1,1 9,8 yes no yes GVHD yes GVHD
55 AIEOP RBM15/MKL1 male 1,0 12,9 yes no yes no event no
56 COG RBM15/MKL1 female 1,3 18,9 yes no yes no event no
57 COG RBM15/MKL1 female 0,2 22,4 yes no no no event no
58 COG RBM15/MKL1 female 0,9 13,8 yes yes yes relapse yes leukemia
59 COG RBM15/MKL1 female 0,1 32,7 yes no yes no event no
60 COG RBM15/MKL1 female 0,8 13,2 no no no non-remitter yes leukemia
61 COG RBM15/MKL1 female 0,6 11,7 yes no no no event no
62 COG RBM15/MKL1 male 0,1 27,6 yes no yes no event no
63 COG RBM15/MKL1 female 2,0 16,4 yes no no no event no
64 COG RBM15/MKL1 male 0,4 14,8 no no yes non-remitter no
65 COG RBM15/MKL1 female 2,6 5,6 yes no no no event no
66 DCOG/BFM RBM15/MKL1 male 0,2 NA yes no no died in CR yes toxicity
67 DCOG/BFM RBM15/MKL1 female 0,2 NA yes no no no event no
68 DCOG/BFM RBM15/MKL1 male 0,6 6,9 yes no yes no event no
69 DCOG/BFM RBM15/MKL1 female 0,6 23,4 no no no early death yes hemorrhage
70 DCOG/BFM RBM15/MKL1 female 2,7 5,9 yes no NA no event no
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Supplementary Table 5.3. Patient characteristics and karyotype data for patients negative for 
CBFA2T3/GLIS2, NUP98/KDM5A, RBM15/MKL1, and KMT2A-rearrangements. (part 1/2)
PIN Patient origin Karyotype Sex
Age at 
diagnosis (y)
WBC at 
diagnosis
71 AIEOP 46,XX Female 0,8 8,4
72 AIEOP 46,XX Female 1,5 13,4
73 AIEOP 46,XX Female 2,2 8,6
74 AIEOP 46,XY Male 2,2 10,7
75 AIEOP 46,XY Male 1,4 22,4
76 AIEOP 46,XX Female 7,3 59,0
77 AIEOP 46,XX Female 2,4 2,5
78 AIEOP 46,XY Male 1,8 12,9
79 COG 46,XX[20] Female 15,1 1,1
80 COG 46,XX[25] Female 1,3 15,5
81 COG 46,XY[30] Male 2,2 11,9
82 DCOG/BFM 46,XY[16] Male 0,7 16,1
83 DCOG/BFM 46,XY[21] Male 1,1 23,3
84 COG 45,XX,-7[15] Female 17,1 16,8
85 COG 45,XX,-7[6]/45,XY,-7,del(11)(p11.2p15)[14] Female 11,7 90,2
86 DCOG/BFM 38~47,XX,-7,-8,+8,+19[cp14]/46,XX[7] Female 1,5 12,2
87 DCOG/BFM 45,XX,-7[24] Female 0,7 68,4
88 DCOG/BFM 50,XY,del(7)(p13),+8,+19,+21,+21[10] male 1,2 66,0
89 DCOG/BFM 46,XX,-6,-7,del(12)(p12),-19,add(21)(p11),+mar1,+mar2,+r[9]/46,XX[1] Female 1,1 NA
90 AIEOP 49,XY+2,del(6)(q?),-7,-9,?17,+?19,+,mar,1 dmin(cp5)/46,XY(16) Male 0,5 8,7
91 AIEOP 46,XY,i(21)(q10)[16]/46,XY[8] Male 1,7 7,8
92 AIEOP 47,XY,+21[2]/46,XY[21] Male 2,7 14,9
93 AIEOP 48,XX,+21,+21[15]/49,idem,+14[5]/47,XX,+21[1] Female 1,4 19,3
94 COG 47,XY,+21[6]/47,idem,inv(6)(p24q21)[13]/46,XY[1] Male 2,0 22,8
95 DCOG/BFM 47,XX,+21/46,XX Female 1,0 NA
96 DCOG/BFM 48,XY,+19,+21 Male 1,6 14,5
97 DCOG/BFM 49,XY,+16,del(17)(p11),+19,+21,+21,-22[5]/46,XY[22] Male 2,0 52,2
98 DCOG/BFM 48,XY,+19,+21,+21,-22[5]/46,XY[22] Male 2,2 48,6
99 AIEOP 45,XX,t(3;6)(q27;q25)inv(3)(p13q27),-7[22] Female 15,0 8,8
100 AIEOP
48,XY,der(1)t(1;13)(p35.1;q3?2),der(7)t(7;17)(p21;?).der(17),dup(17)(q21q23),+21,+21[cp2]/46,X,-Y,der(7)t(7;17),inv(13)(p12-13q14), -
17,dup(17),+21,+21[20] Male 1,6 6,3
101 AIEOP 51,XX,+2,add(2)(q3?7),del(6)(q2?),del(7)(p1?4),+8,+9,add(9)(q?),+?10,+19[2]/46,XX[18] Female 2,2 14,9
102 COG 45,XX,add(7)(p22),-9,add(10)(q26),add(13)(q34),add(15)(p11.1)[cp7]/46,idem,+8,add(22)(p11.1)[2]/46,XX[11] Female 1,6 9,7
103 COG 45,XY,add(4)(p14),add(6)(p21.3),del(7)(p15),psudic(19;12)(p13.3;p13)[6]/46,XY[17] Male 2,3 2,5
104 COG 46,X,der(X)t(X;22)(p22.1;q13),add(6)(q21),add(22)(q13)[22] Female 0,1 378,5
105 COG
46,XY,+1,der(1:19)(q10:p10),add(4)(q21),-7,add(7)(p13),add(8)(q22),del(11)(q13q23),-12,-13,add(14)(q32),+2-7mar[cp13]/ 
56,idem,+add(4)(q21),+7,+10,+11,+13,+14,+21,+22,+2mar[cp4]/46,XY[4] Male 0,9 23,7
106 COG
46,XY,-1,-2,t(16:21)(q24:q22.1),+der(1)t(1:?)(p36.3:?),+der(2)t(2:?)(q37:?)[3]/48,XY,-1,-2,+19,t(16:21)(q24:q22.1), +der(1) 
t(1:?)(p36.3:?),+der(2)t(2:?)(q37:?),+der(21)t(16:21)(q24:q22.1)[4]/46,XY,-1,-2,-4,t(16:21)(q24:q22.1),+der(1),t(1:?)(p36.3:?), 
+der(2)t(?:2)(2:?)(?:p25q37:?),+der(4)t(1:4)(q32:q35)[6]/46,XY,-3,-20,t(16:21)(q24:q22.1),+der(3)t(3:?)(p2?6:?),+der(20) 
t(?:20)(20:?)(?:p13q13.3:?)[6]/46,XY[1]/46,XY,add(1)(p36.3),add(2)(q37),t(16:21)(q24:q22.1)[3]/48,idem,+19, +der(21) 
t(16:21)(q24:q22.1)[4]/46,idem,add(2)(q37),+der(2)add(2)(p25)add(2)(q27),der(4)t(1:4)(q32:q35)[6]/46,idem,+1,-add(1)(p36.3),+2, -
add(2)(q37),add(3)(p2?6),der(20)add(20)(p13)add(20)(q13.3)[6]/46,XY[1]
Male 5,7 6,7
107 COG 46,XY,t(3;21)(q25;q22.3),del(5)(q31),r(7)(::p22->q36::?p15->?p22::),der(11)(11pter->11q13::11q24->11q22::7p15->7pter) Male 2,5 18,2
108 COG 46,Y,inv(X)(p11.2q26),add(2)(q21),t(6;8)(q13;q13),t(15;20)(q22;q13.3),add(17)(p13)[12]/46,XY[10] Male 1,6 26,2
109 COG 47,XX,add(3)(q21),add(5)(p14),add(10)(q26),der(11)add(11)(p13)del(11)(q13q22),+21[21] Female 1,7 43,7
110 COG
47,XX,der(5)t(5;17)(p13;q21)t(1;5)(q21;q31),der(17)t(5;17)(p13;q21),+19[7]/56,idem,+2,+4,+5,+6,+10,+13,+20,+21, 
+22[cp13]/46,XX[1] Female 1,2 90,8
111 COG
47,XY,der(2)del(2)(p11.2)t(2;7)(q11.2;p14),der(7)t(2;7)(q11.2;p14),t(11;16)(q14;q22),del(15)(q11.2q15),add(17)(q25), 
+mar[cp4]/46,XY[16] Male 1,3 56,3
112 COG
48,XX,t(2;19)(q14.3;p13.3),der(3)inv(3)(p13q26.3)t(3;4)(q26.3;q21),der(4)t(4;7)(q21;p15),der(7)t(3;7)(q26.3;p15),del(9)(q13q22), 
+10,+der(19)t(2;19)[12]/46,XX[10] Female 1,1 13,0
113 COG 49,Y,t(X;1)(q24;q22.1),+6,+8,+mar[15]/46,XY[5] Male 1,6 18,6
114 COG 50,XX,+2,+4,add(7)(p12),del(7)(p15p21),+17,add(17)(p11.2),+mar[cp2]/46,XX[21] Female 2,1 13,2
115 COG 50,XX,+7,+8,+10,der(17)t(2;17)(q21;p13),+19[14]/46,XX[11] Female 2,0 19,1
116 COG 50,XY,+6,+7,t(7;10)(p15;q11.2),+8,+19[6]/46,XY[13] Male 1,2 54,7
117 COG 51,XX,+8,+12,+19,+20,+21[15]/46,XX[5] Female 0,1 4,0
118 COG 58,X,t(X:7:1)(q22:p15:q21),+5,+6,+8,+8,+8,+der(9)t(9:14)(q22:q32),t(9:14)(q22:q32),+t(9:14),+10,+15,+19,+22[16]/46,XY[4] Female 1,5 10,1
119 COG 61,XX,+2,+6,+6,+7,+8,+8,+10,+13,+13,+17,+19,+19,der(19)t(1:19)(q11:q13.4),+20,+21,+21[cp10]/122,idemx2[cp4]/46,XX[6] Female 2,3 8,7
120 COG
63,XY,+Y,+der(1:12)(p10:p10),+2,add(3)(q25),+4,der(7)t(3:7)(p22:q36),+der(7)t(3:7)(p22:q36),+8,+9,-10, 
+14,+15,+18,+19,+19,+20,+21,+22,+3mar[16]/46,XY[22] Male 1,1 14,4
121 COG 84,XXX,-X,-1,-2,-4,-5,add(5)(q33)x2,-7,-9,+10,-11,-14,-16,-18,+20,+21,+21,-22,add(22)(q11.2)[13]/46,XX[7] Female 3,0 9,8
122 DCOG/BFM 42-44,XX,-2,add(5p),add(6q),+8,-16,-17,-19,+mar1,+mar2[cp10]/46,XX[14] Female 2,1 47,6
123 DCOG/BFM 47,XY,+3,der(20)t(1;20)(q12;q2?1)[14]/47,X,der(Y)t(1,Y)(q12,q12),+3[7] Male 0,5 8,5
124 DCOG/BFM 48,X,t(X;7)(q22?;p15),+10,-16,+der(16)t(2;16)(q12;p13),+der(1q)t(19;?)(p133;?) Female 1,8 16,8
125 DCOG/BFM
50~55,XY,t(2;7)(p11;p11),+der(2)?t(2;7)(p11;p11),+6,+der(7)t(7;14)(p12;q11)[2],+8,+8[3],+13[9],-14[2], 
+der(10)t(10;19)(q21;q13.4)[8],+der(19)t(10;19)(q21;q13.4),+21[4][cp13]/46,XY[7] Male 1,5 13,7
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Supplementary Table 5.3. Patient characteristics and karyotype data for patients 
negative for CBFA2T3/GLIS2, NUP98/KDM5A, RBM15/MKL1, and KMT2A-
rearrangements. (part 2/2)
Abbreviations: PIN indicates patient identification number; WBC, white blood cell count x109/L; CR, 
complete remission; SCT, stem cell transplantation; COD, cause of death; NA, not available.
PIN Patient origin Karyotype Sex
Age at 
diagnosis (y)
WBC at 
diagnosis
126 DCOG/BFM 52chromosomes,XY,+8,+14,+16,+21,+21,+21[16] Male 2,1 8,5
127 DCOG/BFM 52,XY,del(1)(q41),+4,+6,t(7;22)(q31;q13),+del(8)(q24),+9,+19+21,inc[7]/46,XY[5] Male 0,8 NA
128 DCOG/BFM
76~80,XX,+X,+X,+1,+2,+3,+3,+4,+5,+5,-6,+del(6(q16),+7,+8,+8,+der(9)t(1;9)(q2?2;q34)x2, 
+10,+11,+12,+13,+14,+15,+17,+18,+18,+19,+19,+der(21)t(16;21;?)x2,+22,+22,+1~4mar[cp24]/46,XX[2] Female 12,5 8,7
129 AIEOP 47,Y,t(X;16)(q26;q23),+21[19]/47,XY,+21[5] Male 0,5 8,3
130 COG 46,XX,t(1;22)(q13;q13)[6]/46,XX[14] Female 0,4 12,3
131 COG 46,XY,del(5)(q31q34)[10]/46,XY,del(9)(q12q32)[2]/46,XY[8] Male 13,2 1,1
132 DCOG/BFM 46,XY,t(1;22)(p13;q13)[8]/46,XY,[12] Male 0,3 NA
133 DCOG/BFM Hyperdiploidyat55~71chromosomes Male 0,6 31,6
134 DCOG/BFM Reported as complex karyotype, no specific data available. Male 0,9 5,6
135 AIEOP Not available Male 2,0 26,2
136 AIEOP Not available Female 1,0 14,4
137 AIEOP Not available Female 3,5 10,9
138 AIEOP Not available Female 1,4 8,5
139 AIEOP Not available Male 1,5 8,6
140 AIEOP Not available Female 0,6 18,7
141 AIEOP Not available Male 1,7 52,3
142 AIEOP Not available Male 1,9 5,7
143 AIEOP Not available Female 1,1 15,7
144 AIEOP Not available Male 0,9 5,4
145 COG Not available Male 0,9 16,9
146 COG Not available Male 6,0 19,9
147 COG Not available Female 2,3 11,0
148 COG Not available Female 2,6 5,5
149 COG Not available Female 2,0 7,7
150 DCOG/BFM Not available Male 5,1 14,8
151 DCOG/BFM Not available Male 2,4 16,8
152 DCOG/BFM Not available Female 2,1 49,1
153 DCOG/BFM Not available NA 1,5 NA
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Supplementary Table 5.4. Overview of aberrations found in the karyotypes of pediatric 
AMKL (n=153). Each column represents a single case. A cell colored means positive for 
the aberration corresponding with that particular row.
X; karyotype is not available, only information given is hyperdiploid, or complex karyotype.
Abbreviations: KMT2A-r indicates KMT2A-rearrangement; +21, trisomy 21; CN, cytogenetically normal; -7, 
monosomy 7.
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Abstract
ETV6 encodes a transcription factor that acts as tumor suppressor and is required for 
proper hematopoiesis of all lineages. ETV6-aberrations strongly associate with leukemia. 
In pediatric AML, the MNX1/ETV6 fusion is found in infants, and characterizes by a poor 
clinical outcome. However, the role of alterations of the ETV6 gene in pediatric AML 
have not been fully addressed. We aimed to determine whether ETV6 aberrations are 
recurrent by screening for mutations with direct sequencing, for deletions by MLPA, 
and for translocations using split-signal FISH and RNA-sequencing, and analyzed the 
clinical relevance by studying outcome parameters. In a cohort of de novo pediatric 
AML patients (n=275) we identified 6 patients with mutations in ETV6, 4 patients with 
an ETV6 deletion and 9 patients with an ETV6 translocation. In patients with an ETV6 
mutation or deletion, several genes were significantly up-regulated, including CLDN5, 
DPEP1 and BIRC7, as reported earlier for T-cell ALL with functional ETV6 silencing. 
Six patients were identified harboring MNX1/ETV6. RNA-sequencing revealed three 
additional translocations; ETV6/ARNT1, ETV6/HOXCas2 and ETV6/HOXA11as. Poorer 
survival parameters for ETV6 aberrated cases were found for overall survival. We 
conclude that ETV6 mutations, deletions and translocations are rare but recurrent in 
pediatric AML.
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Introduction
The overall survival (OS) of pediatric acute myeloid leukemia (AML) is ~70% and 
the 5 year event-free survival (EFS) is ~50-60%.1-3 Treatment stratification is based 
on early treatment response and the presence of prognostically relevant genomic 
aberrations.4-6 Although many recurrent pathologic mutations in pediatric AML have 
been defined, in ~20% of the patients the oncogenic event(s) driving the malignancy 
remain unidentified.1, 7
The ETS-Variant gene 6 (ETV6, also known as Translocation Ets Leukemia (TEL)) 
located on chromosome 12p13 encodes a transcription factor that is required for 
homing and survival of all hematopoietic lineages in the bone marrow niche.8-10 ETV6 
operates as a transcriptional repressor using its C-terminal ETS domain for binding ETS 
binding sites and its N-terminal helix-loop-helix (HLH) domain for homodimerizaton. 11-
17 ETV6 was originally identified due to its involvement in translocation t(5;12)(q33;p13) 
found in chronic myelomonocytic leukemia (CMML).17 This translocation generates the 
fusion protein ETV6/platelet derived growth factor receptor, beta polypeptide (ETV6/
PDGFRB). 
Over 30 fusion partners of ETV6 have been described, and these gene 
rearrangements show strong association with leukemia.18 In pediatric acute 
lymphoblastic leukemia (ALL), t(12;21)(p13;q22) (ETV6/RUNX1, also known as TEL/
AML1 or TEL/CBFA2) is the most common alteration with a prevalence of ~25%.19 It 
is often accompanied by a complete or partial deletion of the non-translocated ETV6 
allele, leading to absent expression of ETV6. 20-22 However, in some cases it has been 
shown that the expression of ETV6 is absent, although the second ETV6 allele is present, 
suggesting that other mechanisms, such as hyper-methylation or point mutations, may 
silence the ETV6 gene.22
In early immature adult T-cell acute lymphoblastic leukemia (T-ALL), 
mutations affecting the predicted amino-acid sequence of ETV6 were found in 24%.23 
These mutations result in the expression of N-terminally of C-terminally truncated 
ETV6 proteins unable to repress gene expression, leading to a gene expression 
profile dominated by up-regulation of target genes. In adult AML, silencing somatic 
heterozygous ETV6 mutations and deletions have been found. 24, 25
In pediatric AML, translocations involving ETV6 (t(7;12)(q36;p13) (MNX1/
ETV6 or HLXB9/ETV6) and t(7;12)(q32;p13)) have only been described under the age 
of 18 months. These translocations associate with a poor clinical outcome, and are 
characterized by over-expression of MNX1.26, 27 Mutations of ETV6 have been identified 
in pediatric AML using whole genome sequencing.28 However, the role of alterations of 
the ETV6 gene in pediatric AML have not been fully addressed. Therefore, we screened 
a cohort of pediatric AML patients for mutations, deletions and translocations of the 
ETV6 gene.29 We identified repetitive abnormalities in a small number of cases including 
heterozygous mutations affecting the predicted amino-acid sequence of ETV6, partial 
or complete heterozygous deletions of ETV6, and translocations of ETV6, with MNX1, 
ARNT1 and novel fusion partners. We also assessed the clinical outcome of ETV6 gene 
alterations, we determined outcome parameters in patients with ETV6 gene alterated 
cases.
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Material and methods
Patient samples
Samples were provided by the Dutch Childhood Oncology Group (DCOG, The Hague, 
The Netherlands), the AML–Berliner-Frankfurt-Münster (BFM) Study Group (Germany 
and Czech Republic), and the Saint-Louis Hospital (Paris, France). The cohort of newly 
diagnosed pediatric AML patients with available peripheral blood or bone marrow 
samples taken at initial diagnosis included in this study was previously described by us 
(n=293; age, 0-19 years).29 In case of positivity for an ETV6 gene alteration, available 
peripheral blood or bone marrow samples drawn at remission, and relapse material 
in case of a relapse, were obtained from the cell-banks. Clinical characteristics, 
morphological classification and karyotyping were centrally reviewed by each study 
group.
After thawing the samples, leukemic cells were purified as previously described.30 
Blast percentages were assessed morphologically using cytospins stained with a May-
Grünwald-Giemsa staining. Isolation of genomic DNA and total cellular RNA from the 
samples was performed using Trizol reagent. All patients were treated with intensive 
collaborative group cytarabine-anthracycline based pediatric AML treatment protocols. 
Each collaborative study group provided us with centrally reviewed morphological and 
cytogenetic classification and clinical follow-up data. Institutional review board approval 
for these studies had been obtained in the participating centers.
Detection of ETV6 mutations
Using reverse transcriptase polymerase chain reaction (RT-PCR) and direct-sequencing 
ETV6 exon 2 through exon 8 were screened for mutational status. Exon specific 
primers were used (supplementary table 1). Purified PCR products were directly 
sequenced on a PRISM 3100 genetic analyzer (Applied Biosystems) and analyzed using 
CLCWorkbench (Version 3.5.1; CLC Bio, Aarhus, Denmark). Reference genome used was 
ENST00000396373.
Multiplex ligation-dependent probe ampliciation (MLPA)
MLPA was performed on DNA using the SALSA MLPA kit p335-B1 ALL-IKZF1 (MRC 
Holland, Amsterdam, The Netherlands), which contains 6 probes covering ETV6: 
2 probes are located in exon 1, the other probes are located in exon 2, 3, 5 and 8. 
Additionally there are 4 probes covering the BTG1 gene, which is located on 12q22.33, 
for confirmation of the presence of chromosome 12 (data available on http://www.
mlpa.com). The data were analyzed with GeneMarker (version 1.85; SoftGenetics, State 
College, Pennsylvania, USA). The data were normalized to reference probes and healthy 
control samples. A deletion was defined as a peak ratio below 0.75, an amplification was 
defined as a peak ratio above 1.25 in two independent MLPA experiments. A succeeded 
MLPA was considered if all reference probes had a peak ratio between 0.75 and 1.25, 
excluding cases where the karyotype showed a monosomy of the chromosome of the 
correlating reference probe.31
Array comparative genome hybridization (Array-CGH)
Array-CGH was performed on 1µg DNA using the human genome CGH Microarray 
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105K (Agilent Technologies, Santa Clara, California, USA) according to manufacturer’s 
protocol, and data were analysed with Genomic Workbench (version 5.0.14; Agilent 
Technologies, Santa Clara, California, USA).
Gene expression profiling
Gene expression profiling (GEP) data of 293 pediatric AML patients were available from 
earlier studies.29 Checking RNA integrity, processing the Affymetrix Human Genome 
U133 Plus 2.0 Array (Affymetrix, Santa Clara, California, USA), and normalizing and 
analyses of the data were performed as previously described.29 Original data are 
available in the Gene Expression Omnibus repository (http://www.ncbi.nlm.nih.gov/
geo;accession GSE17855).
Identification of translocations involving ETV6
Split signal FISH experiments were performed for detection of ETV6 rearrangements, 
and to confirm deletions as identified with MLPA. Split signal FISH was performed on 
all cases, excluding the cases where already another driving oncogenic type-II event 
had been identified. Dual-color FISH experiments were performed using the Y5400 
probe (Dako, Glostrup, Denmark) with a texas red-labelled DNA-probe covering the 
upstream ETV6-part including exon 1-3, and a fluorescein-labelled DNA-probe covering 
a downstream segment of 12p13, on thawed cytospin slides. At least 100 cells were 
counted. A negative split signal was defined as 2 fusions in ≥80% of the cells. A positive 
split signal was defined as >20% split signal cells and one fusion present in one sample. A 
deletion was defined as one fusion in >20% with the expected second fusion absent. All 
positive samples for split signal were confirmed in a second experiment. The presence 
of the fusions MNX1/ETV6 and ETV6/PDGRFB was analysed by RT-PCR (primers in 
Supplementary Table 6.1). Paired-end transcriptome sequencing was performed on 
diagnostic leukemic cells on the pediatric AML cases with a positive split signal FISH 
and available high-quality RNA using the Illumina platform as previously described by 
Zhang et al.32
Cytogenetic and molecular characterization
Samples were screened for cytogenetic aberrations using standard chromosome 
banding analysis at initial diagnosis by the collaborative study groups. To identify other 
aberrations, RT-PCR was performed on hotspot areas of the following genes; NRAS, 
KRAS, NPM1, MLL-PTD, CEBPA, FLT3, PTPN11, KIT and WT1, as previously described by 
us.33
Validation of expression levels
We performed specific real-time quantitative PCR (RT-qPCR) to validate HOXC9 and 
HOXC10 gene expression levels. RT-qPCR was performed in duplicate in cases with at 
least 80% blasts only. Primer and probe sets are shown in Supplementary Table 6.1. 
The average cycle threshold (CT) value was used to determine the expression levels 
of ETV6 in comparison to the expression levels of the reference gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), using the comparative cycle time method. 
Correlation between GEP data and RT-qPCR was examined.
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Figure 6.1. Six patients demonstrated a mutation affecting the predicted amino-acid sequence of ETV6. 
(A) Schematic representation of the protein structure of ETV6. The boxes with numbers represent exons 
1 through 8 of the ETV6 gene.The in blue highlighted region represents the HLH-domain, the in yellow 
highlighted region represents the ETS-domain. The letters in green are internal translation initiation sites.24 
The letters in red are the identified point mutations. The letters in pink indicate the amino acids were the 
identified frame shifts start. (B) The in green highlighted regions represent changed amino acid sequence 
due to the identified frame shifts.
Figure 6.2. Heterozygous ETV6 deletions in 
AML. Multiplex ligation-dependent probe 
amplification results of a patient with 
heterozygous deletion of exons 1-8 of ETV6.
Figure 6.3. Dual-color split-signal FISH analysis of ETV6. Split-signal FISH of a (A) negative cell line and (B) 
positive patient, using the Y5400 probe (Dako, Glostrup, Denmark) with a texas red-labelled DNA-probe 
covering the upstream ETV6-part including exon 1-3, and a fluorescein-labelled DNA-probe covering a 
downstream segment of 12p13, on thawed cytospin slides.
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Statistical analysis
Statistical analyses were performed with IBM SPSS 21 (IBM, Armonk, New York, 
USA) and SAS for Windows, version 9.3 (SAS, Cary, North Carolina, USA). Categorical 
variables were compared using the chi-square or Fisher exact test and continuous 
variables using Mann-Whitney U test. Correlation coefficients were measured using 
Spearman’s correlation. To assess outcome the following parameters were used; 
complete remission (CR), defined as less than 5% leukemic blasts in the bone marrow, 
with regeneration of tri-lineage hematopoiesis, and absence of leukemic cells in the 
cerebrospinal fluid or elsewhere; probability of event-free survival (pEFS), defined as 
the time between diagnosis and first event including non-responders calculated as an 
event on day 0, death of any cause and second malignancies; and probability of overall 
survival (pOS), defined as the time between diagnosis and death. Both pEFS and pOS 
were estimated by using the Kaplan-Meier method and groups were compared using 
the log-rank test. The cumulative incidence of relapse (pCIR), defined as time between 
diagnosis and relapse, was analysed by the Kalbfleisch and Prentice method and groups 
were compared with the Gray’s test. Statistical significance was considered if p-values 
were below 0.05.
Results
Mutations affecting the predicted amino acid sequence of ETV6 are recurrent in 
pediatric AML.
We screened exon 2 through 8 of ETV6 by direct sequencing on 20ng genomic DNA 
of 275 pediatric AML patients. In one patient (patient #1) we found a silent point 
mutation (TTA>TTG, p.L79L) that has not been previously described (Table 6.1, Figure 
6.1A). In 6 patients, we identified heterozygous mutations affecting the predicted 
amino-acid sequence of ETV6 (Table 6.1, Figure 6.1A). Three of these 6 patients 
demonstrated a heterozygous point mutation, leading to the change of one amino 
acid. Two of those mutations (Patient #2: p.R127W and Patient #3: p.D155N) were 
located in exon 4, upstream of the HLH-domain (Figure 6.1A). The mutation found 
in patient #4 (p.M389V) was located in exon 7 and resulted in an amino acid change 
in the ETS-domain of the ETV6 gene (Figure 6.1B). SIFT analyses (http://sift.jcvi.org/) 
predicted that the point mutations found in patient #2 (p.R127W) and #4 (p.M389V) 
are damaging to the protein function (Table 6.1). Patients #5, #6 and #7 presented with 
a heterozygous insertion (c.250insCC, c.613insC and c.845insC, respectively) resulting 
in a frame shift and a shorter predicted amino acid length of 89, 215 and 298 amino 
acids, respectively (Figure 6.1C). Patient #4, #5, and #6 had remission material available, 
which were negative for mutations in ETV6. Patient #4 and #7 had relapse material 
available, which showed in both cases the mutation retained at relapse. Together these 
data demonstrate recurrent mutations affecting the predicted amino acid sequence of 
ETV6 at a low frequency (6/275=2.2%) in pediatric AML patients.
ETV6 deletions are recurrent in pediatric AML patients.
To determine deletions of the ETV6 gene we performed MLPA analyses in 259 cases 
with available material. We specifically analyzed the probe sets located on chromosome 
12, for ETV6 and the B-cell translocation gene 1 (BTG1). We analyzed 14 healthy control 
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Figure 6.4. Survival estimates of ETV6-aberrations compared to other AML. (A) Kaplan-Meier estimates of 
the 3-year overall survival, event-free survival and cumulative incidence of relapseaccording to the Kalbfleisch 
and Prentice method of ETV6-mutated or deleted cases versus other pediatric AML. (B) Kaplan-Meier 
estimates of the 3-year overall survival, event-free survival and cumulative incidence of relapse according to 
the Kalbfleisch and Prentice method of ETV6-translocated cases versus other pediatric AML. (C) Kaplan-Meier 
estimates of the 3-year overall survival, event-free survival and cumulative incidence of relapse according to 
the Kalbfleisch and Prentice method of ETV6-aberrated cases versus other pediatric AML.
Figure 6.5. ETV6-inactivating mutations and deletions associate with an up-regulation of gene expression. 
Left panel shows plot of the 13 significantly up-regulated genes, ordered by p-value, based on gene expression 
profiles of ETV6-mutated cases versus non-mutated cases. Right panel shows plot of the 38 significantly up-
regulated genes of ETV6-deleted cases versus non-deleted cases.
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samples as negative controls, and the Reh cell line, a B-cell precursor leukemia cell line 
harboring the ETV6/RUNX1 fusion and a heterozygous deletion of ETV6, as positive 
control. In three patients, we detected a heterozygous deletion of all analyzed ETV6 
exons (Figure 6.2). In none of these cases the BTG1 gene was deleted, indicating the 
event was focal. Array CGH analyses confirmed that the chromosome 12p deletions 
included the ETV6 gene locus (Table 6.1). In one patient, we detected a partial ETV6 
deletion, covering exon 1 through 5 and amplification of exon 8 of the ETV6 gene and 
the BTG1 gene by MLPA. Array CGH analyses of this patient confirmed deletion of 
chromosome 12p13.2, including the telomeric part of the ETV6 gene (Table 6.1), and 
demonstrated amplification of chromosome 12q (including the BTG1 gene) and the 
centromeric part of 12p, including ETV6 exon 8. Together, these results show that ETV6 
deletions are recurrent in pediatric AML patients at a low frequency (4/259=1.6%).
ETV6 gene translocations are recurrent in pediatric AML patients.
To identify ETV6 translocations, we only screened the patients without a known type II 
mutation (n=65), assuming these type II mutations are mutually exclusive. We used an 
ETV6 split signal FISH approach on cytospins to identify translocations involving ETV6, 
including two patients previously identified with the MNX1/ETV6 translocation as 
confirmation and positive control (patients #13 and #17, Table 6.2). Three patients were 
identified with a positive ETV6 split signal as defined as >20% of the cells containing 
a split signal and one fusion, were negative for MNX1/ETV6 as screened with RT-PCR 
(Figure 3, patients #18-20, Table 6.2).
To determine the translocation partner of ETV6 in these patients, we 
performed paired-end RNA sequencing. This resulted in the identification of three 
different translocations. We identified one case with translocation ETV6/ARNT, a fusion 
previously described in pediatric AML and T-ALL.34, 35 We found 2 HOX-antisense genes 
as novel ETV6 translocation partners in pediatric AML; ETV6/HOXC-AS2, and ETV6/
HOXA11-AS. The antisense molecules are not protein coding, and these fusions are 
most likely to result in a loss of function of ETV6, as well as a loss of the specific HOX-
antisense. 
 All fusions were confirmed using RT-PCR and direct sequencing (primers in 
Supplemental Table 6.1). Together these data demonstrate ETV6 translocations are 
recurrent in pediatric AML. 
Clinical characteristics of the pediatric AML cohort
The median age at diagnosis of the pediatric AML cohort was 9.6 years (range 0.1-
18.5yrs), 43% of the cases were female, and the median white blood cell count (WBC) 
at diagnosis was 45.2x109/L (range 1.2-481.8). Cytogenetic aberrations in this group 
showed a representative distribution for the frequencies seen in pediatric AML in 
general (Supplementary Table 6.2).1, 5 Age at diagnosis (<2 years of age) or treatment 
including a hematopoietic stem cell transplantation did not influence outcome (HR:0.65; 
95%CI0.38-1.11, p=0.113 and HR:0.99; 95%CI0.95-1.95, p=0.97, respectively), and 
standard risk cytogenetics conferred to a favourable prognostic outcome as expected 
(HR:0.27, 95%CI0.15-0.50, p<0.01).
The median age of patients with an ETV6-mutation or deletion (n=10, 
excluding the silent mutation) was 11.3 years (range 4.0-15.3 years) and 40% was 
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female. Median WBC was significantly lower (15.1x109/L, range 2.8-196.0, p<0.01) in 
comparison to all other pediatric AML cases. Co-occuring cytogenetic aberrations found 
in the ETV6-mutated or deleted cases were RUNX1/RUNX1T1 (n=3), PML/RARA (n=1), 
MLL/AF6 (n=1) and one NPM1-mutated case (Table 2). Other co-occuring aberrations 
in the translocated group were a KIT mutation, and the fusion of BCR and ABL1, both 
considered to increase cell proliferation, and therefore classified as type-1 mutation.36, 
37All ETV6-mutated or deleted cases achieved complete remission, versus 80% of the 
other AML cases. Six out of ten patients encountered a relapse and one patient died in 
complete remission, suggesting poor clinical outcome (Table 6.2) although this could 
not be proven statistically, as the 3-yr pOS was 50±16% in the ETV6-mutated or deleted 
group (n=10) versus 63±3% in the other AML cases (n=251, p=0.09), the pEFS was 
30±14% vs 45±3% (p=0.54), and the pCIR was 60±17% vs 37±3% (p=0.16) (Figure 6.4). 
Four out of 9 translocated cases encountered a relapse, one patient did not achieve 
remission and these 5 died due to the leukemia, another two patients died due to 
treatment-related toxicity.
The 3-yr pOS was 22±14% in the ETV6-translocated (n=9) versus 64±3% in the 
other AML cases (n=252, p<0.01), the pEFS was 22±14% vs 46±3% (p=0.04), and the 
pCIR was 56±29% vs 38±3% (p=0.82, Figure 6.4). 
The age at diagnosis for patients with an ETV6-translocation (n=9) was 
significantly lower compared to all other pediatric AML cases (median 1.1 years, range 
0.2-10.4, p=0.0006), median WBC was 21.8x109/L (range 2.4-226.8 x109/L) vs 45.7x109/L 
(p=0.52), and 44% was female (table 2).The 3-yr pOS for all combined ETV6-aberrant 
cases (n=19) was 37±11% vs 65±3% for the other pediatric AML cases (n=242, p=0.002), 
3-yr pEFS was 26±10% vs 46±3% (p=0.07), and 3-yr pCIR 47±13% vs 37±3% (p=0.24). 
Harboring an ETV6 mutation or deletion was an independent factor for prognosis with 
an increased risk for poor outcome concerning OS (Hazard Ratio (HR):2.45; 95%CI1.11-
5.43, p=0.027), but not EFS (HR:1.42; 95%CI0.66-3.08, p=0.373), which was also true 
for harbouring any ETV6 aberration (HR:2.27; 95%CI1.27-4.07, p=0.006 and HR:1.62; 
95%CI0.94-2.79, p=0.082), also when other well-known risk factors such as sex, age at 
diagnosis, WBC, treatment including a hematopoietic stem cell transplantation, and 
standard risk cytogentics such as CBF-AML and PML/RARA were included in the model. 
ETV6-inactivating mutations and deletions associate with an up-regulation of gene 
expression.
To assess the effect of ETV6 inactivation on gene expression, we compared the gene 
expression profiles of patients with an ETV6 mutation (n=6) or deletion (n=4) to those 
of pediatric AML patients without an ETV6 gene alteration (n=260). In patients with an 
ETV6 mutation (n=6) or deletion (n=4) 13 and 38 genes, respectively, were significantly 
up-regulated (Figure 5) and no genes were significantly down-regulated, consistent 
with the role of ETV6 as a transcriptional repressor.11-13. Interestingly, Claudin 5 (CLDN5), 
the gene that is at the top of the list of differently expressed genes in patients with ETV6 
mutations, is the only gene that overlaps between the top lists of patients with ETV6 
mutations and of patients with ETV6 deletions. Other genes that are up-regulated in 
the six patients with ETV6-inactivating mutations (Figure 5), are baculoviral IAP repeat 
containing 7 (BIRC7) and dipeptidase 1 (DPEP1).
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ETV6-HOX translocations associate with an up-regulation of specific HOX genes
RNA antisense has been implicated to control RNA sense expression by sense-antisense 
pairing. 38, 39 The antisense genes may be a silencer of the assigned HOX gene.40, 41 When 
comparing gene expression profiles of the ETV6-HOX fusions (n=2), we identified up-
regulation of specific HOX genes. ETV6/HOXC-AS2 showed a high upregulation of two 
HOX genes; HOXC9 and HOXC10, respectively, which was confirmed with qPCR (data not 
shown), and ETV6/HOXA11-AS showed high expression of HOXA11 (gene expression 
previously validated with qPCR42). 
Discussion
In this study we analyzed the occurrence and frequencies of ETV6 aberrations in 
pediatric AML. We identified mutations, deletions and translocations in the ETV6 gene 
as recurrent events in pediatric AML, although at low frequency (7%). ETV6 mutations 
were found in 2.2% of the cases, which is comparable to the frequency found in adult 
AML.24 Additionally we found ETV6 deletions in 1.6% of patients in our cohort. This 
is at a lower frequency then identified by Helton et al28 (6%), but they selected for 
patients that did not have any other cytogenetic or molecular risk features. Helton 
et al found deletions of ETV6 predominantly in patients with core-binding factor 
(CBF-)AML. We found an ETV6 translocation in 9/275 (3.3%) cases, only screening the 
patients without any known type II mutation, assuming that type II aberrations are 
mutually exclusive. This is a much lower frequency in comparison to the frequency of 
ETV6 translocations found in pediatric ALL.23 Among the pediatric AML cases identified 
with an ETV6 mutation, deletion or translocation, various other non-repetetive genetic 
aberrations were detected. Our data underscore the heterogeneity in underlying 
genetic abnormalities seen in AML.6, 33
Comparing gene expression patterns of mutated and deleted cases versus 
other pediatric AML patients, CLDN5 is the only differentially expressed gene in both 
categories. This gene has been described as one of the up-regulated transcripts after 
functional ETV6-silencing in T-ALL.23 This suggests that the mutations and deletions in 
our series also result in impaired ETV6 function. BIRC7 and DPEP1 are upregulated 
in the ETV6 mutated cases. These genes have been associated with leukemia43, 44 and 
are also up-regulated transcripts after functional ETV6-silencing in T-ALL23. No genes 
were significantly down-regulated in our patients with ETV6 mutations or deletions, 
consistent with the role of ETV6 as a transcriptional repressor.11-13 Together, these 
findings indicate that, consistently with the role of ETV6 as a transcriptional repressor, 
ETV6-inactivating mutations and deletions result in an up-regulated expression of 
several genes, amongst which are genes that are associated with leukemia.
ETV6 is known to have many different translocation partners. We identified 
4 different, of which two novel, partner genes for ETV6 in this cohort. The median 
age of all translocated cases was significantly lower compared to the other pediatric 
AML cases. This lower age seems specific for MNX1/ETV6 and ETV6/ARNT, since the 
ETV6-HOX-antisense translocated cases were older, 9 and 10 years of age at diagnosis 
respectively. The novel identified partner genes were HOX antisense genes. We 
previously identified HOX gene upregulation in a large subset of pediatric AML.29, 42 In 
the two identified translocations, the translocation resulted in an upregulation of the 
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assigned HOX gene(s). The function of the HOX-antisense genes is not fully understood. 
They may be a silencer of the assigned HOX gene.40, 41 Assuming this, the fusion may lead 
to a loss-of-function of this silencing, resulting in an up-regulation of the HOX gene(s).
Although the number of patients with ETV6 aberrations is low, the survival 
analyses suggests that ETV6 aberrations associate with a poor clinical outcome. We 
could not prove a statistically higher relapse rate perhaps due to small numbers., The 
poorer outcome in this series was due to both leukemic events and treatment-related 
mortality.
Altogether, we identified ETV6 aberrations as rare but recurrent event in 
pediatric AML, occurring in 7% of the cases, associated with poor overall survival. 
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Table 6.1. ETV6 mutations and deletions identified in pediatric AML patients.
Abbreviations: ID indicates identification number; MLPA, multiplex-ligand probe amplification; a-CGH, 
array-comparative genome hybridization; SIFT, sorting intolerant from tolerant; fs, frameshift; NA, not 
available.
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Table 6.2. Patient characteristics of ETV6-aberrated cases.
Abbreviations: ID indicates identification number; y, years; WBC, white blood cell count; L, liter; 
FAB, French-American-British classification; CR, complete remission; SCT, hematopoietic stem cell 
transplantation; COD, cause of death; M, male; F, female.
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Supplementary Data
Supplementary Table 6.1. Primers and PCR conditions used for the identification of 
mutations and translocations. 
Abbreviations: PCR indicates poly chain reaction; qPCR, quantitative PCR. 
Gene Direction Primer-sequence PCR condition
ETV6
Mutational 
screening
Exon 2
Exon 3
Exon 4
Exon 5
Exon 6
Exon 7
Exon 8
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
5’-CCCCGAGATGGTCTCAT-3’
5’-TGGCGAAGTCCTGTGAA-3’
5’-AGGGCTCTTGAGATGTGG-3’
5’-ATCCCTTCCTTGTGATGACT-3’
5’-GGTGCGCTCCAATTGTA-3’
5’-CTTCAGGGAACCAAGAGTGT-3’
5’-CACGCTCCTCCATTTACC-3’
5’-GCTGGCTGCAAAGATCA-3’
5’-TCCCGGTAAAACAAGGAA-3’
5’-TGCCCAGCAAGGAATAA-3’
5’-CAGGCAGCAGCTGAAGA-3’
5’-CCCCGTTATTTAAAGAAAACAG-3’
5’-CGGGGTTCAGTAGCTCTC-3’
5’-TCGCTTCCTTTTCCACTC-3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C)
MNX1
ETV6
ETV6
Exon 1
Exon 3
Exon 4
Forward
Reverse 1
Reverse 2
5’-GCATGATCCTGCCTAAGA-3’
5’-GCCATTCATTTCAAACGT-3’
5’-AATCCGAGGTTTCCTCTG-3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C, 30” 
72°C), 10’ 72°C
ETV6
PDGFRB
ETV6
PDGFRB
Exon 2
Exon 14
Exon 4
Exon 11
Forward
Reverse
Forward
Reverse
5’-TCAGGATGGAGGAAGACTCG-3’
5’-CCCCAACAGGTTGACCACGTTCAG-3’
5’-AGCCGGAGGTCATACTG-3’
5’-TGCCAAAGCATGATGAG-3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C, 30” 
72°C), 10’ 72°C
ETV6
ARNT
Exon 4
Exon 6
Forward
Reverse
5’-AGCCGGAGGTCATACTG-3’
5’-CCCGCAAGGACTTCA-3’
ETV6
HOXA11-AS
Exon 1
Exon 5
Forward
Reverse
5’-GCCGGGAGAGATGCT-3’
5’-CTGCCTGGACCTTGAAG-3’
ETV6
HOXC-AS2
intronic 3-4 
antisense
Forward
Reverse
5’-CAGTGCTTCCTTTAAACACAT-3’
5’-GCAGGCAGCTCAAGAGT-3’
HOXC9
qPCR
Exon 1
Exon 2
Forward
Reverse
5’-ACCCGGACTACATGTACG-3’
5’-GCTCGGTGAGATTGAGAA-3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C)
HOXC10
qPCR
Exon 1
Exon 2
Forward
Reverse
5’-GCCCCAATGAAATCAAG-3’
5’-CTCGCGTCAAATACATATTG-3’
10’ 95°C, 40x (15” 95°C, 1’ 60°C)
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Supplementary Table 6.2. Clinical characteristics of patients with ETV6-inactivating 
mutations or deletions.
pediatric AML 
cohort (n=267)
ETV6 deleted or 
mutated cases 
(n=10)
ETV6 translocated 
cases (n=9)
other pediatric 
AML cases 
(n=248)
Age at dx Median (y) 9.6 11.3 1.1 (p<0.01) 9.6
Range (y) 0.1-18.5 4.0-15.3 0.2-10.4 0.1-18.5
Sex Female (%) 43 40 44 43
WBC Median (x109/L) 46.7 11.3 (p<0.01) 21.8 48.2
Range (x109/L) 1.2-483.0 2.8-193.2 2.4-226.8 1.2-481.8
CR Achieved CR (%) 80 100 89 79
FAB-type M0 14 3 3 8
M1 32 0 1 31
M2 49 4 2 43
M3 19 0 1 18
M4 76 2 1 73
M5 59 0 0 59
M6 2 0 0 2
M7 7 0 1 6
Unknown 9 1 0 8
Type 2
aberrations
MLL-
rearrangement 69 1 0 68
RUNX1/RUNX1T1 25 3 0 22
inv(16) 35 0 0 35
PML/RARA 18 1 0 17
DEK/NUP214 6 0 0 6
KAT6A/CREBBP 6 0 0 6
NUP98-
rearrangement 18 0 0 18
CEBPAdm 14 0 0 14
NPM1 19 1 0 18
Other/Unknown 56 4 9 43
Abbreviations: dx indicates diagnosis; y, years; L, liter; CR, complete remission; FAB, French-American-
British classification; M, morphology type; dm, double mutation.
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Abstract
IKAROS family zinc finger 1/IKZF1 is a transcription factor important in lymphoid 
differentiation, and a known tumor suppressor in acute lymphoid leukemia. Recent 
studies suggest that IKZF1 is also involved in myeloid differentiation. To investigate 
whether IKZF1 deletions also play a role in pediatric acute myeloid leukemia, we 
screened a panel of pediatric acute myeloid leukemia samples for deletions of the 
IKZF1 locus using multiplex ligation-dependent probe amplification and for mutations 
using direct-sequencing. Three patients were identified with a single amino acid variant 
without change of IKZF1 length. No frame-shift mutations were found. Out of 11 patients 
with an IKZF1 deletion, eight samples revealed a complete loss of chromosome 7, and 
three cases a focal deletion of 0.1-0.9Mb. These deletions included the complete IKZF1 
gene (n=2) or exons 1-4 (n=1), both leading to a loss of IKZF1-function. Interestingly, 
differentially expressed genes in monosomy 7 cases (n=8) when comparing to non-
deleted samples (n=247) significantly correlated with gene expression changes in focal 
IKZF1 deleted cases (n=3). Genes with increased expression included genes involved 
in myeloid cell self-renewal and cell cycle, and a significant portion of GATA target 
genes and GATA factors. Together, these results suggest that loss of IKZF1 is recurrent 
in pediatric acyte myeloid leukemia and might be a determinant of oncogenesis in AML 
patients with monosomy 7 and focal IKZF1 deletions. 
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by dysregulated 
hematopoiesis initiated by recurrent non-random genetic aberrations.1, 2 Despite major 
progress in improving treatment over the past decades, AML remains a life-threatening 
malignancy in children. The 5 year event-free survival (EFS) rates of pediatric AML are 
currently ~50-60% and the overall survival (OS) rate ~70%.3, 4 Treatment stratification 
is mainly based on early response to treatment and prognostic relevant genetic 
abnormalities. Although many driving recurrent genetic aberrations causing AML have 
been defined, in approximately 20% of the pediatric AML patients the driving genetic 
events remain unidentified.3 
The DNA-binding protein IKAROS family zinc finger 1 (IKZF1) is a zinc finger 
containing transcription factor that is encoded in 8 exons on chromosome 7 (7p12.2). 
IKZF1 functions upon homo-dimerization and acts as a chromatin remodeling protein 
involved in several chromatin remodeling complexes, such as nucleosome-remodeling 
and histone deacetylation (NuRD).5 Alternative splicing of IKZF1 pre-mRNA gives rise 
to several isoforms.6 The functional differences among the various isoforms of IKZF1 
are mostly due to alterations of zinc finger structures required for DNA binding (4 zinc 
fingers in the N-terminal domain) or protein-protein interactions (2 zinc fingers in the 
C-terminal domain).6, 7 Some of these splice variants lack the ability to properly bind 
DNA and act as dominant-negative repressors when dimerized with functional isoforms.
 Loss of Ikzf1 function in mice homozygous for an Ikzf1 null allele or homozygous 
for a dominant-negative isoform of Ikzf1 results in an early arrest of lymphoid 
differentiation with lack of T- and B-lymphocytes and NK cells, as well as their earliest 
identifiable progenitors.8, 9 In heterozygous Ikzf1 mutant mice, lymphocytes appear 
normal right after birth, but proliferation increases and differentiation arrest occurs 
rapidly, leading to the development of leukemia and lymphoma within three months 
after birth.10 In humans, heterozygous loss of IKZF1 is found in 15% of B-cell precursor 
ALL (BCP-ALL) patients; in 70-80% of BCR/ABL1 (t(9;22)(q34;q11)) positive BCP-ALL 
patients and in 33% of BCR/ABL1 negative BCP-ALL patients. 11-15 In BCR/ABL1 ALL 
patients, heterozygous loss of IKZF1 associates with a poor clinical outcome. In T-ALL 
heterozygous loss of IKZF1 is found in only 4%, but it remains unclear if this has any 
prognostic value.11, 12
While the role of IKZF1 in lymphoid differentiation and ALL is firmly established, 
the role of IKZF1 in myeloid differentiation is less clear. However, there are some strong 
indications that IKZF1 is also involved in myeloid differentiation. In early myeloid 
progenitors, loss of IKZF1 function prolongs cell survival.16 During erythropoiesis, IKZF1 
supports survival of the erythroid lineage, and promotes erythrocyte differentiation at 
the expense of granulocyte and monocyte differentiation.17-19 In early megakaryopoiesis 
IKZF1 represses differentiation by inhibiting genes associated with the NOTCH pathway 
and later on in differentiation towards megakaryocytes by controlling transcriptional 
regulators, such as GATA1 and RUNX1.18, 20 Although IKZF1 is not required for the initial 
differentiation towards granulocytes and monocytes, IKZF1 represses differentiation of 
the basophilic granulocyte lineage and promotes early maturation and survival of the 
neutrophil granulocyte lineage.17, 21, 22
In pediatric AML, monosomy 7 is found in only 4-5% of the patients. The 5-year 
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OS and EFS of pediatric AML patients with monosomy 7 with or without additional 
cytogenetic or chromosomal aberrations are poor.23 In adult AML, monosomy 7 is 
the most frequent single monosomy and has a similar poor 4-year overall survival 
as compared to other single autosomal monosomies.24 Deletions of the short arm of 
chromosome 7, 7p (del7p) were recurrently found in adult de novo AML and secondary 
AML developed from myelodysplastic syndrome (MDS) or myeloproliferative neoplasms 
(MPN).25-27 Furthermore, 7p deletions were mapped to the IKZF1 locus and it was 
shown that loss of IKZF1 is acquired during the progression of MPN to secondairy AML, 
indicating that loss of IKZF1 contributes to the transformation from MPN to AML.25 
Together, these studies demonstrate that IKZF1 may play a role in myeloid 
differentiation and that loss of IKZF1 may contribute to myeloid oncogenesis. We 
therefore hypothesized that in pediatric AML patients with monosomy 7, IKZF1 may 
be an important player. In this study we analyzed the frequency of IKZF1 deletions in a 
pediatric AML cohort, and studied the difference in gene expression of cases with focal 
IKZF1 deletions, and cases with monosomy 7. 
Methods
Patient samples
Samples were provided by the Dutch Childhood Oncology Group (DCOG, The 
Netherlands), the AML–Berliner-Frankfurt-Münster Study Group (Germany and Czech 
Republic), the Saint-Louis Hospital (France), and the Royal Hospital for Sick Children 
(UK). Isolation of genomic DNA and total cellular RNA was performed using Trizol 
reagent. Each study group provided morphological and cytogenetic classification and 
clinical data. Institutional review board approval for these studies had been obtained in 
the participating centers.
Detection of deletions and mutations of IKZF1
Multiplex ligation-dependent probe amplification (MLPA) was performed using the 
p335-B1;ALL-IKZF1 kit (MRC Holland, Amsterdam, The Netherlands, data available 
on http://www.mlpa.com). The data were analyzed with GeneMarker (version 1.85; 
SoftGenetics, State College, Pennsylvania, USA). The data were normalized to reference 
probes and control samples. A deletion was defined as a peak ratio below 0.75, an 
amplification was defined as a peak ratio above 1.25.
Array comparative genomic hybridization (Array-CGH) was performed using the 
human genome CGH Microarray 105K (Agilent Technologies, Santa Clara, California, USA) 
according to manufacturer’s protocol, data were analysed with Genomic Workbench 
(version 5.0.14; Agilent Technologies, Santa Clara, California, USA). 
Direct sequencing was used to analyze mutations or frameshifts in exon 4, 5 
and 8, which are found to be hotspot areas of mutations in pediatric BCP-ALL (primers 
Supplementary Table 7.1).13, 28
Cytogenetic and molecular characterization
Reverse-transcription-PCR was performed on hotspot areas as previously described by 
Balgobind et al29 and to analyse the frequency of the BCR/ABL1 translocation (primers 
Supplementary Table 7.1).
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Gene expression profiling
GEP data were available from earlier studies.30 Quantitative reverse-transcription-PCR 
(qRT-PCR) analysis was performed on a subset of patients to analyze the correlation 
between GEP data and qRT-PCR on relevant genes in patients of different cytogenetic 
subgroups and a variety of expression measured with GEP. The mRNA expression was 
determined using the average cycle threshold (Ct) in comparison to expression levels of 
GAPDH, using the comparative cycle threshold method.
Statistical analysis
Statistical analyses for disease outcome and correlation were performed with IBM SPSS 
21 (IBM, Armonk, New York, USA). To assess clinical outcome, complete remission (CR, 
defined as less than 5% blasts in the bone marrow, with regeneration of tri-lineage 
hematopoiesis, plus absence of leukemic cells), probability of event-free survival 
(pEFS, defined as the time between diagnosis and first event including non-responders 
calculated as an event on day 0), and probability of overall survival (pOS, defined 
as the time between diagnosis and death) were analyzed. Both pEFS and pOS were 
estimated by the Kaplan-Meier method and differences compared using logrank-tests. 
The cumulative incidence of non-response or relapse (pCIR, defined as time between 
diagnosis and relapse and with non-responders included as an event on day 0) was 
analysed by the Kalbfleisch and Prentice method and compared with the Gray’s test. 
Statistical significance was considered if p-values were below 0.05. 
Differential expression analyses between groups were conducted using the 
R-package ShirnkBayes31 at the probe level. In contrast to commonly used two-sample 
tests, this test is proven to be powerful for small sample sizes. Bayesian false discovery 
rate (BFDR)<0.05 was considered statistically significant. 
Results
Identification of IKZF1 deletions in pediatric AML 
The cohort of newly diagnosed pediatric AML patients with available peripheral blood 
or bone marrow samples taken at initial diagnosis included in this study was previously 
described by Hollink et al (n=293; age, 0-18 years).30 Of 293 well-characterized pediatric 
AML cases, 258 with available high quality DNA were analyzed with MLPA using 250ng 
of DNA. Cytogenetic aberrations in this group were representative for the frequencies 
seen in pediatric AML.3, 32 In addition, 14 healthy control samples as negative controls, 
and one pediatric ALL sample known to harbor an IKZF1 deletion as positive control were 
analyzed. A succeeded MLPA was considered if all reference probes had a peak ratio 
between 0.75 and 1.25, except where a deletion or amplification of a reference probe 
could be explained by an aberration visible in the karyotype. The P335-B1;ALL-IKZF1 
MLPA kit contains a probe in each of the 8 exons of IKZF1. All probes on chromosome 
7 were analyzed individually, including reference probe 15370-L13762 located on 
7q11.23 in P450 cytochrome oxidorectase (POR). Additional high-resolution array-CGH 
was performed on patients with an IKZF1 deletion detected by MLPA, but without 
knowledge of the existence of monosomy 7, and one additional case of monosomy 7 
from which no material was available for MLPA analysis. Mutational screening of exon 
4, 5 and 8 of IKZF1 was performed on the same cohort of 258 patients. This revealed 
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no patient harboring a frameshift mutation, as described to be damaging in BCP-ALL. 
We did identify three patients with a heterozygous point mutation, p.V382M, which 
was predicted as tolerated by SIFT analysis and as benign by PoyPhen analysis, and 
p.G158S and p.L188P, which were predicted as deleterious by SIFT analysis and probably 
damaging by PolyPhen analysis, but not resulting in a truncated protein. 77/258 
patients presented with synonymous SNP rs61731355, 17/258 with synonymous SNP 
rs61731356, and 1/258 with non-synonymous SNP rs376657964 (p.T333A), which 
is in line with the presence of this SNP’s in the normal population (21%, 4% and 1% 
respectively).33  
In total, 10 patients carried a heterozygous IKZF1 deletion as identified by 
MLPA, and one additional case as identified by array-CGH (Table 7.1). From 258 patients, 
as determined by MLPA, 9 cases showed an IKZF1 deletion in all 8 exons, and 1 case 
showed a deletion of exon 1-4 with a normal peak ratio in the remaining exons (Figure 
7.1). Four of these 10 cases showed a monosomy 7 with conventional karyotyping 
(Table 7.1). Using array CGH on 7 patients, we identified 2 cases with monosomy 7 
in patients with an unknown karyotype, 2 patients with monosomy 7 of whom the 
karyotype was (wrongly) defined as cytogenetically normal, and 3 cases with a focal 
0.1-0.9Mb deletion of 7p12.2, where the IKZF1 gene is located (Figure 7.2, Table 7.1). 
Combining the data gathered from MLPA, karyotype and array CGH, we defined 
11 patients with an IKZF1 deletion, 8 of which showed complete loss of one copy of 
chromosome 7 (monosomy 7), and 3 of which showed a focal IKZF1 deletion. As shown 
in Figure 7.2, patient #10 demonstrated a focal deletion (~0.1Mb) including exon 1-4 of 
IKZF1. The focal deletion in patient #2 included the IKZF1 gene and part of the C7orf72 
gene (~0.3Mb), whereas patient #3 showed a focal deletion (~0.9Mb) including the 
IKZF1 gene and the genes for VWC2, ZPBP, C7orf72 and DDC. Together, these results 
map the deletions in these patients to the IKZF1 gene locus as the common deleted 
region.
Characteristics of IKZF1 deleted cases in pediatric AML
IKZF1 deleted cases did not differ significantly from the other pediatric AML cases 
concerning age at diagnosis (median age 9.1 years, range 0.7-14.1, compared to 9.5 
Figure 7.1. Heterozygous IKZF1 deletions in pediatric AML. (A) Multiplex ligation-dependent probe 
amplification results of a patient with heterozygous deletion of exons 1-8 of IKZF1 including the reference 
probe in POR located on 7q11.23. (B) MLPA results of a patient with heterozygous deletion of exons 1 
through 4 of IKZF1. 1-8 indicates IKZF1 exons 1-8; D, reference D-fragment 96, a control probe for 
denaturation during the procedure; P, POR (7q11.23); X, X-chromosome specific fragment, a reference 
probe for gender; Y, Y-chromosome specific fragment, a reference probe for gender; Z, ZFY (Yp11.31), a 
reference probe for gender.
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Figure 7.2. Array CGH analysis of monosomy 7 and focal IKZF1 deletions. DNA isolated from pediatric AML 
samples taken at initial diagnosis and containing IKZF1 deletion based on MLPA results were analyzed using 
array CGH. Representative samples for monosomy 7 (patient #4, upper panel) and IKZF1 focal del7p12.2 
deletions (patient #2, #3 and #10, lower panel) are shown.
Figure 7.3. IKZF1 haploinsufficient AML cells display an AML-specific gene expression signature. AML 
(n=297, red) and B-ALL (n=107, blue) patients were projected onto the first two principal coordinates, 
obtained via multidimensional scaling of expression values of AML specific genes (A), ALL specific (B) genes 
and the combination of these (C) (Thomas et al., 2001). Focally deleted IKZF1 (dark green triangles) and 
monosomy 7 (light green squares) AMLs were located among other AMLs and away from B-ALLs.
ch7-10.indd   139 14-4-2016   19:06:33
Chapter 7: IKZF1 deletions in pediatric AML 
years, range 0.1-18.5, respectively, p=0.41); nor in gender (55% female versus 42% 
female, p=0.41); nor in white blood cell count at diagnosis (median 30.2 x109/L versus 
47.5 x109/L, p=0.24, Supplementary Table 7.2). All AML patients were treated with 
intensive collaborative group cytarabine-anthracycline based pediatric AML treatment 
protocols. Clinical outcomes were not significantly different between IKZF1 focal 
deleted, monosomy 7 and other AML cases. The 3-year pOS in IKZF1 deleted cases 
(n=11) was 70±14% versus 63±3% (p=0.82) in cases with 2 IKZF1 alleles (n=231). The 
3-year pEFS was 36±15% versus 46±3% (p=0.87), and 3-year pCIR was 64±16% versus 
36±3% (p=0.09) respectively (Supplementary Figure 7.1).
No specific morphology subtypes based on the French–American–British (FAB) 
classification were related to IKZF1 deletions. IKZF1 deleted samples showed none 
or various additional somatic mutations, most frequently activating the RAS pathway 
with mutations in NRAS or PTPN11 (n=4, Table 7.1). As in BCP-ALL, IKZF1 deletions are 
associated with BCR-ABL1 fusions, we additionally screened the IKZF1 deleted cases for 
the BCR/ABL1 fusion and all were negative.12
IKZF1 haploinsufficient AML cells display an AML-specific gene expression signature
Original gene expression data are available in the Gene Expression Omnibus repository 
(http://www.ncbi.nlm.nih.gov/geo;accession GSE17855). Focal IKZF1 deletions are also 
found in mixed phenotype acute leukemia.34 To ensure the included cases were AML 
patients and not patients with a mixed ALL and AML phenotype we used a previously 
defined AML vs ALL classifier.35 Patients with focal IKZF1 deletions and patients with 
monosomy 7 clustered amongst the other AML patients and away from the ALL 
patients, based on the expression signatures of the AML-specific genes, the ALL-specific 
genes and the combined AML/ALL- specific genes (Figure 7.3). This indicates that the 
IKZF1 haploinsufficient AML cells of included patients indeed displayed pure AML cell 
gene expression profiles. Only of one of the three patients with a focal IKZF1 deletion 
immunophenotypical data was available (patient #2). This patient was classified as 
PML/RARA-negative AML FAB M3V (TdT-/MPO+/cyCD79a-/CD34+/HLADR+/CD19-/
CD10-/CD7+/CD13+/CD33+).
Similarity between gene expression profiles of monosomy 7 and focal IKZF1 deleted 
cases
Loss of IKZF1 function, a well-known tumor inducing event in ALL, is conceivably one of 
the reasons for the recurrent heterozygous loss of chromosome 7, as this would include 
losing the IKZF1 locus on 7p12.2. We hypothesized that, if loss of IKZF1 would be one of 
the driving leukemic events in monosomy 7, the gene expression signature of monosomy 
7 AML cells may resemble those that only have a focal IKZF1 deletion. However, we 
anticipated that this similarity might be quite weak because of the heterogeneity across 
the samples in our cohort, both derived from somatic and germ line genetic variation 
and the small sample size of monosomy 7 and IKZF1 deleted cases. Therefore, we 
performed genome wide differential gene expression analyses using a robust Bayesian 
method implemented in the R-package ShrinkBayes.31 Probe sets were limited to those 
targeting a unique genes or having a selectivity score of >0.8 (www.geneannot.com). 
Further statistical analyses were performed in R, version 3.0.0. R scripts are available 
upon request. We first compared gene expression profiles of monosomy 7 samples 
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Figure 7.4. Monosomy 7 and focal IKZF1 deletion associate with gene expression profiles with significant 
similarity. (A) Analysis of differences in gene expression between monosomy 7 samples (n=8) and IKZF1-
non-deleted samples (n=247). Genes are ranked on Bayesian false discovery rate (BFDR) (y-axis) and binned 
in their chromosome of origin (x-axis). Using a BFDR of 5% (dashed line), a total of 198 genes are detected 
differentially expressed, of which 111 are not encoded on chromosome 7. (B,C) Mean differences per 
gene between monosomy 7 and non-IKZF1-deleted samples versus those of IKZF1 focal deletions and non-
IKZF1-deleted samples for chromosome 7 encoded genes (B) and non-chromosome 7 encoded genes (C). 
Pearson’s correlation coefficients (r) are indicated in the plot, together with accompanying p values. (D) 
Bootstrap analyses of the correlation between monosomy 7 cases (n=8) and 3 randomly picked IKZF1-non-
deleted samples (n=247). The red dashed line indicates correlation coefficient from the analyses displayed 
in C. (E) Top correlating genes (dashed elipse in (C)) between monosomy 7 and focal IKZF1 deletions. 
Highlighted in red are those reported to be positively acting on leukemic cell self-renewal or cell cycle.
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(n=8) to those of IKZF1-non-deleted samples (n=247). We detected 244 probe sets 
representing 198 genes differently expressed (BFDR<0.05) between these two groups 
(Figure 7.4A). As might be expected, a large proportion of these genes (44%) is located 
on chromosome 7, and is down-regulated (Figure 7.4B).  
Next, we compared the mean differences in expression of these 198 genes 
in monosomy 7 samples (n=8) to those in samples with IKZF1 focal deletions (n=3) 
(Figure 7.4C). For non-chromosome 7 genes, highly significant positive correlation was 
observed in gene expression differences (r=0.50, p=3e-10). A less significant positive 
correlation (r=0.33, p=5e-4) was observed for chromosome 7 genes (Figure 7.4B). To 
further test that the correlation of gene expression changes between monosomy 7 and 
focal IKZF1 deletions is not based on chance, we performed a bootstrap analyses taking 
3 random patients and comparing them to the 8 patients with monosomy 7. As shown 
in Figure 7.4D, none of 100,000 comparisons displays a correlation approaching a value 
of 0.5 found for the patients with focal IKZF1 deletions.
We next asked which non-chromosome 7 genes were responsible for the 
similarity between monosomy 7 and focal IKZF1 deletion gene expression profiles. 
Genes that substantially contribute to the correlation between monosomy 7 and IKZF1-
only deleted gene expression differences are up-regulated in both groups (Figure 7.4C). 
Interestingly, the gene most clearly up-regulated in both monosomy 7 and IKFZ1-focal 
deleted samples was Hemogen (HEMGN), of which over-expression has been described 
to induce expansion of myeloid progenitor cells in a murine model.36 Other genes 
with known pro-leukemic functions in the top-correlating list are Four and a half LIM 
domains 2 (FHL2), Frizzled 6 (FZD6) and SET binding protein 1 (SETBP1) (Figure 7.4E). 
Very strong correlations (r=0.9117-0.9562, p<0.0001) were found between the GEP 
data and qRT-PCR analyses for HEMGN and FHL2, and strong correlations (r=0.7913-
0.7962, p<0.0001) were found for SETBP1 and FZD6 (n=30, Supplementary Figure 7.2).
As up-regulation of HEMGN in IKZF1 hemizygous cells is relative to a fairly 
heterogeneous group, we stratified the control group in various more homogenous 
cytogenetic AML subgroups (Figure 7.5A). Median expression of HEMGN in each of those 
subgroups is clearly lower than in the IKZF1 deleted group. The same is true for FHL2, 
FZD6 and SETBP1 (Figure 7.5B-D), although it should be noted that FZD6 and SETBP1 
are also highly expressed in patients with MNX1-ETV6 (t(7;12)). When excluding the 
patient harboring both an IKZF1 deletions and MNX1-ETV6 (t(7;12)), FZD6 and SETBP1 
remain significantly higher expressed in the IKZF1-deleted cases compared to the other 
pediatric AML subgroups (Figure 7.5E-F). These data indicate that up-regulation of these 
genes in IKZF1 deleted samples is not confounded by specific cytogenetic aberrations in 
pediatric AML.
Gene expression profiles of the IKZF1-deleted samples demonstrate enrichment in up-
regulated GATA targets. 
HEMGN, the gene most clearly up-regulated in both monosomy 7 and IKFZ1-focal 
deleted samples, is transcriptionally activated by GATA1 in the myeloid cell line K562.37 
We therefore investigated whether other genes that demonstrated a correlation 
between monosomy 7 and focally deleted IKFZ1 samples are also GATA1 targets in K562. 
For this purpose, we used a GATA1 ChIP seq dataset in K562 cells.38 From the 23 genes 
significantly up-regulated in the IKZF1-deleted samples, 11 genes had a GATA1 peak 
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Figure 7.5. HEMGN, FHL2, FZD6 and SETBP1 expression in IKZF1-deleted patients as compared to other 
cytogenetically classified AML groups. Comparison of mRNA abundances in IKZF1-deleted samples to 
major cytogenetic AML subgroups revealed that the median expression of HEMGN, FHL2, FZD6 and SETBP1 
in the IKZF1 deleted group is clearly higher than in each of the subgroups, except for FZD6 and SETBP1 in 
comparison to t(7;12)/MNX1-ETV6. When excluding the patient harboring both the IKZF1 deletion and 
t(7;12)/MNX1-ETV6, FZD6 and SETBP1 remain significantly higher expressed in the IKFZ1-deleted cases 
compared to the other pediatric AML subgroups (p=0.003 and p=0.005 respectively). 
Figure 7.6. Genes commonly upregulated in IKZF1 focally deleted and monosomy 7 cases are enriched 
in myeloid GATA1 targets. (A) GATA1 chromatin interaction values (GATA1 peak value) in K562 cells of 
commonly upregulated genes (n=23) in monosomy 7 and focal IKZF1 deletion (ΔIKZF1). (B) Proportion of all 
matching genes (n=22564) or ΔIKZF1 upregulated (n=23) displaying a GATA1 chromatin interaction in K562 
cells. p value from Fisher’s exact test. (C) mRNA expression of GATA1, GATA2 and GATA3 in IKZF1 deleted 
samples (red) versus IKZF1 WT samples (grey). p values according to Mann-Whitney tests.
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ratio larger than 25, indicating the gene being a GATA1 target (Figure 7.6A). Further 
analysis showed that whereas 13% of genes on our expression platform is a GATA1 
target, 55% of genes that are up-regulated in IKZF1 deleted cases are GATA1 targets 
(p=3.5 e-7, Figure 7.6B). While GATA transcription factors exhibit diverse functions in 
cellular proliferation, differentiation and gene regulation, only GATA1, GATA2, and GATA3 
are expressed in developing blood cells and are critical for hematopoiesis.39,40 As shown 
in Figure 7.6C, GATA1 (p=0.07) and GATA3 (p=0.006) were up-regulated in the IKZF1-
deleted samples (n=11) as compared to the rest (n=247). Direct interaction of IKZF1 
with GATA proteins was previously demonstrated.41 Together, these data emphasize the 
similarity in gene expression between monosomy 7 and focal IKZF1 deleted pediatric 
AML patients.
Discussion
In the last ten years, IKZF1 has been widely studied in the context of B-cell differentiation 
and acute lymphoblastic leukemia, both in adults and children. Accumulating evidence 
indicates that IKZF1 also plays a role in various stages of myeloid differentiation. So far, 
the best indication that loss of IKZF1 may contribute to myeloid leukemogenesis are 
deletions of the short arm of chromosome 7 associated with MPN-preceded secondary 
AML in adults, where the commonly deleted region is mapped to the IKZF1 locus.25 Our 
finding of recurrent focal deletions that map to the IKZF1 gene locus in pediatric AML 
patients cells now provides additional support for a role for IKZF1 in myeloid leukemia.
 Reduced IKZF1 gene function is a well-known recurrent event in BCP-ALL. In 
pediatric BCP-ALL, the overall frequency of focal IKZF1 deletions is around 15%, but is 
greatly enriched in BCR/ABL1 positive BCP-ALL at 70-80%.15, 42 Here we report that focal 
IKZF1 deletions are also a recurrent event in pediatric AML, although with much lower 
frequency. In a cohort of 258 patients, representing all cytogenetic AML subgroups, 
we found 3 cases of a focal inactivating deletion of this gene (1.2%). In addition, three 
patients were identified with a single nucleotide variation leading to amino acid changes. 
In contrast to mutations found in BCP-ALL, no frame shift mutations were detected, and 
the functional status of these SNV containing alleles remain to be determined.
In adult and pediatric BCP-ALL, in addition to focal IKZF1 deletions, monosomy 
7 is a recurrent chromosomal aberration. In BCR/ABL1 positive BCP-ALLs, 16% (adult) 
and 13% (pediatric) of the cases of IKZF1 deletion can be attributed to monosomy 
7.14, 42 In pediatric AML, monosomy 7 is a recurrent chromosome loss, in particular in 
myeloproliverative diseases, such as juvenile myelomonocytic leukemia, progressed 
towards AML (40% of cases), but also in primary AML (4-5% of cases).23, 43 In our pediatric 
de novo AML cohort, we found 8 cases (3.1%) of monosomy 7, consistent with earlier 
estimates. Across these monosomy 7 AML cases, we find various additional somatic 
mutations, most prominently PTPN11 (n=2) and NRAS mutations (n=2), adding up to 
half of cases presenting with an activated RAS pathway.
We hypothesized that in pediatric AML, as presumed in BCP-ALL, an important 
biological determinant for leukemogenesis in monosomy 7 patients is loss of the IKZF1 
gene.44 Evidence for this hypothesis was obtained by comparing gene expression profiles 
of monosomy 7 and focal IKZF1 deletions. We found a statistically significant correlation 
on non-chromosome 7 genes. We attribute the changes in chromosome 7 genes to 
bystander effects of deletion of the entire chromosome 7, leading to a widespread 
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reduction in chromosome 7 encoded genes, many of which can be assumed to be 
without much consequence to the leukemogenic process. In contrast, the effects on 
non-chromosome 7 genes can be expected to be more enriched for leukemia related 
changes in the genetic program due to loss of one or more chromosome 7 encoded 
driving oncogenic mutations. The similarity of gene expression signatures between 
AML cases with monosomy 7 and those with a focal IKZF1 deletion therefore suggests 
that IKZF1 is one of the driving oncogenic events in monosomy 7 pediatric AML. 
Further data supporting this hypothesis is the observation that pediatric AML patients 
harboring monosomy 7 have a worse disease outcome compared to those harboring 
7q deletions.23 Our findings may also explain the prevalence of monosomy 7 and focal 
IKZF1 deletions in mixed phenotype acute leukemia, as loss of IKZF1 now appears to be 
able to contribute to both acute lymphoblastic and myeloid leukemogenesis.34
 Several genes up-regulated in both monosomy 7 and focal IKZF1 deleted AML 
cases are previously implicated in leukemogenesis. In a large cohort in adult BCP-
ALL, comparison between focal IKZF1 deletions and IKZF1 wild-type cases revealed 
up-regulation of genes involved in cell cycle, JAK-STAT signaling and stem cell self-
renewal.45 We find up-regulation of HEMGN, a transcription factor implicated in 
myeloid self-renewal36, FHL2, enhanced expression of which leads to enhanced cell 
cycle entry, FZD6, that has shown to be involved in the pathologically reactivation of 
the Wnt/Fzd-mediated self-renewal signals that are enlisted during B-cell development 
and may be pathologically reactivated in the neoplastic transformation of mature B 
cells, and SETBP1, of which over-expression promotes the self-renewal of myeloid 
progenitors.46,47,48 It is interesting that similar cellular processes are affected in the IKZF1 
deleted cases, while none of the genes deregulated in IKZF1 deleted adult BCP-ALL are 
found deregulated in this pediatric IKZF1 deleted AML cohort.45 
 Of note, we find a strong enrichment of myeloid GATA1 targets among genes 
commonly up-regulated in focal IKZF1 deleted AML cases and monosomy 7 AML cases. 
This could be the confirmation that the genes commonly up-regulated in IKZF1 focal 
deletions and monosomy 7 did not present themselves by chance. However, it is 
tempting to speculate that IKZF1 haploinsufficiency in pediatric AML is influencing GATA 
transcription factor function. Supporting this idea, IKZF1 over-expression in transgenic 
mice represses GATA1 expression, implying that loss of IKZF1 function may increase 
GATA1 function.21 
 Together, we find evidence for IKZF1 as a tumor suppressor gene in pediatric 
acute myeloid leukemia and suggest that IKZF1 deletion might be one of the driving 
events of monosomy 7 in various myeloid diseases.
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Table 7.1. Patient characteristics of IKZF1 deleted pediatric AML cases (n=11).
Abbreviations: del indicates deletion; WBC, white blood cell count; FAB, French-American-British classification; 
CR, complete remission; SCT, stem-cell transplantation; COD, cause of death; NA, not available. *Aberrations 
screened are AML associated fusions and hotspot areas in NRAS, KRAS, KIT, WT1, CEBPA, FLT3, and PTPN11.
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Supplementary data
Supplementary Figure 7.1. Survival estimates of IKZF1-deleted patients compared to other AML. 
Kaplan-Meier estimates of the 3-year overall survival, event-free survival and cumulative incidence of 
relapse according to the Kalbfleisch and Prentice method of IKZF1-deleted patients versus other pediatric 
AML. 
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Supplementary Figure 7.2. Comparison of microarray values with qRT-PCR values. Four of the genes 
most highly upregulated in monosomy 7 and focal IKZF1 deletions based on microarray analysis were 
selected for qRT-PCR validation using RNA from 30 primary AML cases. GAPDH qRT-PCR values were used 
for normalization. HEMGN and FHL2 showed very strong correlations (r>0.9), SETBP1 and FZD6 showed 
strong correlations (r>0.7) comparing micro-array values with qRT-PCR values.
ch7-10.indd   151 14-4-2016   19:06:35
Chapter 7: IKZF1 deletions in pediatric AML 
Supplementary Table 7.1. Primer sequences used for RT-PCR and qRT-PCR.
Gene Location Direction Primers
RT-PCR primers
IKZF1 Exon 4 Forward
Reverse
5’-GCTGCTGTGTTGTTTTG-3’
5’-TGCTTTCCTCCTTCAAACCC-3’
IKZF1 Exon 5 Forward
Reverse
5’-CGTGGGAAACAACTTTCTCG-3’
5’-CAGAGTGGAGGAATCCCG-3’
IKZF1 Exon 8 Forward
Reverse
5’-GACCTGACCGGTTCC-3’
5’-CAGTCTATGCTGCTGGCG-3’
BCR
ABL1
Exon 13
Exon 3
Forward
Reverse
5’-TTCCGCTGACCATCA-3’
5’-CGCTGCTCAGCAGATACT-3’
qRT-PCR primers
HEMGN Exon 3
Exon 4
Forward
Reverse
5’-CCTGGAGTTTGAGAAACAGA-3’
5’-AGGCTCCACCTTCAATTC-3’
FHL2 Exon 5
Exon 6
Forward
Reverse
5’-CGCAGTGCAGAAACTCA-3’
5’-CTGCCCTTGTACTCCATCT-3’
SETBP1 Exon 2
Exon 2
Forward
Reverse
5’-CCGGAAGACTGTAGAGATTG-3’
5’-CCGCTTTGTGGTCTGA-3’
FZD6 Exon 4
Exon 5
Forward
Reverse
5’-CCGGAACCAAGAAAAACTA-3’
5’-ATGCCAACAATTAATGTCATC-3’
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Supplementary Table 7.2. Patient characteristics of pediatric AML cohort (n=258).
IKZF1 deleted 
cases (n=3)
Monosomy 7 
cases (n=8)
Other pediatric 
AML (n=247)
Age at diagnosis Median (y) 2.3 9.4 9.5
Range 1.5-11.3 0.7-14.1 0.1-18.5
Sex Female (%) 33 63 42
WBC Median (x109/L) 127.9 26.7 47.3
Range 29.0; 226.8 4.4-66.0 1.2-483.0
FAB-type M0 0 0 16
M1 0 0 32
M2 0 2 43
M3 1 0 19
M4 1 2 70
M5 1 3 51
M6 0 1 1
M7 0 0 8
Type 2 aberration
MLL-
rearrangement 0 0 62
RUNX1/RUNX1T1 0 1 22
inv(16) 0 0 33
PML/RARA 0 0 18
ETV6/MNX1 1 0 3
DEK/NUP214 0 0 6
KAT6A/CREBBP 0 1 5
NUP98-
rearrangement 0 0 18
CEBPAdm 0 1 12
NPM1 0 0 17
Other 0 0 2
Unknown 2 5 49
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Letter to the editor
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by 
the presence of different collaborating cytogenetic and molecular aberrations that are 
associated with treatment response.1-3 Approximately 20% of pediatric AML patients 
are classified as cytogenetically normal AML (CN-AML).4 In the past decade, new 
prognostic relevant aberrations have been identified in CNAML, such as NPM1, WT1, 
FLT3-ITD and CEBPA double mutations (CEBPAdm), which may improve future riskgroup 
stratification.5-8 In addition to these mutations, we recently described recurrent cryptic 
NUP98/NSD1 and NUP98/KDM5A translocations in pediatric CN-AML.9, 10 Still, some CN-
AML samples have not been fully characterized. Recently, Grossmann et al. discovered 
a somatic mutation in the BCL6 co-repressor (BCOR) gene in an adult CNAML patient 
using whole-exome sequencing.11 BCOR mutations were subsequently identified in 10 
of 262 (approx. 4%) adult CN-AML patients, unselected for cytogenetic abnormalities, 
and for whom a poor outcome had been predicted. In addition, Li et al. discovered 
mutations in the BCL6 corepressor-like 1 (BCORL1) gene in 2 of 8 patients with secondary 
adult AML.12 Further exploration identified somatic BCORL1 mutations in 10 of 173 (6%) 
of adult AML patients, of which 5 cases were diagnosed with secondary or treatment-
related AML. In 8 of 10 patients these included nonsense, splice site, and frame-shift 
mutations that were predicted to result in truncation of the protein, suggesting that 
BCORL1 is a tumor suppressor gene that may be inactivated by mutations.13 In pediatric 
AML, the role of BCOR and BCORL1 is unknown. Therefore, we explored the frequency 
and impact of BCOR and BCORL1 mutations in pediatric AML in a molecularly well 
documented cohort of 230 pediatric AML patients. 
Genomic DNA was PCR amplified using the primers described in Supplementary 
Table 8.1. Purified PCR products were directly sequenced. Sequence data were analyzed 
using CLCWorkbench (CLC Bio, Aarhus, Denmark). BCOR variations were determined in 
comparison to the coding DNA sequence ENST00000342274, and BCORL1 variations to 
ENST00000540052. A mutation was defined as a nucleotide change not reported in the 
dbSNP database. SNPs were defined as a nucleotide change as described in the dbSNP 
database. Characteristics of the 230 pediatric AML patients included in this mutational 
screening are listed in Table 8.1. 
The complete coding sequence of BCOR and BCORL1 was screened in a 
nested cohort of 83 de novo pediatric AML patients, and 17 AML cell lines. This cohort 
represented all relevant cytogenetic subgroups in pediatric AML, with an enrichment 
for CN-AML (n=48). All CNAML patients were screened for NPM1, CEBPAdm, FLT3- ITD, 
IDH1/2, WT1, cKIT, N/K-RAS, DNMT3A, ASXL1 and RUNX1 mutations, and MLL-PTD, 
NUP98/NSD1, NUP98/KDM5A, and MLL-rearrangements (Table 8.3). None of the cell 
lines showed a mutation. In 4 of 83 patients a BCOR mutation (detailed in Table 8.2) 
was identified; 3 in exon 4 and 1 in exon 12. Three of these cases were CN-AML (3 of 
48, 6.3%), and the fourth mutation was seen in an MNX1/ETV6 translocated AML. In 
only one of 83 patients a BCORL1 mutation was identified which resulted in a stop 
codon (Table 8.2). This CN-AML patient had an underlying xeroderma pigmentosum. 
An additional 147 pediatric AML patients were screened for mutations in BCOR and 
BCORL1 exon 4, based on the occurrence of mutations in this exon; 136 cases were de 
novo AML, 11 cases were secondary AML, of which 6 cases were MDS which progressed 
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to AML and 5 were secondary to earlier therapy because of another malignancy. None 
of the additional cases were CN-AML. No additional mutations were found. In 2 of 230 
cases a missense SNP was found in BCOR (p.V679I, rs144722432) and in 35 of 230 (15%) 
a missense SNP in BCORL1 (p.G209S, rs5932715). Both SNPs are predicted as tolerated 
by SIFT analysis, and in line with the predicted prevalence in the normal population.14 
In one case missense SNP rs139887979 (p.D94N) was identified in BCORL1, predicted 
as damaging by SIFT analysis. We were unable to confirm this in germline or remission 
because such material was not available for these patients. 
Altogether we identified a BCOR mutation in 4 of 230 (1.7%) cases. The frequency 
of mutations in pediatric CNAML patients (6.3%; 95%CI: 2.1-16.8) was comparable to 
that in adult CN-AML (3.8%; 95%CI: 2.1-6.9; P=ns). The frequency of BCORL1 mutations 
(1 of 83, 1.2%; 95%CI: 0.2-6.5) was significantly lower than in adults (10 of 173, 5.8%; 
95%CI: 3.2-10.3; P<0.05) in patients of whom we screened the complete exon, and 
also lower when only analyzing exon 4 of BCORL1 [1 of 230, 0.4% (0.1-2.4) vs. 7 of 173, 
4.0% (2.0-8.1); P<0.05]. This may be due to the enrichment for secondary AML and 
treatment-related AML in the adult cohort, 73 of 173 (42%) in the cohort of Li et al. 
versus 12 of 230 (5%) in this cohort.11, 13, 14
Apart from mutation analyses, we studied BCOR and BCORL1 gene expression 
levels using RT-qPCR in 65 patients of the initial cohort, including all mutated cases. 
Expression levels were determined using a SYBRgreen (Finnzymes Inc, Woburn, MA, 
USA) Taqman assay and average cycle threshold (CT) values were compared to the 
reference gene GAPDH, using the comparative cycle time method. Expression levels 
of 2 BCOR-mutated cases seemed lower than the other pediatric AML cases, but the 4 
mutated cases did not significantly deviate from the nonmutated pediatric AML patients 
(Supplementary Figure S8.1). This is in accordance with findings in adult AML patients 
where both decreased and normal BCOR levels were observed in cases with BCOR 
mutations.11 In adult AML, BCORL1 mutations did not affect mRNA levels, similar to the 
finding of our single case [0.297% expression relative to GAPDH, mean in group (n=65) 
0.275%, range 0.049-1.358].13, 14 In the adult CN-AML cohort, the presence of BCOR 
mutations conferred a poor outcome. In our cohort, the low frequency of mutations 
did not allow survival analysis to be performed. Clinical outcome of the mutated cases 
is shown in Table 8.2. The presence of the non-synonymous SNP in BCORL1, rs5932715, 
did not influence clinical outcome (5-year probability of overall survival 57±9% vs. 
64±4%, P=0.4; 5-year probability of event-free survival 49±9% vs. 45±4, P=0.9). 
In conclusion, in pediatric AML, BCOR and BCORL1 mutations rarely occur. 
Consequently, the clinical relevance is difficult to determine. 
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Table 8.1. Clinical characteristics of pediatric acute myeloid leukemia cohort.
BCOR and BCORL1 
complete coding sequence
BCOR and BCORL1 
exon 4
Number 83 147
Median age (y)
range
9.8
0.2-18.0
8.2
0.1-18.0
Female, n (%) 36 (43) 58 (42)
Median WBC x109/L
range
94.3
1.2-377.6
45.2
2.4-475.0
Karyotype, n (%)
11q23 5 (6) 46 (31)
t(8;21) 5 (6) 13 (9)
inv(16) 6 (7) 28 (19)
t(15;17) 7 (8) 9 (6)
t(7;12) 5 (6) -
CN 48 (58) -
Other 7 (8) 40 (27)
Unknown - 11 (8)
FAB-type, n (%)
M0 8 (10) 6 (4)
M1 17 (21) 10 (7)
M2 19 (23) 19 (13)
M3 9 (11) 9 (6)
M4 22 (27) 49 (33)
M5 4 (5) 42 (29)
M6 - 2 (1)
M7 1 (1) 7 (5)
Unknown 3 (4) 3 (2)
NUP98/NSD1, n (%) 10 (12) 2 (1)
NPM1, n (%) 14 (17) 4 (3)
CEBPAdm, n (%) 7 (8) 3 (2)
Abbreviations: y indicates years; n, number; CN, cytogenetically normal; FAB, French-American-British classification.
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Table 8.2. Characteristics of BCOR and BCORL1 aberrations detected in pediatric 
cytogenetically normal AML patients. 
Abbreviations: UPN indicates unique patient number; y, years; M, male; F, female; WBC, white blood cell count; L, liter. 
Table 8.3. Characteristics of pediatric CN-AML cases (n=48) screened for BCOR and 
BCORL1 mutations. Each column represent a single case.  A colored field means this 
case is positive for a mutation or translocation in the corresponding gene(s). A white 
field indicates the case was tested negative for a mutation or translocation in the 
corresponding gene(s).
UPN Age (y) Sex
WBC 
x109/L FAB
Other 
mutations Relapse Death Karyotype
BCOR 
mutation
BCORL1 
mutation
1 4 M 351.0 M1 CEBPAdm, 
WT1, NRAS
No No 46,XY[20] p.A854T
2 11 F 48.2 M4 FLT3-itd, NPM1 No No 46,XX p.T60M
3 12 F 140.6 M5 FLT3-itd, WT1 No No 46,XX[20] p.D1302E
4 0 F 217.9 M2 MNX1/ETV6, 
KIT
Yes Yes 47,XX,t(7;12)
(q36;p13),+19[32]
p.G86E
5 17 M 9.8 M1 RUNX1 No Yes 46,XX[26] p.G158*
BCOR and BCORL1 BCOR
positive cases BCORL1
Type 2 mutation NUP98/NSD1
CEBPAdm
NPM1
MLL-PTD
Type 1 mutation WT1
N/K-RAS
FLT3-ITD
PTPN11
Epigenetic regulator IDH1/2
gene mutations DNMT3A
RUNX1
TET2
ASXL1
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Supplementary data
Supplementary figure 8.1. BCOR expression levels determined by RT-qPCR per cytogenetic subgroup. 
Graphs showing expression levels of BCOR for a selected cohort of pediatric AML patients (n=65, initial 
cohort). Each dot represents a patient and horizontal bars represent median expression for every 
cytogenetic subgroup. Black indicates wild-type for BCOR, red indicates mutated for BCOR. 11q23 indicates 
MLL-rearranged or MLL-ptd; t(8;21), the RUNX1/RUNX1T1 translocation; t(15;17), PML/RARA; inv(16),
CBFB/MYH11. Other or unknown indicates patient group without the other mentioned aberrations.
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Supplementary Table 8.1A. Overview of BCOR primers.
PCR cycle: 10’95 ⁰C, 40x(15”95⁰C, 1’60⁰C, 30”72⁰C), 10’72⁰C
qRT-PCR cycle: 10’95⁰C, 40x(15”95⁰C, 1’60⁰C)
Exon Direction Primer
2 ForwardReverse
5'-GGCTCCCAGACCACTGT-3'
5’-GCGGGAAGCTCTTTCTCT-3’
3 ForwardReverse
5'-GCGGAGGGTTAAGGACA-3'
5’-GGGGCCTTGTCCTCTC-3’
4.1 ForwardReverse
5’-GCCGGAAGCCTGTCTT-3’
5’-GGCAGCCGCAGATAAC-3’
4.2 ForwardReverse
5’-GCCAGCGACAAACAGAG-3’
5’-GGGGGCAACAGGAGA-3’
4.3 ForwardReverse
5’-CCACGCCTATCCTCACA-3’
5’-AGCTTTGGAAGCATCTACATC-3’
4.4 ForwardReverse
5’-AGCGGTTCAAGACAGAAAA-3’
5’-GCCCACGTGCTGAATAA-3’
4.5 ForwardReverse
5’-CACCGATGCTGTCATCAC-3’
5’-GTGCCCAGGAAACAGACT-3’
4.6 ForwardReverse
5’-GAGGGCATTGCTGTAAGTC-3’
5’-TCGCTTTTGACAACAGTCTT-3’
4.7 ForwardReverse
5’-TCCCCACCGACAAGAA-3’
5’-GGGGGTCACATCCACA-3’
4.8 ForwardReverse
5’-TGGCCCTGCTGTAACTTT-3’
5’-CCCCAATCCTGTTTACACA-3’
5 ForwardReverse
5’-AAAGGTTGCTTAAAGGGATAGA-3’
5’-ACCATGGCCCACAAACT-3’
6 ForwardReverse
5'-TTTGGGCACTTTTCTTTGA-3' 
5'-GGTTGCCACCATTCATAAG-3'
7 ForwardReverse
5'-CCCTCCCTCTGGAAAGTT-3' 
5'-CCGCACATCCACATCTC-3'
8 ForwardReverse
5'-CCCCCACCCCATTAGT-3' 
5'-CCCGCATACCTTGTTCA-3'
9 ForwardReverse
5'-CGCCCGCTTCTTCTC-3' 
5'-AAGCCGGGGTCAAGAG-3'
10 ForwardReverse
5'-CTCTCCACGCAGGTTTG-3' 
5'-CTCGCCCACCACAGTC-3'
11 ForwardReverse
5'-GCCCGAGAGGTTCTCAG-3' 
5'-ATTGGGAGCTTTACATCTACATT-3'
12 ForwardReverse
5'-TGGCGGTGACTGTGC-3' 
5'-TCGGCTGCTCTCCTAAAA-3'
13 ForwardReverse
5'-CTTCCAGCCTGTCATGAAT-3' 
5'-GCCCACCATCCACTTTC-3'
14 ForwardReverse
5'-CTGGGAAAGAATCTTGTTATTTA-3' 
5'-CCCCCCACCACACTG-3'
15 ForwardReverse
5'-GGCGCACTTTTCATTTTAC-3' 
5'-CCAGCTTGCTCACCAGTAG-3'
RT-qPCR ForwardReverse
5’-ACCGATTCAAATGTGTCACT-3’ 
5’-GGCCACCTTCTCTTTCTT-3’
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Supplementary Table 8.1B. Overview of BCORL1 primers.
PCR cycle: 10’95 ⁰C, 40x(15”95⁰C, 1’60⁰C, 30”72⁰C), 10’72⁰C
qRT-PCR cycle: 10’95⁰C, 40x(15”95⁰C, 1’60⁰C)
Exon Direction Primer
2 Forward Reverse
5'-CTTCCCGGTTTAGACCTTAAT-3'
5'-CCCAGGCCCTATTGTATG-3'
3 Forward Reverse
5'-CCCCCTCACAAGTTACTACAG-3' 
5'-AGCCAGCCAATTTGTGTC-3'
4.1 Forward Reverse
5'-CGGGCCTCAGGACAC-3' 
5'-GGGCTGGCAGAGGACT-3'
4.2 Forward Reverse
5'-AGGCCAGCAACAGCAG-3' 
5'-AGGGGGTTCGAGTCAGA-3'
4.3 Forward Reverse
5'-TGTTCCAGTCCAAGTTGCCACTTC-3' 
5'-ATGGGTGTAGGGGCTGGAGTAAA-3'
4.4 Forward Reverse
5'-TGCCCACGCTCATCTC-3' 
5'-TGGAGGCGGGATATATACC-3'
4.5 Forward Reverse
5'-CCGGCCTCCTTCAGTT-3' 
5'-CAGGGGAGCCTGTTCA-3'
4.6 Forward Reverse
5'-CCCGAGCTCCGTTCTT-3' 
5'-CAGGCAGGAGGTGACATT-3'
4.7 Forward Reverse
5'-CCCCCATGCCTGTGT-3' 
5'-GTGGGTTTCCACAAAGAGA-3'
4.8 Forward Reverse
5'-AGCCCCATCTCCATCATTG-3'
5'-AGGCCCCTGATTCATTC-3'
4.9 Forward Reverse
5'-CTGCCAAGCCTTATGAAG-3' 
5'-GCCCAACAGGACTGTGT-3'
5 Forward Reverse
5'-ACCCCTGGAGAGCTTTCT-3' 
5'-CTGCCCTCACCACTGTG-3'
6 Forward Reverse
5'-TGGGCTTTCTGGTCTTTAAG-3'
5'-GTGGGCAATATTTGAGGACT-3'
7 Forward Reverse
5'-GTCCAGGGCATTCACTTC-3' 
5'-AGCACCGGGTTTCTCTG-3'
8 Forward Reverse
5'-GGGCTGGGAGCTGTCT-3' 
5'-CGCCACACACACCTTCTA-3'
9 Forward Reverse
5'-GTGGCTCAGGACTGATGTT-3'
5'-GGCAAGGTCTTTTGAGTGA-3'
10 Forward Reverse
5'-TTCCCCTGATGCAGTAGC-3' 
5'-GCCCCAAGGACAACAGT-3'
11 Forward Reverse
5'-TGGCAGTCTCTGACTGAGAA-3'
5'-TGAGGGATGGCTGTGTC-3'
12 Forward Reverse
5'-GTGCCCTCTGAAGGATGT-3' 
5'-AGCCTTTGTCATGTGTGATG-3'
13 Forward Reverse
5'-TGGGCTTTGCAGAGTGT-3' 
5'-GGTCGGGGAAAGACAAG-3'
RT-qPCR Forward Reverse
5’-TGCCTCCAGAAAGACAGT-3’
5’-CCACCGCATCATGAAC-3’
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Letter to the editor
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease characterized by 
the presence of different collaborating cytogenetic aberrations which are associated 
with outcome 1, 2. In the past decade, new prognostically relevant genetics aberrations 
have been identified, such as mutations in NPM1 and FLT3, which further improve 
risk-group stratification. In ~20% of the pediatric AML cases the underlying genetic 
abnormalities are not fully understood 1, 2. Unravelling the underlying aberrations 
involved in leukemogenesis may improve risk-group stratification. 
PHF6 is an X-linked tumor suppressor gene, with a role in transcriptional 
regulation, and was identified as germline mutation causing Borjeson-Forssman-
Lehmann syndrome 3, 4. Mutations of PHF6 are reported in adult T-ALL, and somatic 
mutations in PHF6 were identified in 3% of adult AML, predominantly in males, in cases 
classified as French-American-British (FAB) M0, M1 and M2 5-7. Using whole genome 
sequencing, PHF6 mutations were identified in 2% of a pediatric AML series strongly 
enriched for core-binding factor AML 8. However, a large pediatric AML cohort has 
never been examined. In this study, we screened a large pediatric de novo AML cohort 
including all FAB-types, enriched for FAB-M0, M1 and M2, for PHF6 mutations.
Samples were provided by the Dutch Childhood Oncology Group (DCOG, The 
Netherlands), the AML–Berlin-Frankfurt-Münster Study Group, and the Saint-Louis 
Hospital (France). Each study group provided centrally reviewed morphological and 
cytogenetic classification, and clinical data, such as age at diagnosis, white blood cell 
count (WBC) and outcome. Institutional review board approval had been obtained in 
the participating centres. Genomic DNA was PCR amplified. Purified PCR products were 
directly sequenced, and analyzed using CLC Workbench (CLC Bio, Aarhus, Denmark, 
primers: Supplementary Table 9.1). In case of an aberration, RNA and germline or 
remission DNA was analyzed, if available. Reverse-transcription-PCR was performed on 
known hotspot areas and for the presence of fusion genes as previously described 9.
318 de novo paediatric AML cases were eligible for mutational screening, 
including 20 FAB-M0, 47 FAB-M1 and 76 FAB-M2 cases (Table 9.1A). 175 males and 141 
females were screened (2 patients unknown). Direct sequencing analysis revealed the 
presence of PHF6 mutations in 6/318 (2%;95%CI:0.9-4.1%) AML cases, representing 
6/143 (4%;95%CI:1.9-8.9%) pediatric FAB M0, M1 and M2 cases. Most mutations were 
predicted to result in a loss-of-function with four truncating frameshift mutations, and 
one point mutation in an intron resulting in loss of exon 4 on RNA-level (Supplementary 
Figure 9.1A). In the latter case germline material derived from fibroblasts did not harbor 
this aberration. 
Additionally, one missense variation (p.S145N, Supplementary Figure 9.1B) 
was identified, which was also present in material obtained at complete remission and 
relapse, and predicted as damaging in SIFT and PolyPhen analysis. No SNPs are known 
at this position (dbSNP, dbVar, accessed 2015/02/17). However, the variation localized 
outside the most conserved PHD-finger domains. Based on the material obtained at 
complete remission this may be considered a germline variation. 
Median age at diagnosis was 12.6 years in the PHF6-mutated group, compared 
to 9.5 years in other pediatric AML (p=0.11). Median WBC was 3.8x109/L and 43.0x109/L 
respectively (p=0.03, Table 9.1A). After successful induction, 4/6 mutated cases had 
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a relapse, and 1 patient did not experience an event. One other patient was a non-
remitter. Two patients are alive in complete remission, and four died from the disease. 
All PHF6-mutated cases were morphology subtype FAB M0, M1 or M2. Other 
genetic abnormalities found in these cases were translocations RUNX1/RUNX1T1 and 
NUP98/KDM5A, and mutations in WT1, RAS, ETV6, TET2, IDH1 and BCORL1 (Table 
9.1B). None of these aberrations were recurrent in the PHF6-mutated group. Wang et 
al reported that in T-cell ALL PHF6 mutations were associated in combination with the 
SET/NUP214 translocation 10. This translocation was present in 11 cases in our series, 
but none harboured a PHF6 mutation. 
In all reported series of PHF6 mutations in T-ALL and adult AML mutations were 
almost exclusively found in males 5, 7. In our data, 4/6 of the patients with a mutation 
were female. Distribution of sex among the mutated cases did not differ significantly 
(Fisher’s exact test; p=0.1), in contrast to the findings in adult AML 7. One female 
PHF6-mutated case showed loss of a sex chromosome in the leukemic cells based on 
karyotyping. PHF6 is hypothesized to be inactivated on one copy of the X-chromosome 
in females due to lyonization. Quantitative real-time PCR (qRT-PCR) analysis of mRNA 
expression of XIST was performed using the average cycle threshold (Ct) in comparison 
to expression levels of GAPDH, using the comparative Ct method. XIST is highly 
expressed (>5% compared to GAPDH) if at least two X-chromosomes are present. The 
patient with known loss of an X-chromosome indeed showed low expression (<1% 
compared to GAPDH) of XIST. The other females with a PHF6 mutation showed high 
expression of XIST, indicating both X-chromosomes were present in the leukemic blasts. 
Whereas on DNA the frameshift mutations were heterozygous in female, analysis of the 
frameshifts on RNA level showed mono-allelic presence of the mutated gene, indicating 
inactivation of the wild type PHF6 gene (Supplementary Figure 9.1C). 
qRT-PCR analysis of PHF6 was performed on patients with available RNA (n=240). 
FAB-types M0, M1 and M2 did not show lower mRNA expression compared to other 
FAB-types (Figure 9.1A). There was no difference in PHF6 expression between males 
and females (p=0.7, Figure 9.1B). PHF6 was significantly lower expressed in patients 
with a frameshift mutation compared to patients with normal predicted amino-acid 
length, suggesting the frameshifts result in a loss-of-function (p=0.038, Figure 9.1C). 
When comparing mutated cases to patients with FAB-M0, M1 or M2 paediatric AML 
without PHF6 mutation, again a significant difference was found (p=0.026, Figure 
9.1D). Hairpin-mediated suppression of Phf6 promoted AML in vivo.4 Accordingly, the 
presence of loss-of-function mutations in PHF6 in pediatric AML suggests a role for 
PHF6 in leukemogenesis.
Overall, our data show that PHF6 mutations occur in a low frequency in pediatric 
AML, exclusively in FAB-M0, M1 and M2, with a significantly lower mRNA expression of 
PHF6. In contrast to T-ALL and adult AML, we found mutations of PHF6 in both female 
and male patients in pediatric AML. The potential prognostic impact of PHF6 mutations 
needs to be determined in a larger series.
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Table 9.1A. Clinical characteristics of PHF6 mutated and PHF6 wild type pediatric 
AML patients.
Abbreviations: y indicates years; WBC, white blood cell count; FAB-type, French-American-British 
morphology type.
PHF6 mutated 
cases (n=6)
PHF6 wild type 
cases (n=312)
p-value
Age at diagnosis Median (y) 12.6 9.5 p=0.11
Range (y) 6.3-17.0 0.1-18.0
Sex Female 67% 44% p=0.06
WBC Median (x109/L) 3.8 43.0 p=0.03
Range (x109/L) 2.2-196.0 1.0-534.6
FAB-type M0 2 18
M1 2 45
M2 2 74
M3 0 20
M4 0 75
M5 0 62
M6 0 2
M7 0 9
Not available 0 7
Type-II aberrations RUNX1/RUNX1T1 1 32
NUP98-rearrangements 1 20
Inv(16) 0 35
KMT2A-rearrangements 0 70
PML/RARA 0 18
DEK/NUP214 0 11
Other/Unknown 4 126
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Table 9.1B. Patient characteristics of pediatric AML with a PHF6 mutation. 
U
PN
PH
F6
 
m
ut
ati
on
 
(l
oc
ati
on
)
Pr
ed
ic
te
d 
am
in
o 
ac
id
 
le
ng
th
Ag
e 
(y
rs
)
Se
x
W
BC
 
(x
10
9 /
L)
FA
B
M
ut
ati
on
s
Re
m
Re
l
De
at
h
SC
T
Ka
ry
ot
yp
e
XI
ST
 
ex
pr
es
si
on
1
pS
14
5N
(e
xo
n 
6)
-
6.
3
M
19
6.
0
M
0
W
T1
, R
AS
, 
ET
V6
CR
Y
Y
N
46
,X
Y,
de
l(1
7)
(p
12
,p
13
) o
r 
ad
d(
17
)
(p
11
)[
2]
-
2
c.
22
4d
el
A
A
(e
xo
n 
3)
94
10
.3
F
N
A
M
0
-
CR
N
N
N
46
,X
X,
t(
3;
4)
(q
11
-
12
;p
15
-1
6)
[6
]/
 
47
,X
X,
 t
(3
;4
)(
q1
1-
12
;p
15
-1
6)
,+
m
ar
 
[1
2]
/4
6,
XX
[2
]
Hi
gh
 
(1
3.
9%
)
3
c.
83
4-
83
9d
el
G
TT
TT
A
 
in
sT
CA
G
TT
C
(e
xo
n 
6)
14
6
14
.3
M
2.
2
M
2
TE
T2
, R
AS
PR
N
N
Y
46
,X
Y
-
4
c.
28
in
sA
(e
xo
n 
2)
21
10
.9
F
3.
8
M
2
RU
N
X1
/
RU
N
X1
T1
CR
Y
Y
Y
46
,X
,-
X,
+8
,t
(8
;2
1)
(q
22
;q
22
)[
15
]
Lo
w
 
(0
.8
4%
)
5
c.
90
4d
el
C
(e
xo
n 
9)
35
0
14
.6
F
2.
2
M
1
NU
P9
8/
KD
M
5A
CR
Y
Y
N
N
ot
 a
va
ila
bl
e
Hi
gh
 
(1
0.
0%
)
6
D
el
eti
on
 o
f 
ex
on
 4
92
17
.0
F
9.
4
M
1
ID
H1
, 
BC
O
RL
1
N
R
-
Y
N
46
,X
X[
26
]
Hi
gh
 
(6
.6
%
)
Abbreviations: UPN indicates unique patient number; yrs, years; WBC, white blood cell count; FAB, French-
American-British morphology subtype; SCT, stem cell transplantation; M, male; F, female; Y, yes; N, no. 
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Figure 9.1. PHF6 mRNA expression as measured with qPCR. Mean expression is indicated with the red 
line. (A) Patients divided per FAB-type. Patients with a frameshift mutation are found in FAB-M0, M1 and 
M2, and indicated in red. (B) Patients divided per sex. Patients with a frameshift mutation are indicated in 
red. There is no significant difference in mRNA expression of PHF6 between male and female pediatric AML 
patients (Mann-Whitney test, p=0.7). (C) Comparing mRNA expression levels of pediatric AML patients 
with a frameshift mutation to other pediatric AML, patients with a frameshift have a significant lower 
mRNA expression compared to wild type PHF6 pediatric AML patients (Mann-Whitney test, p=0.0378). (D) 
Comparing mRNA expression levels of pediatric AML patients with FAB M0, M1 and M2, patients with a 
frameshift mutation have a significant lower mRNA expression compared to wild type PHF6 pediatric AML 
patients of the selected FAB-types (Mann-Whitney test, p=0.0259). 
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Supplementary data
Supplementary Figure 1. PHF6 mutations in pediatric AML cases. (A) A point mutation (G>A) in intron 
4-5 resulting in deletion of exon 4 in a girl. The mutation, indicated with orange background, is present in 
the initial diagnosis sample, but not in germline material of this patient. On cDNA the sequence of exon 
3-5, missing exon 4. The uppercase letters indicate the sequence of exons 3, 4 and 5, the lowercase letters 
indicate the sequence of intron 4-5. (B) A point mutation (G>A) resulting in p.S145N in a boy. The mutation, 
indicated with orange background, is present in samples of initial diagnosis, remission and relapse. A wild 
type sequence of a different patient is added as reference. (C) A deletion of C resulting in a frameshift in 
exon 9 in a girl with high XIST expression. On DNA this deletion is seen heterozygously, while the sequence 
on cDNA shows solely the mutated allele, indicating silencing of the X-chromosome with wild type PHF6.
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Supplementary Table 9.1. Primers used for mutational screening and qRT-PCR.
* This primer is only used for direct sequencing of exon 5.
Ex
on
D
ir
ec
ti
on
Pr
im
er
PC
R
 c
yc
le
2
Fo
rw
ar
d 
Re
ve
rs
e
5’
-T
TT
CT
TG
G
G
G
CT
TA
G
A
G
TG
-3
’ 
5’
-A
A
AT
G
G
CA
TA
G
CA
TT
A
G
TG
A
-3
’
10
’9
5⁰
C,
 4
0x
(1
5”
95
⁰C
, 1
’6
0⁰
C,
 1
5”
72
⁰C
),
 1
0’
72
⁰C
3
Fo
rw
ar
d 
Re
ve
rs
e
5’
-G
CT
AT
G
CC
AT
TT
TT
A
CT
A
G
A
A
A
-3
’ 
5’
-G
CT
G
G
CT
CA
G
A
G
A
A
A
A
A
A
A
A
-3
’
10
’9
5⁰
C,
 4
0x
(1
5”
95
⁰C
, 1
’6
0⁰
C)
4-
5
Fo
rw
ar
d 
Re
ve
rs
e 
Fo
rw
ar
d*
5’
-C
CC
CA
G
A
A
G
A
AT
TT
TA
TT
CC
-3
’
5’
-A
A
A
CG
TG
G
CT
A
A
AT
G
AT
G
TA
-3
’
5’
-A
AA
GG
GT
GT
TT
TT
GA
TA
AG
A-
3’
10
’9
5⁰
C,
 4
0x
(1
5”
95
⁰C
, 1
’6
0⁰
C,
 2
0”
72
⁰C
),
 1
0’
72
⁰C
6-
7
Fo
rw
ar
d 
Re
ve
rs
e
5’
-A
G
G
CC
A
CA
TG
TT
G
CT
A
G
T-
3’
5’
-G
G
CT
TT
A
G
AT
CA
CA
G
G
G
G
A
A
A
C-
3’
10
’9
5⁰
C,
 4
0x
(1
5”
95
⁰C
, 1
’6
0⁰
C,
 4
5”
72
⁰C
),
 1
0’
72
⁰C
8
Fo
rw
ar
d 
Re
ve
rs
e
5’
-C
TC
CA
CA
CT
G
G
CA
G
TC
CT
CA
TT
TT
-3
’
5’
-G
G
CA
G
CC
CT
G
TG
TA
TG
TG
TT
CT
TT
-3
’
10
’9
5⁰
C,
 4
0x
(1
5”
95
⁰C
, 1
’6
0⁰
C,
 4
5”
72
⁰C
),
 1
0’
72
⁰C
9
Fo
rw
ar
d 
Re
ve
rs
e
5’
-G
A
G
G
G
CT
TA
TC
A
A
A
G
TA
TG
G
-3
’
5’
-A
G
G
A
A
A
AT
G
CC
A
AT
TG
TA
G
T-
3’
10
’9
5⁰
C,
 4
0x
(1
5”
95
⁰C
, 1
’6
0⁰
C)
10
Fo
rw
ar
d 
Re
ve
rs
e
5’
-T
G
G
G
CA
CT
A
G
CC
TC
AT
CC
A
CT
A
AT
-3
’
5’
-G
CA
A
G
CC
TA
CA
A
A
AT
CC
TC
A
G
CA
-3
’
10
’9
5⁰
C,
 4
0x
(1
5”
95
⁰C
, 1
’6
0⁰
C)
qP
CR
Fo
rw
ar
d 
Re
ve
rs
e
5’
-A
GG
GG
AG
GA
AG
AA
AA
TG
A-
3’
5’
-G
TG
CC
A
G
A
A
G
A
A
A
A
CA
A
CA
-3
’
10
’9
5⁰
C,
 4
0x
(1
5”
95
⁰C
, 1
’6
0⁰
C)
ch7-10.indd   176 14-4-2016   19:06:37
177
9
ch7-10.indd   177 14-4-2016   19:06:37
Chapter 10: t(10;17)(p15;q21) results in ZMYND11/MBTD1 
ch7-10.indd   178 14-4-2016   19:06:37
179
Chapter 10
Recurrent translocation t(10;17)(p15;q21) in minimally 
differentiated acute myeloid leukemia results in 
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Abstract
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease, characterized by 
different collaborating karyotypic and molecular abnormalities, which are used in risk 
group stratification. In ~20% of the pediatric AML cases a specific genetic aberration 
is still unknown. Minimally differentiated myeloid leukemia or FAB-type M0 is a rare 
morphological subtype of AML. The translocation t(10;17)(p15;q21) is described to be 
recurrent in minimally differentiated AML, but the involved genes and location of the 
breakpoints have so far not been identified. 
In this study we show that this translocation results in an in-frame translocation 
fusing exon 12 of the tumor suppressor gene ZMYND11 to exon 2 of the chromatin 
protein MBTD1, encoding a protein of 1054 amino acids, while the reciprocal fusion 
product is predicted to lack a productive start codon. Gene expression profiling of the 
leukemic cells showed high HOXA expression. ZMYND11, also known as BS69, is a tumor 
suppressor that specifically recognizes H3K36me3, which is linked to aberrant HOXA 
expression in leukemogenesis. Aberrant expression of the genes involved in this fusion 
may thus contribute to the HOXA-phenotype observed with gene expression profiling.
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Introduction
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease, characterized 
by different collaborating gene aberrations, such as translocations and mutations. 
These abnormalities, together with early treatment response, predict outcome.1-3 In 
~20% of the pediatric AML cases no specific genetic aberration has been identified.4 
Based on morphology, minimally differentiated AML (French-American-British (FAB) 
type M0) is defined by expression of markers such as CD13, CD33 and CD117 in the 
absence of lymphoid differentiation and myeloperoxidase (MPO) positivity. Minimally 
differentiated AML is seen in <5% of all AML cases, being more common in adult AML 
patients compared to children.5 The translocation t(10;17)(p15;q21) is recurrent in 
minimally differentiated AML, but the translocation partners in this fusion remain 
unknown to date.6-8 In total 6 cases of AML harboring this karyotypic aberration have 
been described in the literature in both pediatric and adult AML, and one case was 
described in a pediatric precursor B-cell acute lymphoblastic leukemia (Supplementary 
Table 10.1). Based on FISH analyses it has been suggested that this translocation in AML 
most likely results in fusion of ZMYND11 on chromosome band 10p15 and MBTD1 on 
17q21.7 In this study we confirm this by identifying the translocation at the molecular 
level in a not previously described patient, and suggest the translocation results in high 
HOXA expression.
Material and methods
Patient Material
Blood and bone marrow samples taken at initial diagnosis and at relapse of the index 
patient were provided by the Dutch Childhood Oncology Group (DCOG). Leukemic cells 
were purified as described before.9 Isolation of genomic DNA and total cellular RNA 
was performed using Trizol reagent. Conventional karyotyping was performed at the 
center of diagnosis and centrally reviewed. 
Molecular Screening
Molecular work-up included mutational analysis on hot-spot areas in CEBPA, NPM1, 
WT1, KIT, NRAS, KRAS, FLT3 (including FLT3-ITD), PTPN11, IDH1/2, DNMT3A, ETV6, and 
RUNX1, and recurrent translocations were screened for, such as RUNX1/RUNX1T1, 
KMT2A(formerly known as MLL)-rearrangements and NUP98-rearrangements. 
To investigate whether the t(10;17)(p15;q21) resulted in the ZMYND11/MBTD1 
fusion as previously suggested7, reverse transcriptase polymerase chain reaction (RT-
PCR) primers were designed in exon 8, 10, 11, 12, 13 and 15 of ZMYND11, and exon 1 
and 3 of MBTD1 (Supplementary Table 10.2) and compared to the coding sequences 
ENST00000397962 for ZMYND11 and ENST00000586178 for MBTD1. 
Gene expression profiling (GEP) of 274 de novo pediatric AML samples and 
confirmation of mRNA expression results by quantitative reverse-transcription-PCR 
(qRT-PCR) analysis for HOXA5, HOXA7, HOXA9 and HOXA10 was available from earlier 
studies.10 Original data are available in the Gene Expression Omnibus repository (http://
www.ncbi.nlm.nih.gov/geo; accession GSE17855). A centered principal component 
analysis, based on singular value decomposition, was performed using all HOX-gene 
probesets available. K-means clustering optimizing squared Euclidean distances was 
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Figure 10.1. Fusion of ZMYND11 and MBTD1. (A) Sequence of ZMYND11 exon 12 fused to MBTD1 exon 3. 
In red the sequence found in the sample obtained at diagnosis. In green the sequence found in the sample 
at time of relapse. (B) Fusion protein of ZMYND11/MBTD1. In blue the protein originating from ZMYND11, 
in red the protein originating from MBTD1, * indicates the stopcodon. (C) Schematic overview of the fused 
exons in ZMYND11/MBTD1 and MBTD1/ZMYND11. The purple rectangles indicate untranslated region of 
the exon. A green arrow indicates a start-codon. The white rectangles indicate translated region of the 
exon. (D) Schematic overview of the different domains of ZMYND11, MBTD1 and ZMYND11/MBTD1.
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performed to create three clusters. 
Results and discussion
The index patient was a 13 year old boy, who was diagnosed with pediatric AML with FAB 
type-M0. The white blood cell count at diagnosis was 6.5x109/L. Immunophenotyping 
showed the leukemic blasts to be positive for CD7, CD33, CD34, CD45, CD56, CD117, 
and negative for MPO and HLA-DR. Conventional karyotyping showed 46,XY,t(10;17)
(p15;q21)[9]/46,XY[1]. The boy was treated according to the DCOG ANLL97/MRC 
AML 12 protocol. He achieved complete remission 4 weeks after start treatment, but 
relapsed 11 months after diagnosis. Conventional karyotyping at this time showed 
47,XY,t(10;17)(p15;q21),+13[1]/48,idem,+7[11]/46,XY[8]. He was treated with 
reinduction chemotherapy according to the Relapsed AML2001/01 protocol and stem 
cell transplantation with a matched unrelated donor. The post-transplantation period 
was complicated due to severe graft versus host disease (GVHD) of the skin, intestines 
and liver, followed by pulmonary chronic GVHD. He was treated with high dose immune-
suppressive therapy. Unfortunately he died 30 months after initial diagnosis due to a 
combination of infection and hemorrhage. 
Screening for all aforementioned mutational hot-spot areas and other known 
AML gene rearrangements was negative. Samples of this patient from diagnosis and 
relapse were screened for the ZMYND11/MBTD1 fusion and MBTD1/ZMYND11 fusion 
with the designed primer sets. Direct sequencing was performed for obtained bands 
present on agarose gel. This led to the identification of the fusion product ZMYND11/
MBTD1 and its reciprocal product in both bone marrow and peripheral blood samples 
taken at initial diagnosis and relapse. Sequencing showed that the translocation 
resulted in an in-frame fusion fusing exon 12 of ZMYND11 to exon 3 of MBTD1, 
encoding a 1054 amino acid long protein (Figure 10.1A and 10.1B) on the der(17). The 
reciprocal product MBTD1/ZMYND11 resulted in fusion of exon 2 of MBTD1 to exon 13 
of ZMYND11. Because exon 1, 2 and a minor part of exon 3 of MBTD1 encode part of 
the 5’ untranslated region, no productive start codon is encoded in this fusion transcript 
(Figure 10.1C) on the der(10). 
Gene expression profiling was available for the initial diagnosis sample, 
but not for the relapse sample. HOX genes have various roles in hematopoiesis, and 
dysregulation may lead as a common pathway to leukemogenesis induced by various 
underlying genetic events.11 Different HOX expression patterns are described and the 
distinct HOX expression pattern is most likely the result of the underlying translocation 
or mutation activating different HOX-genes.11-13 In previous studies we could identify 
three distinct clusters of pediatric AML cases based on HOX expression.10, 14, 15 Although 
overexpression of several HOX genes is described to correlate with poor outcome, 
other studies describe outcome to be correlated with the underlying translocation or 
mutation resulting in the aberrant HOX expression.14-17 Understanding the underlying 
mechanism causing HOX gene dysregulation, may lead to the development of targeted 
treatment options for the HOX overexpressing cases. The development of DOT1L 
inhibitors for KMT2A-rerranged leukemias is a prime example of this.18
To investigate the HOX expression in this case we used the first three principal 
components, together 85% component variance, to form the three requested clusters 
based on k-means clustering using (Figure 10.2A). This method identified the previously 
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described HOX clusters.10, 14, 15 Performing a principal component analysis on all these 
HOX genes, the index-patient clustered in the group with high HOXA expressing cases, 
showing an expression profile similar to the expression observed in KMT2A-rearranged 
cases (Figure 10.2B). 
ZMYND11, also known as BS69, is a tumor suppressor, specifically repressing 
active genes through binding of H3.3K36me3.19-21 ZMYND11 contains a PHD finger, 
bromodomain, PWWP domain and a MYND domain (Figure 10.1D). In the fusion 
product ZMYND11/MBTD1, the MYND domain is replaced by the full length MBTD1 
protein (Figure 10.1D). Wen et al showed that deletion of the MYND domain did not 
affect the binding of H3K36me3.19 MBTD1 is a poorly characterized putative Polycomb 
Group (PcG) protein, which functions as transcriptional repressor of genes affecting 
differentiation and tumor suppression.22-24 MBTD1 contains four malignant brain 
tumor (MBT) repeats, which specifically recognize H4K20me1/2.22, 25 In another family 
member of MBTD1, the dSfmbt protein, the MBT repeats are described to specifically 
bind mono- or dimethylated states of the H3 and H4 histones, thereby targeting HOX 
gene Polycomb response elements, required for silencing HOX gene expression.26 
Together, the genes involved in this fusion are likely to play a role in gene repression 
by epigenetic mechanisms, and may conceivably be responsible for the observed high 
HOXA expression. 
In conclusion, we identified in this pediatric AML case the genes involved in the 
t(10;17)(p15;q21), resulting in fusion of ZMYND11 and MBTD1 on the der(17)t(10;17). 
This fusion might result in HOXA overexpression, which is a well-known leukemogenic 
pathway in AML.
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Figure 10.2. HOX expression in pediatric AML. (A) Three clusters were created using k-means clustering 
using all available HOX-gene probesets. The index patient is indicated with a halo. (B) Principal component 
analysis based on HOX genes. Indicated in red with halo is the index case harboring the ZMYND11/MBTD1 
fusion. 
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Supplementary Table 10.2. Primers used for identification of involved genes and the 
breakpoint of ZMYND11/MBTD1.
Abbreviations; id indicates identification number; Fw, forward; Rv, reverse.
id karyotype Type Age at diagnosis reference
1 46,XY,del(6)(q14q16),t(10;17)(p15;-q21),?der(11) AML-M1
NA 
(range 15.2-76.8 y)
Barjesteh van Waalwijk van 
Doorn-Khosrovani S et al., 2003
2 46,XY,t(10;17)(p15;q21)/47,idem,+13 AML-M1 13 y Tempescul A et al., 2007
3
46,XX,t(10;17)(p15;q21)/46,idem,-
der(11)del(11)(q13q23)t(11;13)(q14;-
q34),der (13)t(11;13)(q23;q34)
AML-M1 40 y Tempescul A et al., 2007
4 46,XX,t(10;17)(p15;q21)/47,idem,+7 AML-M0 NA 
(range 20-86 y)
Dicker F et al., 2007
5
46,XY,t(10;17)(p15;q21)/46,idem,-
del(6)(q15q23),del(9)(p21p22),-
del(14) (q21q24)
AML-M0 16 y Pollak C et al., 1987
6 46,XY, i(7)(q10),t(10;17)(p15;q21) AML-M1 11 y Shah D et al., 2001
7 46,XX,t(10;17)(p15;q21)[24]/46,XX[3] Pre B-ALL 6-y Silva ML et al., 2002
Primer id Location Direction Used together with Primer sequence
1 ZMYND11 exon 8 Fw 5 5’-TTGCGAGGATGCTATATAAAG-3’
2 ZMYND11 exon 10 Fw 5 5’-GGCCAGCCAAAGTCAT-3’
3 ZMYND11 exon 12-13 Fw 5 5’-GAGCCCAAAAAGGAAGAA-3’
4 ZMYND11 exon 13 Fw 5 5’-AAGCGGGAGACAGAGC-3’
5 MBTD1 exon 3 Rv 1-4 5’-TGCCCATTGTTTTTGATAA-3’
6 MBTD1 exon 1 Fw 7-9 5’-AGGCCCTGATGGAAAA-3’
7 ZMYND11 exon 11 Rv 6 5’-CCTCGGTCCTCATTCTTAG-3’
8 ZMYND11 exon 13 Rv 6 5’-ATCCGGTCTTTGAAGTCAT-3’
9 ZMYND11 exon 15 Rv 6 5’-ACCGCTGTGTCTGAAAAG-3’
Supplementary Data
Supplementary Table 10.1. Overview of cases of t(10;17)(p15;q21) described in 
literature.
Abbreviations; id indicates identification number; AML-M, AML FAB-type; y, years.
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Summary
In studies presented in this thesis, novel recurrent aberrations were identified in 
pediatric AML, with a specific focus on pediatric non-Down syndrome AMKL. With 
the identification of NUP98/KDM5A, HOX-rearrangements and GATA1s mutations 
in pediatric AMKL, a standard risk and high risk group could be identified in patients 
diagnosed with this rare subtype of AML.
Chapter 2 describes the identification of the fusion of NUP98 to JARID1A 
(later referred to as KDM5A) as a novel recurrent event in approximately 11% of 
patients with pediatric AMKL. This is a cryptic fusion, because the telomeric location 
of both genes, and therefore it can easily be missed with conventional karyotyping. 
The frequency of the NUP98/KDM5A fusion in AMKL was comparable to the RBM15/
MKL1 fusion (~10%). Patients with this abnormality showed poor outcome compared 
to the latter group, although this did not reach statistical significance, most likely due 
to small numbers. Murine models previously showed the capacity of NUP98/KDM5A 
to result in a differentiation arrest with a short latency time to develop leukemia. This 
suggested that the translocation of NUP98/KDM5A can indeed be classified as a type-2 
aberration, based on the model of genetic events in AML as postulated by Kelly et al.1, 
2 AML patients carrying the CBFA2T3/GLIS2 fusion, another cryptic event, had a similar 
poor outcome. These three fusions are more or less specific for pediatric AMKL, as 
they are rarely or never seen in other morphological subtypes of pediatric AML. The 
fourth group identified in this study consisted of the MLL-rearranged (later referred 
to as KMT2A) cases, which are not specific for AMKL, but are also found in other 
morphologic leukemia subtypes. Fusions of KMT2A with the partner-genes MLLT3 and 
MLLT10 were most frequently found in this study.3, 4 Altogether, we identified a driving 
leukemic aberration in roughly 60% of the pediatric AMKL cases. 
Recent evidence showed that NUP98 aberrations, specifically NUP98/NSD1, are 
frequently co-expressed with FLT3/ITD (in 56–91%) and WT1 mutations (in 36–50%). In 
the samples positive for a NUP98/KDM5A-aberration in this study, all were negative 
for an aberration in one of these genes, suggesting the presence of another specific 
leukemic mechanism in NUP98/KDM5A rearranged AMKL.1, 5 In chapter 3, RB1, a tumor 
suppressor which is linked to proliferation by its role in cell cycle checkpoints, and one of 
the most frequently described cancer genes, was identified to be deleted in all NUP98/
KDM5A positive non-Down syndrome AMKL. Interestingly, RB1 deletions were not found 
in non-AMKL NUP98/KDM5A rearranged cases, or any other subtype of pediatric AML, 
underlining its specificity for cooperation with translocation NUP98/KDM5A in pediatric 
AMKL. Furthermore, this chapter describes the evidence that loss of RB1 is required to 
offset a NUP98/KDM5A induced cell cycle arrest, and the combination results in both 
a differentiation arrest and proliferation advantage. A decreased proliferation rate was 
observed in NUP98/KDM5A expressing, early myeloid cells, accompanied with a G0-
G1 cell cycle arrest, which could be rescued by RB1 depletion. This is consistent with 
the idea that the NUP98/KDM5A fusion protein constitutes a loss of KDM5A function 
in regulating RB1, leading to an anti-proliferative effect. While it was shown that the 
NUP98/KDM5A fusion also prevents differentiation through up-regulation of HOXA and 
HOXB genes, creating a stem cell phenotype, this anti-proliferative effect may prevent 
the development of a full blown leukemia with two RB1 copies present. Therefore was 
ch11-14 echt.indd   193 14-4-2016   19:07:23
Chapter 11: Summary 
hypothesized that loss of one RB1 allele is required to compensate for this effect. In the 
majority of cases the other RB1 allele was intact, contrary to the “classical” loss of RB1 
function in for instance retinoblastoma, which requires loss of both alleles.6, 7 
The use of next-generation sequencing, including RNA-sequencing and whole 
exome sequencing, on pediatric non-Down Syndrome AMKL samples, led to the 
identification of more distinct cytogenetic groups within pediatric non-Down syndrome 
AMKL, as described in chapter 4. Using samples derived from an international 
collaboration, two additional groups next to the in chapter 2 described aberrations, 
were identified. In 9% of the cases, a truncating GATA1 mutation was found. This is 
the driving leukemic aberration found in the majority of Down syndrome AMKL cases. 
The patients in whom a GATA1 mutation was identified were however not diagnosed 
with Down syndrome, but the GATA1 mutations were frequently seen in combination 
with an acquired trisomy of chromosome 21. Another group that was identified were 
HOX-rearrangements. We analyzed gene expression signatures to confirm the unique 
character of all cytogenetic groups identified in this study, and samples clustered 
according to specific group and were distinct from any of the other cytogenetic 
groups identified. Similar to KMT2A-rearrangements and NUP98-KDM5A positive 
cases, the HOX-rearrangements were characterized by a ‘HOX signature’, but in these 
cases the HOX gene showing upregulation was the specific HOX gene involved in the 
translocation. HOX genes play a significant role in normal hematopoietic development 
and deregulated expression has a central role in the etiology of several subtypes of 
acute leukemia, in part through the acquisition of enhanced self-renewal.8 In this study 
the leukemic potential was further studied using murine colony formation assays to 
assess the ability to serially replate HOX-rearrangements, which showed differences in 
replating-capacity for the different HOX-fusions. 
In the study described in chapter 5, the aim was to further refine the current 
risk group stratification within pediatric non-Down syndrome AMKL. We reported an 
international collaborative study on the prognostic value of the recently identified 
recurrent cytogenetic aberrations found in non-Down syndrome pediatric AMKL, with a 
special focus on cases positive for NUP98/KDM5A, CBFA2T3/GLIS2, RBM15/MKL1 and 
KMT2A-rearrangements. Cases positive for these translocations represented 46% of the 
pediatric AML cases in this study, and harboring translocation CBFA2T3/GLIS2, NUP98/
KDM5A, or a KMT2A-rearrangement appeared to be an independent prognostic factor 
for poor outcome. This poor outcome was mainly due to a high incidence of relapse in 
these patients. This study showed, similar to the study described in chapter 2, that age 
was not an independent prognostic factor in pediatric non-DS AMKL, nor was sex, nor 
WBC, nor treatment with a SCT. In addition, there were no differences in presenting 
characteristics between the various genetic groups with the exception of RBM15/MKL1 
positive cases, which presented with a significantly lower age at diagnosis (median age 
0.7 years, range 0.1-2.7). When looking at treatment, we could not provide an answer 
whether children benefitted from SCT. In general, the value of SCT for pediatric AML is 
under discussion: there is clear evidence that SCT has anti-leukemic potential, but this 
may be off-set by transplant-related mortality.9-11 Nevertheless, SCT in first remission 
is recommended for high risk cases in many AML treatment protocols, as defined by 
specific high-risk genetic aberrations or poor early response to treatment (high MRD 
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after 1 or 2 courses of chemotherapy). Based on our results, no definitive answer could 
be provided on the potential benefit of SCT in pediatric AMKL, but we suggest that 
children with good-risk AMKL may be spared from this intensive treatment. 
In part 2 of this thesis, we analyzed the presence of different aberrations in a 
pediatric AML cohort, including all morphologic subtypes. In chapter 6, ETV6, a well-
known gene to be aberrant in other types of leukemia, was studied, based on a finding 
by the COG groups of ETV6 abnormalities in AML as presented at the ASH 2012.12 Using 
MLPA, direct sequencing and FISH, we identified deletions, mutations and translocations 
in the ETV6 gene as recurrent events in pediatric AML in 7% of the cases. ETV6 
mutations were found in 2.2% of the cases included in this cohort, which is comparable 
to the frequency found in adult AML.13 Additionally we found ETV6 deletions in 1.6% 
of patients in our cohort, and ETV6 translocation in 9/275 (3.3%) cases, however, we 
only screened the patients without any known type II mutation, assuming that type II 
aberrations are mutually exclusive. This was a much lower frequency in comparison 
to the frequency of ETV6 translocations found in pediatric ALL.14 Comparing gene 
expression patterns of mutated and deleted cases versus other pediatric AML patients, 
several genes were upregulated, such as CLDN5, BIRC7 and DPEP1. These three genes 
have been described as up-regulated in ETV6-silenced in T-ALL.15-17 This suggested 
that the mutations and deletions in our series also result in impaired ETV6 function. 
In addition, we identified 4 different ETV6 translocations in this cohort. Next to ETV6/
MN1, identified in 6 cases, we identified single cases of ETV6/ARNT, ETV6/HOXCas2 
and ETV6/HOXA11as. The translocations involving HOX antisense genes both showed 
high HOX expression specific for the HOX gene involved in this fusion, confirming the 
HOX gene upregulation in the HOX-rearrangements found in chapter 4. Although the 
number of patients with ETV6 aberrations was low, the survival analyses suggested that 
ETV6 aberrations associated with a poor clinical outcome. 
To investigate the presence of ETV6 aberrations in pediatric AML, we used 
the MLPA probe mix, which also contained probes for the analysis of IKZF1. Chapter 
7 describes the identification of IKZF1 deletions as recurrent event in pediatric AML. 
IKZF1, localized on chromosome 7, has been widely studied in the context of B-cell 
differentiation and ALL, both in adults and children. Reduced IKZF1 gene function is a 
well-known recurrent event in B-Cell Precursor (BCP-)ALL, and caused by focal IKZF1 
deletions in approximately 15%. The frequency however is greatly enriched in BCR/ABL1 
positive BCP-ALL at 70%-80%.18, 19 In this study, focal IKZF1 deletions were shown to be a 
recurrent event in pediatric AML, although in a low frequency, and not in combination 
with BCR/ABL1. In contrast, mutations of IKFZ1, also found in BCP-ALL patients, were 
not detected in this AML cohort. In pediatric de novo AML, monosomy 7 is a recurrent 
cytogenetic abnormality seen in ~4% of the cases, and monosomy 7 is also seen in 
myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) 
which could progressed towards AML.20, 21 In this pediatric de novo AML cohort, 8 cases 
(3.1%) of monosomy 7 were identified. We found a statistically significant correlation 
in gene expression profile between focally IKZF1 deleted cases (n=3) and monosomy 
7 cases, when analyzing the expression of non-chromosome 7 genes. The similarity of 
gene expression signatures between AML cases with monosomy 7 and those with a 
focal IKZF1 deletion suggested that IKZF1 may be one of the driving oncogenic events 
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in monosomy 7 pediatric AML. 
In chapter 8 and 9, mutations described in adult AML were analyzed for their 
frequency in pediatric AML. Mutations in BCOR and BCORL1 were identified in adult 
AML using whole exome sequencing, and given their frequency in adult cytogenetically 
normal AML we studied a pediatric cohort for their frequency.22, 23 BCOR mutations 
were identified in 6.3% of the pediatric cytogenetically normal AML cases, which was 
comparable to the frequency in adult CN-AML. The frequency of BCORL1 mutations was 
significantly lower than in adults. This may be due to the enrichment for secondary AML 
and treatment-related AML in the adult cohort: 73 of 173 (42%) in the adult cohort of Li 
et al., versus 12 of 230 (5%) in this cohort.22-24 Expression levels of BCOR-mutated cases 
did not significantly deviate from the non-mutated pediatric AML patients, which was 
in accordance with findings in adult AML patients. In adult AML, BCORL1 mutations did 
not affect mRNA levels, similar to the finding of our single case. In the adult CN-AML 
cohort, the presence of BCOR mutations conferred a poor outcome. In our cohort, the 
low frequency of mutations did not allow survival analysis to be performed, and is yet 
to be determined in a larger cohort.
Mutations in PHF6, an X-linked tumor suppressor gene, with a role in 
transcriptional regulation, were previously identified as germline mutation causing 
Borjeson-Forssman-Lehmann syndrome.25, 26 Mutations of PHF6 are reported in adult 
T-ALL, and somatic mutations in PHF6 were identified in 3% of adult AML, predominantly 
in males, in cases classified as French-American-British (FAB) M0, M1 and M2. 27-29 
Given the presence in adult AML, we studied a pediatric cohort to reduce the number 
of cases with unknown aberrations. In chapter 9, we identified mutations in PHF6 
in 6/318 (2%; 95% CI: 0.9-4.1%) AML cases. They were exclusively found in FAB-M0, 
M1 and M2, representing 6/143 (4%; 95%CI: 1.9-8.9%) pediatric FAB M0, M1 and M2 
cases. Presenting with a significantly lower mRNA expression of PHF6, mutations were 
predicted to result in a loss of function. In contrast to T-ALL and adult AML, we found 
mutations of PHF6 in both female and male patients in pediatric AML. The potential 
prognostic impact of PHF6 mutations needs to be determined in a larger series. 
In chapter 10, a translocation resulting in high HOX expression was described. 
The recurrent described t(10;17)(p15;q21) was analyzed for its breakpoints using 
reverse transcriptase PCR in a single case found in a pediatric de novo AML cohort. 
This resulted in the identification of translocation of ZMYND11 and MBTD1. The case 
harboring this fusion was identified with a high HOXA expression, suggesting the fusion 
to result in a well-known leukemogenic pathway in AML. 
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Samenvatting
In dit proefschrift worden nieuwe afwijkingen beschreven die voorkomen bij AML op 
de kinderleeftijd, met specifieke aandacht voor acute megakaryoblastaire leukemia 
(AMKL) bij kinderen zonder Downsyndroom. Met de ontdekking van NUP98/KDM5A, 
HOX-herschikkingen en GATA1s mutaties in de leukemische cellen van deze kinderen, is 
er een groep met een slechte prognose, en een groep met een gemiddelde prognose 
geïdentificeerd, met een direct gevolg voor risicostratificatie en behandeling voor 
kinderen met deze zeldzame groep binnen de AML. 
In hoofdstuk 2 wordt de fusie van NUP98 met JARID1A (later hernoemd tot 
KDM5A) beschreven. Deze afwijking is gevonden in ongeveer 11% van de kinderen 
met AMKL. Het is een cryptische translocatie die vaak wordt gemist met conventionele 
karyotypering, gezien de telomerische locatie van de genen die getransloceerd zijn. Het 
voorkomen van deze translocatie is vergelijkbaar met de in AMKL veel beschreven fusie 
van RBM15 en MKL1, maar geeft een infauste prognose in vergelijking met deze fusie. 
In vivo studies hebben aangetoond dat NUP98/KDM5A leidt tot een differentiatiestop, 
deze fusie wordt daarom gezien als type-2-afwijking zoals beschreven door Kelly et 
al. 1, 2 In deze studie werd ook de translocatie CBFA2T3/GLIS2 gevonden, een andere 
cryptische afwijking, met eveneens een slechte prognose. Als vierde groep binnen de 
AMKL-patiënten op de kinderleeftijd werden de KMT2A-herschikkingen gevonden, 
en dan met name KMT2A/MLLT3 en KMT2A/MLLT10. 3, 4 Deze laatste groep wordt 
bij alle morfologische subtypes van AML gevonden, terwijl de andere groepen maar 
zeer zelden voorkomen bij andere morfologische subtypes en voornamelijk worden 
gezien bij AMKL. In deze studie is de onderliggende afwijking in 60% van de patiënten 
gevonden. 
Naast de type-2-afwijkingen zoals beschreven door Kelly et al, is er ook gezocht 
naar additionele afwijkingen binnen de groep van NUP98/KDM5A getransloceerde 
patiënten. In hoofdstuk 3 wordt de deletie van RB1 besproken, een tumorsuppressorgen, 
met een belangrijke rol in de proliferatie van de cel, met name vanwege zijn rol in 
het checkpoint van de celcyclus. In alle NUP98/KDM5A positieve AMKL-patiënten 
werd een deletie van RB1 gevonden, en bij geen enkele andere AML-patiënt. Deze 
deleties waren nog niet eerder beschreven in AML op de kinderleeftijd, maar deleties 
van chromosoomband 13q14, de locatie van RB1, waren al wel geobserveerd in 
AMKL-cellen. 3, 30 In een cellijn model werd gevonden dat NUP98/KDM5A leidde tot 
hoge Hoxa en Hoxb expressie, zoals ook gezien werd in patiënten, en dat de fusie een 
differentiatiestop gaf, maar eveneens een stop gaf van de G0- naar de G1-fase in de 
celcyclus. De deletie van RB1 zorgde er in dit model voor dat deze stop in de celcyclus 
afzwakte, en de combinatie van NUP98/KDM5A en een RB1 deletie resulteerde in een 
differentiatiestop met daarbij een proliferatie voordeel. 
Door het gebruik van nieuwe, meer sensitieve, technieken, zoals RNA-sequencing 
en whole exome sequencing, werden nog twee nieuwe groepen geïdentificeerd binnen 
de AMKL op de kinderleeftijd. In hoofdstuk 4 is de identificatie van GATA1 mutaties, 
voorkomend in 9% van de kinderen met AMKL zonder Downsyndroom, en de groep 
van HOX-herschikkingen beschreven. De GATA1-mutaties zijn de meest voorkomende 
afwijking gevonden in AMKL bij kinderen met het Downsyndroom. In de patiënten 
zonder Downsyndroom in deze studie worden in de meerderheid van de patiënten in 
ch11-14 echt.indd   197 14-4-2016   19:07:23
Chapter 11: Samenvatting
de leukemiecel ook een additioneel chromosoom 21 gevonden. De HOX-herschikkingen 
bestaan uit fusies met een HOX-gen. Hiervan werden verschillende varianten gevonden. 
Met behulp van genexpressieprofielen werd gevonden dat de samples met een HOX-
herschikking een gelijkend genexpressieprofiel hadden. Ook alle andere groepen 
gevonden in deze studie lieten een uniek genexpressieprofiel zien, waarbij de samples 
van patiënten met dezelfde afwijking bij elkaar groepeerden en de verschillende 
subgroepen niet bij elkaar. Daarnaast werd een specifieke HOX-expressie gezien bij de 
samples met een HOX-herschikking, naast de bekende HOX-profielen bij samples positief 
voor NUP98/KDM5A of KMT2A-herschikkingen. HOX-genen spelen een belangrijke rol 
in de normale hematopoëse en verschillende studies hebben aangetoond dat een 
gedereguleerde HOX-expressie een rol kan spelen in het ontstaan van leukemie. In deze 
studie hebben we het leukemisch effect van de HOX-herschikkingen bekeken door de 
capaciteit te analyseren om de cellen positief voor een HOX-herschikking in serie uit te 
platen. Deze methode liet zien dat verschillende HOX-herschikkingen een matige tot 
grote capaciteit hebben om in serie uitgeplaat te worden. 
In hoofdstuk 5 is gekeken naar de prognostische waarde van de meest 
voorkomende cytogenetische subgroepen binnen de AMKL op de kinderleeftijd 
van kinderen zonder Downsyndroom. Er werd een internationale samenwerking 
gevormd, waarbij er 153 patiënten werden geanalyseerd voor de aanwezigheid van 
NUP98/KDM5A, CBFA2T3/GLIS2, RBM15/MKL1 of KMT2A-herschikkingen en er werd 
gekeken naar uitkomstparameters. Tot nu toe werden alle kinderen met AMKL zonder 
Downsyndroom geclassificeerd als hoogrisico. Indien de leukemiecel cel positief was 
voor CBFA2T3/GLIS2, NUP98/KDM5A, of een KMT2A-herschikking, resulteerde dit in een 
ongunstige overlevingskans. Deze slechte overlevingskans was met name het gevolg van 
de hoge incidentie van recidieven bij deze patiënten. Wanneer de leukemiecel negatief 
was voor een van deze translocaties was de overlevingskans groter, overeenkomend met 
de standaardrisicogroep. AMKL bij kinderen zonder Downsyndroom ontstaat meestal 
op zeer jonge leeftijd, met een gemiddelde diagnose leeftijd onder de twee jaar. Onze 
studie toonde aan dat leeftijd geen onafhankelijke factor is voor prognose binnen deze 
ziekte, evenals geslacht en hoeveelheid aanwezige witte bloedcellen. Er waren geen 
verschillen in patiëntkarakteristieken tussen de verschillende groepen, met uitzondering 
van de leeftijd van diagnose van kinderen met RBM15/MKL1-positieve AMKL; zij waren 
bij diagnose significant jonger dan de andere kinderen met AMKL. Een belangrijk verschil 
in de therapieprotocollen van de verschillende samenwerkende groepen binnen deze 
studie, is het toepassen van een hematopoietische stamcel transplantatie (hSCT) in het 
geval van een beschikbare donor. In een multivariaatanalyse bleek het behandelen met 
een hSCT niet van invloed op de overlevingskans. Over de waarde van een hSCT binnen 
de behandeling van AML op de kinderleeftijd wordt gediscussieerd; een succesvolle hSCT 
heeft een antileukemisch effect, maar er is een hoge kans op transplantatiegerelateerde 
mortaliteit. 9-11 Desalniettemin wordt in vele therapieprotocollen een hSCT in eerste 
remissie aangeraden voor hoogrisicogroepen binnen de AML. Hoogrisicogroepen 
worden gedefinieerd door specifieke hoogrisico genetische afwijkingen of aan de 
hand van de slechte vroege respons op chemotherapeutische behandeling (hoge 
minimale residuale ziekte na het eerste of tweede blok van de chemotherapie). Onze 
resultaten toonden geen meerwaarde aan van een hSCT als behandeling van AMKL op 
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de kinderleeftijd. Kinderen vallend in de standaardrisicogroep zouden mogelijk niet in 
aanmerking komen voor deze intensieve behandeling. Kinderen zonder Downsyndroom 
met AMKL die niet tot een van de vier groepen in deze studie behoorden, zouden 
mogelijk een GATA1 mutatie of HOX-herschikking kunnen hebben. We hadden echter 
niet de mogelijkheid om dit te testen bij gebrek aan voldoende of kwalitatief goed 
patiëntmateriaal. 
In deel 2 van dit proefschrift hebben we de aanwezigheid van afwijkingen van 
verschillende genen bestudeerd in een cohort met alle morfologische subtypes van AML 
op de kinderleeftijd. In hoofdstuk 6 zijn afwijkingen van ETV6, een gen bekend door de 
afwijkingen in andere types van leukemie, bestudeerd, door de vondst van afwijkingen 
van dit gen binnen AML door de Children’s Oncology Group (Noord-Amerika), zoals 
gepresenteerd op de ASH 2012. 12 Door MLPA, direct sequencing en FISH te gebruiken, 
identificeerden we deleties, mutaties en translocaties van dit gen, voorkomend bij 
7% van de onderzochte patiënten met AML op de kinderleeftijd. ETV6-mutaties zijn 
gevonden bij 2.2% van de geteste patiënten, wat overeenkomt met de beschreven 
frequentie van AML bij volwassenen. 13 Daarnaast werden ETV6-deleties gevonden bij 
1.6%, en ETV6-translocaties bij 3.3% van de kinderen in dit cohort. De translocaties 
komen veel minder vaak voor dan ETV6-translocaties bij kinderen met acute lymfatische 
leukemie (ALL). 14 Bij de vergelijking tussen genexpressieprofielen van kinderen met 
ETV6-mutaties of -deleties versus de profielen van alle andere kinderen met AML in 
deze studie, vonden we verschillende genen met overexpressie, onder andere CLDN5, 
BIRC7 en DPEP1. De overexpressie van deze drie genen is ook beschreven bij T-ALL met 
ETV6-afwijkingen resulterend in een verminderde functie. 15-17 Dit suggereert dat de 
mutaties en deleties die we in deze studie hebben gevonden, ook resulteren in een 
dergelijke ETV6-afwijking. Hiernaast hebben we in deze studie vier verschillende ETV6-
translocaties geïdentificeerd. Naast ETV6/MNX1, een bekende ETV6-translocatie bij 
jonge kinderen met AML die we in zes gevallen vonden, identificeerden we drie unieke 
casus met ETV6/ARNT, ETV6/HOXCas2 en ETV6/HOXA11as. De translocaties met een 
HOX-antisense gen gaven hoge HOX-expressie specifiek voor het betrokken HOX-gen. Dit 
bevestigt de resultaten die we eerder bespraken in hoofdstuk 4. Hoewel de hoeveelheid 
gevonden ETV6-afwijkingen relatief laag waren voor een goede statistische analyse van 
de overlevingskans, suggereerde de analyse een slechte overlevingskans voor kinderen 
met AML met een ETV6-afwijking. 
Voor de studie naar ETV6-afwijkingen bij AML op de kinderleeftijd, hebben we 
MLPA gebruikt met een probe mix, welke onder andere ook probes bevatte voor het 
gen IKZF1. In hoofdstuk 7 beschrijven we de vondst van IKZF1-deleties binnen AML. 
IKZF1 is een gen dat gelokaliseerd is op chromosoom 7. Dit gen is uitgebreid bestudeerd 
met betrekking tot de B-cel differentiatie en binnen de ALL zowel op de kinderleeftijd 
als bij volwassenen. Verminderde IKZF1-genfunctie is een veelvoorkomende afwijking 
bij B-cel precursor (BCP-)ALL en wordt in 15% van deze gevallen veroorzaakt door 
een focale IKZF1-deletie. Dit komt voornamelijk voor bij BCR/ABL1 positieve BCP-
ALL, waarbij IKZF1-deleties voorkomen in 70-80% van de gevallen. 18, 19 In onze studie 
vonden we focale IKZF1-deleties, maar nooit in combinatie met BCR/ABL1. Ook konden 
we geen mutaties van IKZF1 vinden, zoals wel beschreven bij BCP-ALL. Bij AML op de 
kinderleeftijd werd eerder al het voorkomen van een monosomie van chromosoom 
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7 beschreven, dit komt voor bij ongeveer 4% van alle AML op de kinderleeftijd. Ook 
wordt monosomie 7 gezien bij het myelodysplastisch syndroom (MDS) en bij juveniele 
myelomonocytaire leukemie (JMML), die beiden kunnen uitgroeien tot AML. 20, 21 Ook in 
ons cohort vonden we in 3.1% van de casus een monosomie 7. We vonden een statistisch 
significante correlatie in genexpressieprofielen tussen de focale IKZF1-gedeleteerde 
casus (n=3) en de casus met monosomie 7 (n=8), van de genen die zich niet bevonden 
op chromosoom 7. Deze overeenkomst in genexpressieprofielen suggereert dat IKZF1 
een belangrijk gen leidend tot leukemie is bij de patiënten met een monosomie 7. 
In hoofdstuk 8 en 9 wordt de frequentie van mutaties in genen beschreven, 
die eerder werden gevonden bij AML van volwassenen. Mutaties in BCOR en BCORL1 
werden bij volwassenen met AML gevonden door middel van whole exome sequencing. 
Gezien de hoge frequentie met name bij cytogenetisch normale patiënten, onderzochten 
wij een cohort van AML van de kinderleeftijd.22, 23 Wij vonden BCOR mutaties in 
6.3% van ons cytogenetisch normale cohort, vergelijkbaar met het voorkomen bij 
volwassenen. We vonden een lagere frequentie van BCORL1-mutaties in vergelijking 
met volwassenen. Een oorzaak hiervan kan zijn dat het volwassencohort was verrijkt 
met secundaire- en therapie-gerelateerde AML; 73/173 (42%) in het volwassencohort 
van Li et al., versus 12/230 (5%) in ons kindercohort. 22-24 BCOR-genexpressie was niet 
significant verschillend tussen de BCOR-gemuteerde en niet-gemuteerde patiënten, een 
vergelijkbaar resultaat met de bevindingen bij volwassen patienten. Ook de BCORL1-
mutatie leidde niet tot veranderde genexpressie in het volwassencohort, dezelfde 
bevinding als bij de BCORL1-gemuteerde casus uit ons cohort. In het volwassencohort 
leidde een BCOR-mutatie tot een lagere overlevingskans. In ons cohort vonden wij te 
weinig casus voor een betrouwbare analyse met betrekking tot overlevingskans. Dit zal 
in een groter cohort plaats moeten vinden. 
Mutaties van PHF6, een tumorsuppressorgen op het X-chromosoom, met een 
rol in transcriptionele regulatie, zijn gevonden als germline mutatie leidend tot het 
Borjeson-Forssman- Lehmannsyndroom. 25, 26 Mutaties in dit gen zijn ook geïdentificeerd 
in T-ALL en AML bij volwassenen. De mutaties werden voornamelijk gevonden bij 
mannen, en alleen in het geval van AML bij de morfologische classificaties French-
American-British (FAB) M0, M1 en M2. 27-29 Gezien het voorkomen bij mutaties in dit gen 
bij AML bij volwassenen, hebben we een kindercohort geanalyseerd voor mutaties van 
PHF6. In hoofdstuk 9 wordt beschreven dat mutaties voorkomen bij 6/318 (2%; 95% 
CI: 0.9-4.1%) kinderen met AML. Ook bij kinderen zijn ze louter gevonden bij FAB M0, 
M1 en M2. Gezien de significant lagere mRNA-expressie van PHF6, wordt voorspeld dat 
deze PHF6-mutaties leiden tot een verlies van de functie van het gen. In tegenstelling 
tot de bevindingen bij T-ALL en AML bij volwassenen, werden de mutaties bij zowel 
vrouwen als mannen gevonden. De prognostische waarde van deze mutaties moet 
worden beoordeeld in een groter cohort. 
In hoofdstuk 10 wordt een translocatie beschreven welke resulteert in hoge 
HOX-expressie. Het breekpunt van de vaker beschreven t(10;17)(p15;q21) werd, 
geanalyseerd met behulp van reverse transcriptase PCR, in een unieke casus gevonden 
in een cohort van AML ontstaan op de kinderleeftijd. Dit resulteerde in de identificatie 
van de fusie van ZMYND11 en MBTD1. Deze casus resulteerde in hoge HOXA-expressie, 
dat frequent wordt gezien als oorzaak van het ontstaan van leukemie, zoals AML.
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International collaboration is needed to study rare diseases such as pediatric AMKL
Pediatric AML is a heterogeneous disease. By unraveling the underlying aberrations 
resulting in pediatric AML, potential disease-driving mutations may be identified, which 
may be important for risk stratification and targeted therapy, with the final aim to 
improve prognosis. To study rare diseases such as pediatric non-Down syndrome AMKL, 
international collaboration was set-up to be able to not only identify aberrations, but 
also analyze their prognostic impact. In the studies discussed in this thesis, samples 
from various regions of Europe, Asia and North America were included. A potential 
drawback of that approach is that patients were treated on different protocols over a 
longer period of time, which is not ideal to study prognostic factors. However, all AML 
treatment protocols consisted of intensive chemotherapy using an anthracycline and 
cytarabine backbone, including stem cell transplantation in selected cases. Moreover, 
when comparing the clinical characteristics and outcome data of the AMKL patients in 
chapter 5 versus a population-based cohort of the AML-BFM Study Group, no significant 
differences were found, suggesting that this cohort was a representative sample for 
pediatric AMKL. This thesis shows, that with intensive international collaboration, new 
risk groups can be identified. 
Next generation sequencing contributes to the unravelling of aberrations which can be 
used for risk-group stratification
Inaba et al described AMKL risk groups based on cytogenetic analysis obtained with 
conventional karyotyping, resulting in three groups; good risk in patients with AMKL 
carrying 7p abnormalities; poor risk in cases with monosomy 7, or 9p abnormalities 
including the KMT2A/MLLT3, -13/13q- and -15; and intermediate risk in all others.1 
This risk classification may be difficult, since AMKL is frequently associated with 
myelofibrosis, which renders it difficult to obtain sufficient material for cytogenetic 
analysis. In this thesis, we showed in chapter 5 that 32/153 (21%) patients lacked data 
on karyotype, comparable to the findings of Inaba et al1 in pediatric AMKL, but a much 
higher percentage than reported on missing karyotypes in pediatric AML including all 
morphology subtypes (7-13%).2 Moreover, conventional karyotyping will not reveal 
cryptic translocations, such as CBFA2T3/GLIS2 or NUP98/KDM5A. Using RT-PCR as 
screening method, we were able to classify 12/32 cases without an available karyotype, 
not only including the aforementioned cryptic translocations, but patients harboring 
KMT2A-rearrangements and RBM15/MKL1 as well. Therefore, screening of the most 
frequent recurrent aberrations with PCR will add value to risk stratification next to 
cytogenetic analysis based on conventional karyotyping, revealing additional groups 
with poor outcome. Although the overall survival is poor for non-DS AMKL in general, 
with a 4-year probability of overall survival of ~56% in this study, NUP98/KDM5A, 
CBFA2T3/GLIS2 and KMT2A-rearranged cases fared worse. Using RNA-sequencing, we 
were able to identify two additional genetic groups within pediatric AMKL; the GATA1 
mutated cases, and cases with HOX-rearrangements, interestingly both predicting for 
better survival. Altogether we identified an aberration in over 80% of the pediatric 
AMKL cases (chapter 4 and Figure 12.1). 
The group of HOX-rearrangements has a wide variety of different HOX genes 
and partner genes involved, and with that, targeted screening for any of these fusions is 
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hardly feasible. This emphasizes the need for next generation sequencing as screening 
tool. Screening for these translocations combined with conventional karyotyping in 
pediatric non-AMKL is advisable for accurate risk-group stratification. Based on our data 
we suggest that within pediatric non-Down syndrome AMKL NUP98/KDM5A, CBFA2T3/
GLIS2 and KMT2A-rearrangements are stratified as high risk patients. Moreover, 
we propose that RBM15/MKL1, GATA1s mutated cases and HOX-rearrangements 
are stratified as standard risk, with a 5-year pOS of 65±17%, 100%, and 77%±12%, 
respectively.3 For proper risk group stratification conventional karyotyping combined 
with screening for NUP98/KDM5A, CBFA2T3/GLIS2, KMT2A-rearrangements, RBM15/
MKL1 and mutational screening of GATA1 may be used if next generation sequencing 
is not feasible. 
Fusions seen in pediatric non-Down Syndrome AMKL might be present at birth before 
the development of frank leukemia 
Pediatric non-Down Syndrome AMKL arises at a median age below two years. 1,3-5 
Greaves et al showed that AML fusion genes can be detected in circulating bone marrow 
cells derived from neonatal Guthrie cards, suggesting the fusion gene, although in small 
subclones, to be present in utero.6 In Down syndrome AMKL, the GATA1s mutation 
induces transient myeloproliferative disease originating in the fetal liver, followed by 
spontaneous remission in ~80% of cases, and in approximately 20% followed by the 
development of AMKL before the age of 4-5 years.7-10 Guthrie cards may show whether 
the most frequent identified somatic aberrations in non-Down syndrome AMKL, such 
as NUP98/KDM5A, RBM15/MKL1, and CBFA2T3/GLIS2, all seen in leukemias which 
present themselves at a very young age, might be present at birth as well, which later, 
in combination with a second hit, such as a RB1 deletion, may result in frank leukemia. 
Analyzing the presence of the fusion genes specific for pediatric AMKL may reveal 
new insights in the development of frank leukemia, and may be an explanation of the 
specific age pattern for these types of leukemia. Since the incidence of pediatric AML 
is 0.4-1.6 per 100.000 individuals, screening in non-Down syndrome newborns will not 
contribute to early detection. In Down syndrome screening by Guthrie cards may be 
useful, since ~20% of the cases with a transient myeloid leukemia will develop AML.
Non-Down syndrome GATA1 mutated AMKL cases may potentially benefit from less 
intensive chemotherapy
AMKL in children with Down syndrome is treated with a reduced chemotherapy 
treatment protocol compared to non-Down syndrome patients. Given the favorable 
prognostic outcome of GATA1 mutated cases in pediatric non-Down Syndrome AMKL 
not harboring any other fusion event (in our cohort 0/7 patients had an event), it 
may be interesting to see whether patients with this specific genotype of pediatric 
AMKL could be treated with a reduced chemotherapy treatment protocol. The GATA1 
mutation is most likely resulting in a reduced expression of cytidine deaminase.11-14 
Cytidine deaminase is an enzyme that converts cytarabine in its inactive metabolite.12,13 
The decreased expression of cytidine deaminase results in a higher intracellular 
concentration, and therefore a lower dose of cytarabine may have a higher potential in 
anti-leukemic effect in these patients.11,14 When comparing the drug sensitivity of Down 
syndrome AML versus non-Down syndrome AML, Down syndrome AML cells were not 
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only more sensitive for cytarabine, but also for daunorubicin, idarubicin, mitoxantrone, 
etoposide, 6-thioguanine, amsacrine, vincristine, and busulfan.15 This effect was not 
observed in Down syndrome ALL, suggesting that the GATA1 mutation is responsible 
for this effect. Further research should be performed to investigate whether non-Down 
syndrome GATA1s mutated AMKL cells show a similar sensitivity for chemotherapy 
as seen in Down syndrome AMKL, to optimize treatment protocols for this specific 
subgroup of non-Down syndrome AML. In case chemotherapy can be reduced without 
compromising anti-leukemic efficacy this will also diminish treatment-related morbidity 
and mortality, further improving outcome. Nevertheless, it is important to acknowledge 
that GATA1 was not mutually exclusive in our patient cohort. The combination with 
NUP98/KDM5A, as seen in our cohort in one patient, may lead to a poorer outcome. 
Future strategies to treat pediatric AML: newly identified drugable targets and 
immunotherapy may lead to improved outcome of pediatric AML
One option to improve outcome of pediatric AML is through targeted therapy, since 
intensification of the current treatment protocols is not feasible due to the high 
incidence of treatment related morbidity and mortality. Targeted therapy could focus 
on disrupting the complexes formed by fusion genes. In the KMT2A-rearranged cases, 
DOT1L inhibitors are currently under investigation. DOT1L is a protein that is recruited 
in the KMT2A-complex, resulting in the HOXA9 and MEIS-overexpression that drive the 
leukemogenesis.16-18 Where in vitro and in vivo models show a great potential for DOT1L 
inhibitors, clinical studies so far have not shown the promising results anticipated by 
preclinical models.19 
Another interesting player in the field of immunotherapy is the category of 
bispecific T-cell engager (BiTE) antibodies. These anti-cancer drugs use the ability to 
bind T-cells via the CD3 receptor, and tumor cells via a tumor specific molecule; for 
instance CD19 for ALL, or CD33 for AML cells. This causes T-cells to exert cytotoxic 
activity, resulting in apoptosis of the leukemic cells.20-22 In other types of cancer, such 
as Non-Hodkin’s lymphomas and ALL, clinical studies showed a therapeutic potential 
for BiTE-antibodies.23-26 A drawback for this therapy is that CD33 is not specific for the 
leukemic cell; as CD33 is also expressed on healthy myeloid cell progenitors. Therefore 
this therapy may result in severe neutropenia, precluding its use to for instance induce 
remission in a pre-SCT window. Clinical studies in adults are initiated and should provide 
insight in how to best use these drugs. 
Chimeric antigen receptor expressing T (CART) cells already showed great 
potential in the treatment of CD19-positive ALL and lymphoma.27-29 The difficulty 
in using CART cells in AML is the lack of antibodies only expressed at the leukemic 
cells, similar to BITES. Targeting a specific antibody on an AML cell may therefore also 
attack healthy cells in the myeloid lineage and may therefore lead to neutropenia.30 
Specific antibodies or combinations of antibodies that will not attack non-malignant 
cells need to be developed both for BITES and CART technology.31 Further optimization 
and extension of this concept of anti-cancer therapy may well lead to striking clinical 
benefits, without harming the healthy myeloid progenitors.
Perspective
In this thesis, specific novel translocations resulting in HOX upregulation are described, 
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which can be classified according to the HOX clusters as previosuly reported by us 
(Figure 12.2).32 These cases may benefit from targeted therapy assigned to disrupt this 
HOX upregulation in the future. For instance, we identified ZMYND11/MBTD1, NUP98/
KDM5A, and HOX-rearrangements as new groups resulting in HOX overexpression 
(Figure 12.2). Future research should be performed to investigate the interaction 
between the HOX genes and the fusion proteins causing HOX-upregulation. This may 
reveal potential targets for therapy. To find drugable targets in HOX-overexpressed cases 
such as NUP98/KDM5A, methods unraveling protein-protein interaction, such as Chip-
sequencing, can be used to determine molecules involved in the protein interaction 
of the fusion resulting in the HOX-overexpression. Finding key proteins involved in the 
fusion-gene induced protein complexes resulting in leukemia will give lead towards 
targeted therapy. Since HOX-upregulation is not specific for pediatric AML, finding 
targets resulting in HOX-upregulation may be of interest for other leukemias as well. 
Furthermore, screening of neonatal Guthrie cards may reveal the presence of 
fusion genes in utero in non-Down syndrome patients. Analyzing the presence of the 
fusion genes specific for pediatric AMKL may reveal new insights in the development of 
leukemia, and may explain the early onset of the disease. 
To investigate the potential of reduced chemotherapy as treatment for non-
Down syndrome AMKL with a GATA1s mutation, the ex-vivo drug sensitivity of non-
Down syndrome GATA1s mutated leukemic cells needs to be determined.
In conclusion, there is clear medical need for new therapeutic options in 
pediatric AML, since survival is currently ~70%, and intensification of the current 
chemotherapeutic protocols is not feasible due to high rates of treatment related 
morbidity and mortality. We have identified multiple recurrent (cyto)genetic aberrations 
in pediatric AML, which gives leads to new therapeutic options and better risk-group 
stratification. 
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Figure 12.1. Schematic overview of different aberrations found in pediatric non-Down Syndrome AMKL 
using RNA-sequencing. 
Figure 12.2. Principal component analysis based on HOX genes. Three clusters were formed, cluster I 
contains samples with low HOXA and HOXB expression, cluster II contains samples with high HOXA 
overexpression, such as KMT2A-rearrangements and ZMYND11/MBTD1, cluster III contains samples 
resulting in high HOXA and HOXB overexpression, including NUP98-rearrangments. 
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leven en het valt me zwaar dat je die van mij zal missen. Hoe bijzonder is het dat ik 
Yelena en Boy al sinds de eerste seconde van hun leven ken. Ik zal een hoop warme 
herinneringen met ze delen, zodat ze altijd zullen weten hoe speciale moeder jij bent.
Rust zacht, Jocefros ♥ 29 mei 1987 - 10 december 2015 ♥
Juist in moeilijke tijden heb ik ontzettend veel steun gehad aan mijn vrienden, met wie 
ik zowel de mooie als de verdrietige momenten kan delen. 
Lieve Jenny en Maarten, wat een luxe om zo’n goede vriendin te hebben op werk, 
en daarbuiten. Ik ben blij dat we elkaar blijven zien, nu we beiden het lab hebben 
verlaten. We hebben al mooie momenten gedeeld, en er zullen er nog velen volgen, 
zeker nu ook Koen van de partij is.
Daria, jouw enthousiasme was wellicht iets te Amerikaans voor ons lab, maar gelukkig 
heb je dat toch met ons kunnen delen. Hoewel ik New York een heerlijke uitvalbasis 
vind, ben ik blij dat jij en Chris op termijn weer wat meer in de buurt komen wonen, 
zodat we elkaar wat makkelijker kunnen spreken. 
sMoniek, voor ik jou leerde kennen wist ik bijna niks van Brabant, en vervolgens 
ben ik er zelfs even gaan wonen. Je biedt altijd een luisterend oor. Ik geniet van de 
spelletjesavonden met Teun en het knuffelen met Jop.
Wat begon bij de ANWB, leidde tot schorpioenen in Poreč. Kirstin, we hebben een 
hoop meegemaakt, bedankt voor je steun en alle lieve woorden. Je bent ontzettend 
sterk en ik ben trots op alles wat je hebt bereikt ondanks alle tegenslagen.
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Lieve Lilian, Lisette, Tim en Tess, bedankt voor alle ontspannen avondjes. Of we nu 
gingen bowlen in Polen of een filmavondje hadden, het gaf me altijd veel energie. Ik 
kijk uit naar de volgende date!
Team Frou Frou, bedankt voor alle ontspanning zowel op als naast de tennisbaan. Op 
naar meer legendarische overwinningen en feestjes!
Zo oud zijn we nog niet, maar OLD is zeker op ons van toepassing, Yrsa, Kelly en 
Kirsten. Ik kijk uit naar het volgende weekendje. Marloes, je bent mijn favoriete date, 
en ik weet zeker dat we nog vaak zullen winnen, gewoon omdat het kan. Nina, je was 
mijn favoriete collega, en Margaux, ik hoop dat je jouw ingezette trend doorzet met 
naar het Noorden verhuizen. Het is een eer om erelid te zijn van MDD Floreciente, op 
naar meer activiteiten voor oudleden, maar wel graag wat dichter bij de kust ;-)
Lieve Mam, bedankt voor al je steun en alle kansen die je me hebt gegeven. Jij hebt 
me geleerd dat alles mogelijk is, als je er maar écht voor gaat. Of ik nu glitters nodig 
heb, of een kopje thee, ik kan altijd op je rekenen.
Pap, Gne, Emma en Ruben, bedankt voor jullie interesse in mijn onderzoek, en alle 
glazen champagne om elke stap te vieren. Ik kijk uit naar alle weken ontspanning in 
Italië, met of zonder cactussen.
Lieve Diane en Jan Peter, bedankt voor alle steun en interesse die jullie continu 
hebben getoond. Mijn interesse voor de kinderoncologie is op een verdrietige manier 
ontstaan en dat gaf extra motivatie om echt wat te bereiken. Ik heb tijdens mijn 
onderzoek steeds Kathelijne als engeltje op mijn schouder gevoeld.
Lieve Floor, wat fijn dat jij mijn paranimf bent. Je staat altijd voor me klaar, of ik nou 
om schoenen vraag, of een schouder, jij komt brengen wat ik nodig heb. Met jouw 
humor kun je elke uitdaging aan, en geen berg is niet te beklimmen. Bedankt dat je op 
deze belangrijke dag ook weer achter mij staat. 
Lieve Roos, we hebben een heel bijzondere band: zus, vriendin, oud-huisgenoot en nu 
paranimf. Vakanties, tuinieren, de CPC, borrelen, tennissen, er is weinig wat we niet 
samen doen. Het is heerlijk om zo’n fijne zus te hebben. 
Chris, deze laatste woorden van mijn dankwoord zijn natuurlijk voor jou, maar 
geen enkele zin kan de lading dekken. Bedankt voor je relativeringsvermogen en 
onvoorwaardelijke steun. Ik hou van je, op naar een mooie toekomst samen!
Jasmijn
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Uitnodiging voor de 
openbare verdediging 
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Molecular genetic 
aberrations and their 
prognostic relevance in 
pediatric acute myeloid 
leukemia
Dinsdag 14 juni 2016 
om 13:30 
in de Professor Andries 
Queridozaal in het Erasmus MC 
Onderwijscentrum
Wytemaweg 80 te Rotterdam.
 
Aansluitend bent u van harte 
welkom op de receptie ter 
plaatse. 
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Juliana van Stolberglaan 5R
2595CA ‘s Gravenhage
j.derooij@hotmail.com
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